{"items": "233", "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish", "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.", "feed": [{"title": "Cathie Wood's Ark Dumps Coinbase Stock Amid Bitcoin Highs, Shopify Holdings Also Cut - ARK Fintech Innovation ETF  ( ARCA:ARKF ) ", "url": "https://www.benzinga.com/24/12/42545624/cathie-woods-ark-dumps-coinbase-stock-amid-bitcoin-highs-shopify-holdings-also-cut", "time_published": "20241218T030049", "authors": ["Shivdeep Dhaliwal"], "summary": "On Tuesday, Cathie Wood-led Ark Invest made significant trades involving Coinbase Global Inc. COIN and Shopify Inc. SHOP. The investment firm reduced its holdings in both companies. Ark Invest sold 5,646 shares of Coinbase Global Inc. through its Ark Fintech Innovation ETF ARKF on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/17/Cathie-Woods-Monday-Moves-4-8M-Spotify-S.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.967645"}, {"topic": "Earnings", "relevance_score": "0.967645"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Blockchain", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.243852, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "SHOP", "relevance_score": "0.402941", "ticker_sentiment_score": "0.157101", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ADPT", "relevance_score": "0.105141", "ticker_sentiment_score": "0.194943", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FUTU", "relevance_score": "0.105141", "ticker_sentiment_score": "0.352169", "ticker_sentiment_label": "Bullish"}, {"ticker": "PACB", "relevance_score": "0.105141", "ticker_sentiment_score": "0.291069", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TEM", "relevance_score": "0.105141", "ticker_sentiment_score": "0.259383", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "COIN", "relevance_score": "0.491255", "ticker_sentiment_score": "0.203893", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.208464", "ticker_sentiment_score": "0.153095", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Reasons to Retain PacBio Stock in Your Portfolio for Now", "url": "https://www.zacks.com/stock/news/2383005/reasons-to-retain-pacbio-stock-in-your-portfolio-for-now", "time_published": "20241212T172100", "authors": ["Zacks Equity Research"], "summary": "PACB continues to deliver growth from its unique technologies amid business seasonality concerns.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ee/4161.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.239584, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MASI", "relevance_score": "0.113062", "ticker_sentiment_score": "0.093923", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.0378", "ticker_sentiment_score": "0.146376", "ticker_sentiment_label": "Neutral"}, {"ticker": "GMED", "relevance_score": "0.113062", "ticker_sentiment_score": "0.127301", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.330286", "ticker_sentiment_score": "0.266788", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MYGN", "relevance_score": "0.0378", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight - Pacific Biosciences  ( NASDAQ:PACB ) ", "url": "https://www.benzinga.com/24/12/42339149/cathie-woods-ark-invest-keeps-betting-big-on-biotech-pacific-biosciences-grabs-spotlight", "time_published": "20241205T135434", "authors": ["Surbhi Jain"], "summary": "Ark Invest CEO Cathie Wood is doubling down on genomics. What Happened: Pacific Biosciences of California Inc. PACB, known as PacBio, is biotech's new kid on the block. The company's Vega sequencer might be the spark that reignites the genomics flame in Ark Invest's portfolios.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/05/Cathie-Wood-Cashes-Out-On-Rocket-Labs-28.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.198204, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.186738", "ticker_sentiment_score": "-0.045682", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight - Pacific Biosciences  ( NASDAQ:PACB ) ", "url": "https://www.benzinga.com/general/biotech/24/12/42339149/cathie-wood-ark-invest-keeps-betting-big-on-biotech-pacific-biosciences-grabs-spotlight", "time_published": "20241205T135427", "authors": ["Surbhi Jain"], "summary": "Ark Invest CEO Cathie Wood is doubling down on genomics. What Happened: Pacific Biosciences of California Inc. PACB, known as PacBio, is biotech's new kid on the block. The company's Vega sequencer might be the spark that reignites the genomics flame in Ark Invest's portfolios.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/05/Cathie-Wood-Cashes-Out-On-Rocket-Labs-28.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.198204, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.186738", "ticker_sentiment_score": "-0.045682", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cathie Wood's Monday Moves: $4.8M Spotify Stock Sale Meets $4.7M Pinterest Shopping Spree - ARK Fintech Innovation ETF  ( ARCA:ARKF ) , Advanced Micro Devices  ( NASDAQ:AMD ) ", "url": "https://www.benzinga.com/24/12/42281575/cathie-woods-monday-moves-4-8m-spotify-stock-sale-meets-4-7m-pinterest-shopping-spree", "time_published": "20241203T022730", "authors": ["Benzinga Neuro"], "summary": "On Monday, Cathie Wood's Ark Invest made significant moves in its portfolio, notably involving Spotify Technology SA SPOT and Pinterest Inc. PINS.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/12/02/Cathie-Wood-Led-Ark-Invests-Latest-Portf.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.95493"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": 0.399194, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "SPOT", "relevance_score": "0.568148", "ticker_sentiment_score": "0.544935", "ticker_sentiment_label": "Bullish"}, {"ticker": "PACB", "relevance_score": "0.206685", "ticker_sentiment_score": "0.488176", "ticker_sentiment_label": "Bullish"}, {"ticker": "SNTI", "relevance_score": "0.206685", "ticker_sentiment_score": "0.283557", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMD", "relevance_score": "0.206685", "ticker_sentiment_score": "0.377112", "ticker_sentiment_label": "Bullish"}, {"ticker": "ABSI", "relevance_score": "0.206685", "ticker_sentiment_score": "0.488176", "ticker_sentiment_label": "Bullish"}, {"ticker": "PINS", "relevance_score": "0.399734", "ticker_sentiment_score": "0.48524", "ticker_sentiment_label": "Bullish"}, {"ticker": "GRMN", "relevance_score": "0.206685", "ticker_sentiment_score": "0.488176", "ticker_sentiment_label": "Bullish"}, {"ticker": "BFLY", "relevance_score": "0.206685", "ticker_sentiment_score": "0.283557", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cathie Wood Buys Amazon, AMD Stock - Trims Palantir, Block Holdings Amid AI And Bitcoin Euphoria - Advanced Micro Devices  ( NASDAQ:AMD ) ", "url": "https://www.benzinga.com/24/11/42227834/cathie-wood-buys-amazon-amd-stock-trims-palantir-block-holdings-amid-ai-and-bitcoin-euphoria", "time_published": "20241128T014238", "authors": ["Benzinga Neuro"], "summary": "On Wednesday, Cathie Wood-led Ark Invest made some notable trades. The most prominent among these were in Amazon.com Inc AMZN, Advanced Micro Devices Inc. AMD, Palantir Technologies Inc. PLTR, and Block Inc. SQ.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/27/Cathie-Wood-Keeps-Betting-On-Amazons-Hau.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}], "overall_sentiment_score": 0.303619, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RPTX", "relevance_score": "0.158519", "ticker_sentiment_score": "0.257538", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.158519", "ticker_sentiment_score": "0.257538", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ILMN", "relevance_score": "0.158519", "ticker_sentiment_score": "0.257538", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMD", "relevance_score": "0.310843", "ticker_sentiment_score": "0.180324", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RBLX", "relevance_score": "0.158519", "ticker_sentiment_score": "0.350658", "ticker_sentiment_label": "Bullish"}, {"ticker": "PINS", "relevance_score": "0.158519", "ticker_sentiment_score": "0.350658", "ticker_sentiment_label": "Bullish"}, {"ticker": "AMZN", "relevance_score": "0.158519", "ticker_sentiment_score": "0.197973", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BFLY", "relevance_score": "0.158519", "ticker_sentiment_score": "0.257538", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SQ", "relevance_score": "0.235823", "ticker_sentiment_score": "0.18789", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PLTR", "relevance_score": "0.235823", "ticker_sentiment_score": "0.295942", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.235823", "ticker_sentiment_score": "0.150798", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cathie Wood's Latest Tesla Dump: Ark Sells $18M Worth Of Stock - ARK Autonomous Technology & Robotics ETF  ( BATS:ARKQ ) , ARK Innovation ETF  ( ARCA:ARKK ) ", "url": "https://www.benzinga.com/24/11/42205945/ark-invests-bold-move-tesla-shares-sold-amid-market-shifts", "time_published": "20241127T023518", "authors": ["Benzinga Neuro"], "summary": "On Tuesday, Cathie Wood-led Ark Invest executed significant trades involving Tesla Inc. TSLA. The trades included the sale of Tesla shares across multiple ETFs, reflecting strategic adjustments in Ark's portfolio. Ark Invest's decision to sell Tesla shares on Tuesday was a continuation of its ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/26/Other-Key-Trades.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.983783"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.444335, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "AMD", "relevance_score": "0.211191", "ticker_sentiment_score": "0.219314", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.651499", "ticker_sentiment_score": "0.615569", "ticker_sentiment_label": "Bullish"}, {"ticker": "TWST", "relevance_score": "0.106541", "ticker_sentiment_score": "0.318595", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.106541", "ticker_sentiment_score": "0.331736", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ILMN", "relevance_score": "0.106541", "ticker_sentiment_score": "0.409205", "ticker_sentiment_label": "Bullish"}]}, {"title": "Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought", "url": "https://www.fool.com/investing/2024/11/12/cathie-wood-goes-bargain-hunting-3-stocks-she-just/", "time_published": "20241112T165500", "authors": ["Rick Munarriz"], "summary": "The rock star money manager is starting to roll with the rallying market.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F797550%2Fgettyimages-1290369115.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.955357"}, {"topic": "Earnings", "relevance_score": "0.995015"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.17711, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GH", "relevance_score": "0.323785", "ticker_sentiment_score": "0.241295", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.165409", "ticker_sentiment_score": "0.116012", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTD", "relevance_score": "0.513606", "ticker_sentiment_score": "0.292874", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y", "url": "https://www.zacks.com/stock/news/2367532/pacb-stock-falls-despite-q3-earnings-beat-revenues-decline-yy", "time_published": "20241108T151000", "authors": ["Zacks Equity Research"], "summary": "PacBio Q3 2024 revenues decline year over year. However, Consumable, and Service and other revenues increase.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/9c/76884.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": -0.071951, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DGX", "relevance_score": "0.180798", "ticker_sentiment_score": "0.173664", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.268294", "ticker_sentiment_score": "-0.012715", "ticker_sentiment_label": "Neutral"}, {"ticker": "RDNT", "relevance_score": "0.090989", "ticker_sentiment_score": "0.05286", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYGN", "relevance_score": "0.045569", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sweetgreen Posts Downbeat Results, Joins Evolent Health, Redfin, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Pinterest  ( NYSE:PINS ) ", "url": "https://www.benzinga.com/trading-ideas/movers/24/11/41843551/sweetgreen-posts-downbeat-results-joins-evolent-health-redfin-pinterest-and-other-big-stocks", "time_published": "20241108T134742", "authors": ["Avi Kapoor"], "summary": "U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.2% on Friday. Shares of Sweetgreen, Inc. SG fell sharply in today's pre-market trading after the company reported worse-than-expected quarterly financial results.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/11/08/pinterest-shutter3.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.623304"}, {"topic": "Earnings", "relevance_score": "0.9996"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.09236, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.241684", "ticker_sentiment_score": "-0.178939", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SG", "relevance_score": "0.461699", "ticker_sentiment_score": "-0.114858", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.241684", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTD", "relevance_score": "0.241684", "ticker_sentiment_score": "-0.352138", "ticker_sentiment_label": "Bearish"}, {"ticker": "AGL", "relevance_score": "0.241684", "ticker_sentiment_score": "-0.07307", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVH", "relevance_score": "0.241684", "ticker_sentiment_score": "-0.07307", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.241684", "ticker_sentiment_score": "0.205737", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRVI", "relevance_score": "0.241684", "ticker_sentiment_score": "-0.214059", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RDFN", "relevance_score": "0.241684", "ticker_sentiment_score": "-0.280878", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Reports Q3 Loss, Misses Revenue Estimates", "url": "https://www.zacks.com/stock/news/2366928/pacific-biosciences-of-california-pacb-reports-q3-loss-misses-revenue-estimates", "time_published": "20241107T231507", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences (PACB) delivered earnings and revenue surprises of 15% and 4.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default239.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.100869, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "NUWE", "relevance_score": "0.205807", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.138066", "ticker_sentiment_score": "-0.063787", "ticker_sentiment_label": "Neutral"}]}, {"title": "Curious about Pacific Biosciences  ( PACB )  Q3 Performance? Explore Wall Street Estimates for Key Metrics", "url": "https://www.zacks.com/stock/news/2363221/curious-about-pacific-biosciences-pacb-q3-performance-explore-wall-street-estimates-for-key-metrics", "time_published": "20241104T141615", "authors": ["Zacks Equity Research"], "summary": "Evaluate the expected performance of Pacific Biosciences (PACB) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default6.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.988915"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.120631, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.235823", "ticker_sentiment_score": "0.1304", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Advances While Market Declines: Some Information for Investors", "url": "https://www.zacks.com/stock/news/2362226/pacific-biosciences-of-california-pacb-advances-while-market-declines-some-information-for-investors", "time_published": "20241031T221508", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences of California (PACB) reachead $2.17 at the closing of the latest trading day, reflecting a +0.46% change compared to its last close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default197.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.154541, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.462953", "ticker_sentiment_score": "0.093742", "ticker_sentiment_label": "Neutral"}]}, {"title": "Alphatec  ( ATEC )  Reports Q3 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2361046/alphatec-atec-reports-q3-loss-tops-revenue-estimates", "time_published": "20241030T211006", "authors": ["Zacks Equity Research"], "summary": "Alphatec (ATEC) delivered earnings and revenue surprises of -3.70% and 2.19%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default129.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.140246, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ATCN", "relevance_score": "0.069495", "ticker_sentiment_score": "-0.050867", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.138464", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATEC", "relevance_score": "0.399204", "ticker_sentiment_score": "0.143918", "ticker_sentiment_label": "Neutral"}]}, {"title": "Illumina's Q3 Earnings Coming Up: Time to Buy, Sell or Hold the Stock?", "url": "https://www.zacks.com/stock/news/2357071/illuminas-q3-earnings-coming-up-time-to-buy-sell-or-hold-the-stock", "time_published": "20241024T155200", "authors": ["Moumi Mondal"], "summary": "In the third quarter of 2024, ILMN is likely to have benefited from the significant step-up in consumables with growing customer activity on NovaSeq X.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6d/60158.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.96136"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.281436, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.067727", "ticker_sentiment_score": "0.154539", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ILMN", "relevance_score": "0.555653", "ticker_sentiment_score": "0.401136", "ticker_sentiment_label": "Bullish"}, {"ticker": "QGEN", "relevance_score": "0.067727", "ticker_sentiment_score": "0.154539", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold?", "url": "https://www.zacks.com/stock/news/2352964/ilmn-stock-trading-near-52-week-high-should-you-buy-sell-or-hold", "time_published": "20241018T130500", "authors": ["Moumi Mondal"], "summary": "Reaching a new one-year high, Illumina remains in investors' sight owing to its strong strategic execution and positive growth outlook.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3e/2848.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.796627"}, {"topic": "Earnings", "relevance_score": "0.980716"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.350891, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.078354", "ticker_sentiment_score": "0.150332", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ILMN", "relevance_score": "0.508878", "ticker_sentiment_score": "0.413944", "ticker_sentiment_label": "Bullish"}, {"ticker": "QGEN", "relevance_score": "0.078354", "ticker_sentiment_score": "0.150332", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Stock Slides as Market Rises: Facts to Know Before You Trade", "url": "https://www.zacks.com/stock/news/2351901/pacific-biosciences-of-california-pacb-stock-slides-as-market-rises-facts-to-know-before-you-trade", "time_published": "20241016T221519", "authors": ["Zacks Equity Research"], "summary": "In the latest trading session, Pacific Biosciences of California (PACB) closed at $2.06, marking a -1.9% move from the previous day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default34.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928769"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.225249, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.523202", "ticker_sentiment_score": "0.354872", "ticker_sentiment_label": "Bullish"}]}, {"title": "Reasons to Retain PacBio Stock in Your Portfolio for Now", "url": "https://www.zacks.com/stock/news/2350983/reasons-to-retain-pacbio-stock-in-your-portfolio-for-now", "time_published": "20241015T173300", "authors": ["Zacks Equity Research"], "summary": "PACB's strong product demand and continued focus on R&D raise optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.890401"}], "overall_sentiment_score": 0.176742, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAX", "relevance_score": "0.171181", "ticker_sentiment_score": "0.074923", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.29485", "ticker_sentiment_score": "0.152278", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.128822", "ticker_sentiment_score": "0.0852", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.128822", "ticker_sentiment_score": "0.096938", "ticker_sentiment_label": "Neutral"}]}, {"title": "Baidu, XPeng And Other Big Stocks Moving Lower In Monday's Pre-Market Session - XPeng  ( NYSE:XPEV ) ", "url": "https://www.benzinga.com/news/24/10/41312112/baidu-xpeng-and-other-big-stocks-moving-lower-in-mondays-pre-market-session", "time_published": "20241014T125818", "authors": ["Avi Kapoor"], "summary": "U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Monday. Shares of Baidu, Inc. BIDU fell sharply in today's pre-market trading. U.S.-listed Chinese stocks traded lower Monday as China's stimulus measures failed to impress the Street.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/14/Baidu-Inc-ADR-BIDU.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}], "overall_sentiment_score": -0.073039, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.353059", "ticker_sentiment_score": "-0.159432", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "APP", "relevance_score": "0.353059", "ticker_sentiment_score": "-0.159432", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GNFT", "relevance_score": "0.353059", "ticker_sentiment_score": "0.236116", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.353059", "ticker_sentiment_score": "-0.106231", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIDU", "relevance_score": "0.507932", "ticker_sentiment_score": "-0.433591", "ticker_sentiment_label": "Bearish"}, {"ticker": "TIGR", "relevance_score": "0.353059", "ticker_sentiment_score": "0.060638", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOOS", "relevance_score": "0.353059", "ticker_sentiment_score": "-0.159432", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MLCO", "relevance_score": "0.353059", "ticker_sentiment_score": "-0.446301", "ticker_sentiment_label": "Bearish"}]}, {"title": "Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket - Longboard Pharmaceuticals  ( NASDAQ:LBPH ) ", "url": "https://www.benzinga.com/news/24/10/41310058/why-longboard-pharmaceuticals-shares-are-trading-higher-by-around-47-here-are-20-stocks-moving-prema", "time_published": "20241014T110440", "authors": ["Avi Kapoor"], "summary": "Shares of Longboard Pharmaceuticals, Inc. LBPH rose sharply in today's pre-market trading. Lundbeck agreed to acquire Longboard Pharmaceuticals in a transaction valued at approximately $2.6 billion equity value. Longboard Pharmaceuticals shares jumped 46.8% to $57.13 in the pre-market trading ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.882182"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Blockchain", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.088322, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ARBK", "relevance_score": "0.166169", "ticker_sentiment_score": "0.354086", "ticker_sentiment_label": "Bullish"}, {"ticker": "TWG", "relevance_score": "0.166169", "ticker_sentiment_score": "-0.196953", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VEV", "relevance_score": "0.246999", "ticker_sentiment_score": "-0.497279", "ticker_sentiment_label": "Bearish"}, {"ticker": "MTEM", "relevance_score": "0.166169", "ticker_sentiment_score": "0.25047", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LBPH", "relevance_score": "0.325208", "ticker_sentiment_score": "0.48951", "ticker_sentiment_label": "Bullish"}, {"ticker": "TVGN", "relevance_score": "0.246999", "ticker_sentiment_score": "0.29083", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IBG", "relevance_score": "0.166169", "ticker_sentiment_score": "-0.429391", "ticker_sentiment_label": "Bearish"}, {"ticker": "NIVF", "relevance_score": "0.166169", "ticker_sentiment_score": "-0.196953", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NTBL", "relevance_score": "0.166169", "ticker_sentiment_score": "-0.337027", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DXYZ", "relevance_score": "0.166169", "ticker_sentiment_score": "0.33044", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IVA", "relevance_score": "0.166169", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.166169", "ticker_sentiment_score": "-0.238355", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CERS", "relevance_score": "0.166169", "ticker_sentiment_score": "0.2639", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XPON", "relevance_score": "0.166169", "ticker_sentiment_score": "0.373642", "ticker_sentiment_label": "Bullish"}, {"ticker": "BLND", "relevance_score": "0.166169", "ticker_sentiment_score": "0.414848", "ticker_sentiment_label": "Bullish"}, {"ticker": "BYU", "relevance_score": "0.166169", "ticker_sentiment_score": "-0.44398", "ticker_sentiment_label": "Bearish"}, {"ticker": "SPPL", "relevance_score": "0.246999", "ticker_sentiment_score": "0.118315", "ticker_sentiment_label": "Neutral"}]}, {"title": "S&P 500 Moves Higher; BlackRock Reports Upbeat Results - BlackRock  ( NYSE:BLK ) ", "url": "https://www.benzinga.com/news/earnings/24/10/41297524/s-p-500-moves-higher-blackrock-reports-upbeat-results", "time_published": "20241011T185856", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 350 points on Friday. The Dow traded up 0.86% to 42,820.94 while the NASDAQ rose 0.35% to 18,346.63. The S&P 500 also rose, gaining, 0.58% to 5,813.55. Financials shares jumped by 1.9% on Friday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/11/Wall-Street--US-stocks.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.77141"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.185402, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CDT", "relevance_score": "0.142989", "ticker_sentiment_score": "0.280885", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.142989", "ticker_sentiment_score": "0.128408", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.071784", "ticker_sentiment_score": "0.229007", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.071784", "ticker_sentiment_score": "-0.060034", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.142989", "ticker_sentiment_score": "0.109147", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWG", "relevance_score": "0.142989", "ticker_sentiment_score": "0.198174", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BKR", "relevance_score": "0.071784", "ticker_sentiment_score": "0.212791", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Gold Gains 1%; Wells Fargo Shares Gain After Q3 Earnings - Wells Fargo  ( NYSE:WFC ) ", "url": "https://www.benzinga.com/news/earnings/24/10/41295662/gold-gains-1-wells-fargo-shares-gain-after-q3-earnings", "time_published": "20241011T164911", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 250 points on Friday. The Dow traded up 0.63% to 42,722.78 while the NASDAQ rose 0.14% to 18,306.94. The S&P 500 also rose, gaining, 0.39% to 5,802.82. Financials shares jumped by 2% on Friday.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Real Estate & Construction", "relevance_score": "0.25"}], "overall_sentiment_score": 0.182722, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CDT", "relevance_score": "0.147818", "ticker_sentiment_score": "0.286046", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.147818", "ticker_sentiment_score": "0.130876", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.07423", "ticker_sentiment_score": "0.229708", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DSSMY", "relevance_score": "0.07423", "ticker_sentiment_score": "-0.060291", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.147818", "ticker_sentiment_score": "0.111373", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWG", "relevance_score": "0.147818", "ticker_sentiment_score": "0.20207", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WFC", "relevance_score": "0.147818", "ticker_sentiment_score": "0.426315", "ticker_sentiment_label": "Bullish"}]}, {"title": "Fastenal Posts Upbeat Earnings, Joins Wells Fargo, JPMorgan And Other Big Stocks Moving Higher On Friday - Fastenal  ( NASDAQ:FAST ) ", "url": "https://www.benzinga.com/news/24/10/41292429/fastenal-posts-upbeat-earnings-joins-wells-fargo-jpmorgan-and-other-big-stocks-moving-higher-on-frid", "time_published": "20241011T142837", "authors": ["Avi Kapoor"], "summary": "U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Friday. Shares of Fastenal Company FAST rose sharply during Friday's session after the company reported better-than-expected third-quarter financial results.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/10/11/xrdDAFf-XLMTok2-j45108184879-t23041309.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.301965, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSTR", "relevance_score": "0.19661", "ticker_sentiment_score": "0.502414", "ticker_sentiment_label": "Bullish"}, {"ticker": "SYM", "relevance_score": "0.19661", "ticker_sentiment_score": "0.502414", "ticker_sentiment_label": "Bullish"}, {"ticker": "CURV", "relevance_score": "0.19661", "ticker_sentiment_score": "0.401451", "ticker_sentiment_label": "Bullish"}, {"ticker": "APPS", "relevance_score": "0.19661", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DJT", "relevance_score": "0.19661", "ticker_sentiment_score": "0.338343", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AEHR", "relevance_score": "0.19661", "ticker_sentiment_score": "0.335429", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MESO", "relevance_score": "0.19661", "ticker_sentiment_score": "0.129632", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.19661", "ticker_sentiment_score": "0.036912", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.19661", "ticker_sentiment_score": "-0.053409", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.19661", "ticker_sentiment_score": "0.375876", "ticker_sentiment_label": "Bullish"}, {"ticker": "NUVB", "relevance_score": "0.19661", "ticker_sentiment_score": "0.502414", "ticker_sentiment_label": "Bullish"}, {"ticker": "WOLF", "relevance_score": "0.19661", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FAST", "relevance_score": "0.381463", "ticker_sentiment_score": "0.340785", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UBER", "relevance_score": "0.19661", "ticker_sentiment_score": "0.038561", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAPR", "relevance_score": "0.19661", "ticker_sentiment_score": "0.07007", "ticker_sentiment_label": "Neutral"}]}, {"title": "OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies", "url": "https://www.zacks.com/stock/news/2349214/opk-gets-additional-barda-funding-to-develop-multispecific-antibodies", "time_published": "20241011T131800", "authors": ["Zacks Equity Research"], "summary": "OPKO Health's receipt of the additional funding from BARDA is expected to explore the MSTAR platform to prepare for outbreaks and respond rapidly to emerging viral threats.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.13595, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QGEN", "relevance_score": "0.245835", "ticker_sentiment_score": "0.047249", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPK", "relevance_score": "0.38366", "ticker_sentiment_score": "0.194061", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.149038", "ticker_sentiment_score": "-0.014041", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.245835", "ticker_sentiment_score": "0.105509", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024", "url": "https://www.globenewswire.com/news-release/2024/10/10/2961672/16261/en/PacBio-to-Report-Third-Quarter-2024-Financial-Results-on-November-7-2024.html", "time_published": "20241010T200500", "authors": ["Inc.", "Pacific Biosciences of California"], "summary": "MENLO PARK, Calif., Oct. 10, 2024 ( GLOBE NEWSWIRE ) -- PacBio ( NASDAQ: PACB ) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thursday, November 7, 2024, at 4:30 pm Eastern Time.", "banner_image": "https://ml.globenewswire.com/Resource/Download/f408d681-e68c-4113-a7cd-be24486deefc", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.242392, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.462395", "ticker_sentiment_score": "0.282116", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024 - Pacific Biosciences  ( NASDAQ:PACB ) ", "url": "https://www.benzinga.com/pressreleases/24/10/g41280792/pacbio-to-report-third-quarter-2024-financial-results-on-november-7-2024", "time_published": "20241010T200500", "authors": ["Globe Newswire"], "summary": "MENLO PARK, Calif., Oct. 10, 2024 ( GLOBE NEWSWIRE ) -- PacBio PACB announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thursday, November 7, 2024, at 4:30 pm Eastern Time.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.280748, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.407844", "ticker_sentiment_score": "0.257594", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Increasing Advancement in Sequencing Technologies to Drive DNA Sequencing Market Growth at USD 44 Billion by 2031 |SkyQuest Technology", "url": "https://www.benzinga.com/pressreleases/24/10/g41163587/increasing-advancement-in-sequencing-technologies-to-drive-dna-sequencing-market-growth-at-usd-44-", "time_published": "20241003T130000", "authors": ["Globe Newswire"], "summary": "Westford, USA, Oct. 03, 2024 ( GLOBE NEWSWIRE ) -- Global DNA Sequencing Market size was valued at USD 12.29 billion in 2023 to USD 44 billion by 2031, growing at a CAGR of 17.12% in the forecast period ( 2024-2031 ) . Advanced technology and bioinformatics have allowed to detect ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.288112, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.037622", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIO", "relevance_score": "0.037622", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTTF", "relevance_score": "0.037622", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.037622", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ERFSF", "relevance_score": "0.037622", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.037622", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Advances While Market Declines: Some Information for Investors", "url": "https://www.zacks.com/stock/news/2343015/pacific-biosciences-of-california-pacb-advances-while-market-declines-some-information-for-investors", "time_published": "20240927T221523", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences of California (PACB) closed at $1.75 in the latest trading session, marking a +0.57% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default257.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.858979"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.142511, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.469744", "ticker_sentiment_score": "0.168851", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cathie Wood's Ark Invest Buys $4.5M Of PayPal And $3.5M Of Pinterest Shares, Sells Own Bitcoin ETF Amid Crypto Surge, And Continues Offloading Palantir - PayPal Holdings  ( NASDAQ:PYPL ) , ARK 21Shares Bitcoin ETF Common Shares of Beneficial Interests  ( BATS:ARKB ) , Pinterest  ( NYSE:PINS ) , Palantir Technologies  ( NYSE:PLTR ) ", "url": "https://www.benzinga.com/markets/equities/24/09/40994536/cathie-woods-ark-invest-buys-4-5m-of-paypal-and-3-5m-of-pinterest-shares-sells-own-bitcoin-etf-a", "time_published": "20240924T033707", "authors": ["Benzinga Neuro"], "summary": "On Monday, Cathie Wood-led Ark Invest made some significant trades. Notably, the firm bought shares of PayPal Holdings Inc PYPL and Pinterest Inc PINS, while selling its stake in ARK 21Shares Bitcoin ETF ARKB.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/23/Ark-Invest-acquista-azioni-Alphabet-e-Ro.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.795202"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Blockchain", "relevance_score": "0.310843"}], "overall_sentiment_score": 0.363641, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PYPL", "relevance_score": "0.354319", "ticker_sentiment_score": "0.364587", "ticker_sentiment_label": "Bullish"}, {"ticker": "ROKU", "relevance_score": "0.181819", "ticker_sentiment_score": "0.40582", "ticker_sentiment_label": "Bullish"}, {"ticker": "DDD", "relevance_score": "0.181819", "ticker_sentiment_score": "0.40582", "ticker_sentiment_label": "Bullish"}, {"ticker": "PACB", "relevance_score": "0.181819", "ticker_sentiment_score": "0.413869", "ticker_sentiment_label": "Bullish"}, {"ticker": "ADYYF", "relevance_score": "0.181819", "ticker_sentiment_score": "0.413869", "ticker_sentiment_label": "Bullish"}, {"ticker": "VRTX", "relevance_score": "0.181819", "ticker_sentiment_score": "0.413869", "ticker_sentiment_label": "Bullish"}, {"ticker": "PINS", "relevance_score": "0.354319", "ticker_sentiment_score": "0.263288", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PLTR", "relevance_score": "0.181819", "ticker_sentiment_score": "0.450954", "ticker_sentiment_label": "Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.434514", "ticker_sentiment_score": "0.338504", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Surpasses Market Returns: Some Facts Worth Knowing", "url": "https://www.zacks.com/stock/news/2336175/pacific-biosciences-of-california-pacb-surpasses-market-returns-some-facts-worth-knowing", "time_published": "20240913T221508", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences of California (PACB) closed at $1.81 in the latest trading session, marking a +0.56% move from the prior day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default144.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.243285, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.462953", "ticker_sentiment_score": "0.282595", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio Stock Drops After Singapore Collaboration for HiFi Sequencing", "url": "https://www.zacks.com/stock/news/2335336/pacbio-stock-drops-after-singapore-collaboration-for-hifi-sequencing", "time_published": "20240912T150300", "authors": ["Zacks Equity Research"], "summary": "PACB's HiFi sequencing powers the HiFi Consortium's global effort to enhance the diagnosis and treatment of subfertility and recurrent pregnancy loss.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c3/981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.322022, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UHS", "relevance_score": "0.323078", "ticker_sentiment_score": "0.218492", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVAH", "relevance_score": "0.165031", "ticker_sentiment_score": "0.057756", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.271576", "ticker_sentiment_score": "0.213991", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.165031", "ticker_sentiment_score": "0.166815", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Reasons to Retain PacBio  ( PACB )  Stock in Your Portfolio Now", "url": "https://www.zacks.com/stock/news/2334832/reasons-to-retain-pacbio-pacb-stock-in-your-portfolio-now", "time_published": "20240911T163800", "authors": ["Zacks Equity Research"], "summary": "PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.245548, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ABM", "relevance_score": "0.150122", "ticker_sentiment_score": "0.072178", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.187027", "ticker_sentiment_score": "0.155875", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.187027", "ticker_sentiment_score": "0.117458", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio's Stock Up on Munster Deal for Male Infertility Research", "url": "https://www.zacks.com/stock/news/2334729/pacbios-stock-up-on-munster-deal-for-male-infertility-research", "time_published": "20240911T152600", "authors": ["Zacks Equity Research"], "summary": "PACB collaborates with the University Hospital of Munster, using Revio HiFi sequencing to advance research on male infertility and rare diseases in Germany and globally.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c3/981.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.222749, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UHS", "relevance_score": "0.330286", "ticker_sentiment_score": "0.222187", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVAH", "relevance_score": "0.168884", "ticker_sentiment_score": "0.058662", "ticker_sentiment_label": "Neutral"}, {"ticker": "DGX", "relevance_score": "0.277748", "ticker_sentiment_score": "0.217814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.168884", "ticker_sentiment_score": "0.140987", "ticker_sentiment_label": "Neutral"}]}, {"title": "Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday - Quanex Building Prods  ( NYSE:NX ) ", "url": "https://www.benzinga.com/news/24/09/40750443/quanex-building-products-posts-better-than-expected-results-joins-zumiez-guidewire-software-smartshe", "time_published": "20240906T141139", "authors": ["Avi Kapoor"], "summary": "U.S. stocks were mixed, with the Nasdaq Composite falling around 150 points on Friday. Shares of Quanex Building Products Corporation NX rose sharply during Friday's session after the company reported better-than-expected third-quarter financial results and issued FY24 guidance above estimates.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/09/06/Dollaro-in-calo-e-azioni-in-rialzo-anali.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.990786"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.387978, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "TVTX", "relevance_score": "0.188193", "ticker_sentiment_score": "0.004745", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGX", "relevance_score": "0.188193", "ticker_sentiment_score": "0.506155", "ticker_sentiment_label": "Bullish"}, {"ticker": "BRC", "relevance_score": "0.188193", "ticker_sentiment_score": "0.390066", "ticker_sentiment_label": "Bullish"}, {"ticker": "GWRE", "relevance_score": "0.188193", "ticker_sentiment_score": "0.377581", "ticker_sentiment_label": "Bullish"}, {"ticker": "ZUMZ", "relevance_score": "0.188193", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NIO", "relevance_score": "0.188193", "ticker_sentiment_score": "0.158033", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.188193", "ticker_sentiment_score": "0.489393", "ticker_sentiment_label": "Bullish"}, {"ticker": "NX", "relevance_score": "0.279015", "ticker_sentiment_score": "0.437033", "ticker_sentiment_label": "Bullish"}, {"ticker": "PSNY", "relevance_score": "0.188193", "ticker_sentiment_score": "0.489393", "ticker_sentiment_label": "Bullish"}, {"ticker": "BOWL", "relevance_score": "0.188193", "ticker_sentiment_score": "0.350979", "ticker_sentiment_label": "Bullish"}, {"ticker": "SMAR", "relevance_score": "0.188193", "ticker_sentiment_score": "0.268008", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IOT", "relevance_score": "0.188193", "ticker_sentiment_score": "0.499734", "ticker_sentiment_label": "Bullish"}]}, {"title": "Applied Materials, Amcor, RLX Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Applied Mat  ( NASDAQ:AMAT ) ", "url": "https://www.benzinga.com/news/24/08/40415606/applied-materials-amcor-rlx-technology-and-other-big-stocks-moving-lower-in-fridays-pre-market-sessi", "time_published": "20240816T123029", "authors": ["Avi Kapoor"], "summary": "U.S. stock futures were mixed this morning, with the S&P 500 futures falling around 0.1% on Friday. Shares of Applied Materials, Inc. AMAT declined in today's pre-market trading following third-quarter results. Applied Materials reported third-quarter revenue of $6.78 billion, beating the ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/08/16/wall-street-ai17.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.99977"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.875462"}], "overall_sentiment_score": -0.027173, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMAT", "relevance_score": "0.582526", "ticker_sentiment_score": "0.039228", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTE", "relevance_score": "0.254307", "ticker_sentiment_score": "-0.125007", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMCR", "relevance_score": "0.254307", "ticker_sentiment_score": "-0.389345", "ticker_sentiment_label": "Bearish"}, {"ticker": "PACB", "relevance_score": "0.254307", "ticker_sentiment_score": "-0.344826", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LUMN", "relevance_score": "0.254307", "ticker_sentiment_score": "-0.125007", "ticker_sentiment_label": "Neutral"}, {"ticker": "UBXG", "relevance_score": "0.254307", "ticker_sentiment_score": "-0.089076", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNDA", "relevance_score": "0.373378", "ticker_sentiment_score": "0.379129", "ticker_sentiment_label": "Bullish"}, {"ticker": "RLX", "relevance_score": "0.254307", "ticker_sentiment_score": "-0.380148", "ticker_sentiment_label": "Bearish"}]}, {"title": "Next Generation Sequencing  ( NGS )  Market Surges to USD 39.15 Billion by 2031, Propelled by 20.39% CAGR - Verified Market Research\u00ae", "url": "https://www.benzinga.com/pressreleases/24/08/g40340435/next-generation-sequencing-ngs-market-surges-to-usd-39-15-billion-by-2031-propelled-by-20-39-cagr-", "time_published": "20240813T141500", "authors": ["Globe Newswire"], "summary": "Lewes, Delaware, Aug. 13, 2024 ( GLOBE NEWSWIRE ) -- The Global Next Generation Sequencing ( NGS ) Market Size is projected to grow at a CAGR of 20.39% from 2024 to 2031, according to a new report published by Verified Market Research\u00ae.", "banner_image": "https://ml.globenewswire.com/Resource/Download/f1c754ac-5f62-41c8-9ee6-ef8576e71b19/next-generation-sequencing-ngs-market-size-and-forecast-1024x576.jpg", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.259399, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.029113", "ticker_sentiment_score": "0.094696", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.029113", "ticker_sentiment_score": "0.094696", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.029113", "ticker_sentiment_score": "0.094696", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.058188", "ticker_sentiment_score": "0.071973", "ticker_sentiment_label": "Neutral"}, {"ticker": "RSSS", "relevance_score": "0.029113", "ticker_sentiment_score": "0.168928", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.029113", "ticker_sentiment_score": "0.094696", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIO", "relevance_score": "0.029113", "ticker_sentiment_score": "0.094696", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTTF", "relevance_score": "0.029113", "ticker_sentiment_score": "0.094696", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.029113", "ticker_sentiment_score": "0.094696", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences  ( PACB )  Upgraded to Buy: Here's Why", "url": "https://www.zacks.com/stock/news/2320839/pacific-biosciences-pacb-upgraded-to-buy-heres-why", "time_published": "20240812T160011", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default313.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997845"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}], "overall_sentiment_score": 0.3117, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.124486", "ticker_sentiment_score": "0.196289", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio  ( PACB )  Q2 Earnings Beat Estimates, Revenues Down Y/Y", "url": "https://www.zacks.com/stock/news/2319440/pacbio-pacb-q2-earnings-beat-estimates-revenues-down-yy", "time_published": "20240808T160900", "authors": ["Zacks Equity Research"], "summary": "PacBio's (PACB) Product revenues decline in the second quarter of 2024. However, Consumable and Service and other revenues increase year over year.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/80/66138.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998663"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": -0.068932, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "UHS", "relevance_score": "0.208644", "ticker_sentiment_score": "0.078155", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.167612", "ticker_sentiment_score": "0.066536", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.208644", "ticker_sentiment_score": "0.053758", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.167612", "ticker_sentiment_score": "0.088361", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Reports Q2 Loss, Lags Revenue Estimates", "url": "https://www.zacks.com/stock/news/2318585/pacific-biosciences-of-california-pacb-reports-q2-loss-lags-revenue-estimates", "time_published": "20240807T231507", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences (PACB) delivered earnings and revenue surprises of 16.67% and 11.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default9.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.082277, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.137671", "ticker_sentiment_score": "-0.063683", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reasons to Retain PacBio Stock in Your Portfolio Now - Boston Scientific  ( NYSE:BSX ) , Ecolab  ( NYSE:ECL ) ", "url": "https://www.benzinga.com/general/biotech/24/08/40225743/reasons-to-retain-pacbio-stock-in-your-portfolio-now", "time_published": "20240807T184059", "authors": ["Zacks"], "summary": "Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued focus on research and development. The optimism, led by a decent first-quarter 2024 performance and its product development activities, is expected to contribute further.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/charts/3c/73621.jpg?v=785374302", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.26187, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UHS", "relevance_score": "0.162528", "ticker_sentiment_score": "0.169588", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.241684", "ticker_sentiment_score": "0.286149", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.122269", "ticker_sentiment_score": "0.091209", "ticker_sentiment_label": "Neutral"}, {"ticker": "ECL", "relevance_score": "0.122269", "ticker_sentiment_score": "0.094649", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reasons to Retain PacBio  ( PACB )  Stock in Your Portfolio Now", "url": "https://www.zacks.com/stock/news/2318205/reasons-to-retain-pacbio-pacb-stock-in-your-portfolio-now", "time_published": "20240807T142400", "authors": ["Zacks Equity Research"], "summary": "PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.248172, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UHS", "relevance_score": "0.164188", "ticker_sentiment_score": "0.119489", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.244109", "ticker_sentiment_score": "0.279243", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.123526", "ticker_sentiment_score": "0.075514", "ticker_sentiment_label": "Neutral"}, {"ticker": "ECL", "relevance_score": "0.123526", "ticker_sentiment_score": "0.076664", "ticker_sentiment_label": "Neutral"}]}, {"title": "IRadimed  ( IRMD )  Surpasses Q2 Earnings and Revenue Estimates", "url": "https://www.zacks.com/stock/news/2314244/iradimed-irmd-surpasses-q2-earnings-and-revenue-estimates", "time_published": "20240801T135004", "authors": ["Zacks Equity Research"], "summary": "iRadimed (IRMD) delivered earnings and revenue surprises of 16.67% and 1.29%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default199.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.141498, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.136888", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IRMD", "relevance_score": "0.395012", "ticker_sentiment_score": "0.144242", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Flat As Market Sinks: What You Should Know", "url": "https://www.zacks.com/stock/news/2312491/pacific-biosciences-of-california-pacb-flat-as-market-sinks-what-you-should-know", "time_published": "20240730T221516", "authors": ["Zacks Equity Research"], "summary": "The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.05, representing no change from its previous close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default321.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.165859, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.459624", "ticker_sentiment_score": "0.146878", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Ascends While Market Falls: Some Facts to Note", "url": "https://www.zacks.com/stock/news/2308388/pacific-biosciences-of-california-pacb-ascends-while-market-falls-some-facts-to-note", "time_published": "20240724T221520", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences of California (PACB) concluded the recent trading session at $1.88, signifying a +1.62% move from its prior day's close.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default286.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.186276, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.543004", "ticker_sentiment_score": "0.194355", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio's  ( PACB )  Revio System to Boost Novogene's German Lab", "url": "https://www.zacks.com/stock/news/2308021/pacbios-pacb-revio-system-to-boost-novogenes-german-lab", "time_published": "20240724T135600", "authors": ["Zacks Equity Research"], "summary": "PacBio (PACB) announces that Novogene is set to use PACB's Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.227465, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UHS", "relevance_score": "0.202028", "ticker_sentiment_score": "0.091825", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.122062", "ticker_sentiment_score": "0.075119", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.202028", "ticker_sentiment_score": "0.169731", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.162255", "ticker_sentiment_score": "0.107863", "ticker_sentiment_label": "Neutral"}]}, {"title": "Next Generation Sequencing Market to Witness 18.5% CAGR by 2031 | SkyQuest Technology", "url": "https://www.benzinga.com/pressreleases/24/07/g39930416/next-generation-sequencing-market-to-witness-18-5-cagr-by-2031-skyquest-technology", "time_published": "20240724T123000", "authors": ["Globe Newswire"], "summary": "Westford,USA, July 24, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that Next Generation Sequencing Market will attain a value of USD 36.04 billion by 2031, with a CAGR of 18.5% during the forecast period ( 2024-2031 ) .", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "Mergers", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.202164, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ONTTF", "relevance_score": "0.096671", "ticker_sentiment_score": "0.042001", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.048425", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.048425", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.048425", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ERFSF", "relevance_score": "0.048425", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.048425", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Genomics Market Projected to Surpass USD 411.35 Billion by 2031, Witnessing 19.4% CAGR Growth", "url": "https://www.benzinga.com/pressreleases/24/07/g39813983/genomics-market-projected-to-surpass-usd-411-35-billion-by-2031-witnessing-19-4-cagr-growth", "time_published": "20240717T123000", "authors": ["Globe Newswire"], "summary": "Westford, USA, July 17, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the global Genomics Market will attain a value of USD 411.35 billion by 2031, with a CAGR of 19.4% during the forecast period ( 2024-2031 ) . Genomics has been scientifically proven in the prevention, management and ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.282161, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "VCYT", "relevance_score": "0.042953", "ticker_sentiment_score": "0.046717", "ticker_sentiment_label": "Neutral"}, {"ticker": "A", "relevance_score": "0.042953", "ticker_sentiment_score": "0.046717", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.042953", "ticker_sentiment_score": "0.046717", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWST", "relevance_score": "0.042953", "ticker_sentiment_score": "0.046717", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSNL", "relevance_score": "0.042953", "ticker_sentiment_score": "0.046717", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.042953", "ticker_sentiment_score": "0.181222", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BIO", "relevance_score": "0.042953", "ticker_sentiment_score": "0.046717", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.042953", "ticker_sentiment_score": "0.046717", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTRA", "relevance_score": "0.042953", "ticker_sentiment_score": "0.046717", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.042953", "ticker_sentiment_score": "0.046717", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYGN", "relevance_score": "0.042953", "ticker_sentiment_score": "0.046717", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTTF", "relevance_score": "0.042953", "ticker_sentiment_score": "0.046717", "ticker_sentiment_label": "Neutral"}, {"ticker": "ERFSF", "relevance_score": "0.042953", "ticker_sentiment_score": "0.046717", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Rallies To All-Time Highs, Small Caps Outperform Tech, Gold Hits Records On Heightened September Rate Cut Bets: What's Driving Markets Tuesday?", "url": "https://markets.businessinsider.com/news/stocks/dow-rallies-to-all-time-highs-small-caps-outperform-tech-gold-hits-records-on-heightened-september-rate-cut-bets-what-s-driving-markets-tuesday-1033560528", "time_published": "20240716T175811", "authors": ["Piero Cingari"], "summary": "Wall Street continues to experience a series of memorable days, with the bulls riding the rally with increasing confidence, certain that the Federal Reserve will begin cutting interest rates in September.", "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/07/16/Stock-Market-Data---chart-illustration.jpeg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.891286"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.233362, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "STT", "relevance_score": "0.070935", "ticker_sentiment_score": "0.102078", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.14131", "ticker_sentiment_score": "0.12669", "ticker_sentiment_label": "Neutral"}, {"ticker": "PNC", "relevance_score": "0.070935", "ticker_sentiment_score": "0.102078", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.070935", "ticker_sentiment_score": "0.102078", "ticker_sentiment_label": "Neutral"}, {"ticker": "MS", "relevance_score": "0.070935", "ticker_sentiment_score": "0.102078", "ticker_sentiment_label": "Neutral"}, {"ticker": "GRAL", "relevance_score": "0.070935", "ticker_sentiment_score": "0.102078", "ticker_sentiment_label": "Neutral"}, {"ticker": "SCHW", "relevance_score": "0.070935", "ticker_sentiment_score": "0.102078", "ticker_sentiment_label": "Neutral"}, {"ticker": "PGR", "relevance_score": "0.070935", "ticker_sentiment_score": "0.102078", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.070935", "ticker_sentiment_score": "0.102078", "ticker_sentiment_label": "Neutral"}, {"ticker": "BA", "relevance_score": "0.070935", "ticker_sentiment_score": "0.102078", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.14131", "ticker_sentiment_score": "0.12669", "ticker_sentiment_label": "Neutral"}]}, {"title": "Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday - Bank of New York Mellon  ( NYSE:BK ) ", "url": "https://www.benzinga.com/news/24/07/39750475/bank-of-new-york-mellon-posts-upbeat-earnings-joins-archer-aviation-rivian-automotive-and-other-big", "time_published": "20240712T142717", "authors": ["Avi Kapoor"], "summary": "U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday. Shares of The Bank of New York Mellon Corporation BK rose during Friday's session following better-than-expected quarterly financial results.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/12/Stocks-Photo-by-WHYFRAME-on-Shutterstock.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.363494, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "FWRD", "relevance_score": "0.175221", "ticker_sentiment_score": "0.469252", "ticker_sentiment_label": "Bullish"}, {"ticker": "QS", "relevance_score": "0.260189", "ticker_sentiment_score": "0.446038", "ticker_sentiment_label": "Bullish"}, {"ticker": "HIMS", "relevance_score": "0.175221", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ANNX", "relevance_score": "0.175221", "ticker_sentiment_score": "0.469252", "ticker_sentiment_label": "Bullish"}, {"ticker": "BK", "relevance_score": "0.260189", "ticker_sentiment_score": "0.5445", "ticker_sentiment_label": "Bullish"}, {"ticker": "RIVN", "relevance_score": "0.260189", "ticker_sentiment_score": "0.193746", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RXRX", "relevance_score": "0.175221", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LUV", "relevance_score": "0.175221", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCID", "relevance_score": "0.175221", "ticker_sentiment_score": "0.270426", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACHR", "relevance_score": "0.260189", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TYRA", "relevance_score": "0.175221", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.175221", "ticker_sentiment_score": "0.469252", "ticker_sentiment_label": "Bullish"}, {"ticker": "EYPT", "relevance_score": "0.175221", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EVGO", "relevance_score": "0.260189", "ticker_sentiment_score": "0.159827", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AUR", "relevance_score": "0.260189", "ticker_sentiment_score": "0.208735", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTLA", "relevance_score": "0.175221", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday - Methode Electronics  ( NYSE:MEI ) ", "url": "https://www.benzinga.com/news/24/07/39731058/methode-electronics-posts-strong-sales-joins-quantumscape-ribbon-communications-and-other-big-stocks", "time_published": "20240711T141016", "authors": ["Avi Kapoor"], "summary": "U.S. stocks were mostly higher, with the Dow Jones index gaining around 100 points on Thursday. Shares of Methode Electronics, Inc. MEI rose sharply during Thursday's session after the company reported better-than-expected fourth-quarter sales results.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/11/Image-1.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.272256, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MSTR", "relevance_score": "0.172097", "ticker_sentiment_score": "0.017937", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENPH", "relevance_score": "0.172097", "ticker_sentiment_score": "0.361817", "ticker_sentiment_label": "Bullish"}, {"ticker": "QS", "relevance_score": "0.172097", "ticker_sentiment_score": "0.29452", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EMBC", "relevance_score": "0.172097", "ticker_sentiment_score": "0.464411", "ticker_sentiment_label": "Bullish"}, {"ticker": "TERN", "relevance_score": "0.172097", "ticker_sentiment_score": "0.464411", "ticker_sentiment_label": "Bullish"}, {"ticker": "MEI", "relevance_score": "0.33628", "ticker_sentiment_score": "-0.130505", "ticker_sentiment_label": "Neutral"}, {"ticker": "APGE", "relevance_score": "0.172097", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IOVA", "relevance_score": "0.172097", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOUN", "relevance_score": "0.255641", "ticker_sentiment_score": "0.271616", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LNTH", "relevance_score": "0.255641", "ticker_sentiment_score": "0.233421", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.172097", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "U", "relevance_score": "0.172097", "ticker_sentiment_score": "0.259002", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IBP", "relevance_score": "0.172097", "ticker_sentiment_score": "0.464411", "ticker_sentiment_label": "Bullish"}, {"ticker": "POOL", "relevance_score": "0.172097", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "YUMC", "relevance_score": "0.172097", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QTWO", "relevance_score": "0.172097", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JOBY", "relevance_score": "0.255641", "ticker_sentiment_score": "0.183629", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Reasons to Retain PacBio Stock in Your Portfolio Now - Pacific Biosciences  ( NASDAQ:PACB ) ", "url": "https://www.benzinga.com/general/biotech/24/07/39602471/reasons-to-retain-pacbio-stock-in-your-portfolio-now", "time_published": "20240702T192228", "authors": ["Zacks"], "summary": "Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued focus on research and development. The optimism led by a decent first-quarter 2024 performance and its product development activities are expected to contribute further.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/07/02/national-cancer-institute-v7ibb19eubq-unsplash.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.976671"}], "overall_sentiment_score": 0.250434, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UHS", "relevance_score": "0.162255", "ticker_sentiment_score": "0.099839", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.162255", "ticker_sentiment_score": "0.222983", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.081552", "ticker_sentiment_score": "0.084562", "ticker_sentiment_label": "Neutral"}, {"ticker": "ECL", "relevance_score": "0.081552", "ticker_sentiment_score": "0.089672", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reasons to Retain PacBio  ( PACB )  Stock in Your Portfolio Now", "url": "https://www.zacks.com/stock/news/2296273/reasons-to-retain-pacbio-pacb-stock-in-your-portfolio-now", "time_published": "20240702T155600", "authors": ["Zacks Equity Research"], "summary": "PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/34/973.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.976671"}], "overall_sentiment_score": 0.238946, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UHS", "relevance_score": "0.124593", "ticker_sentiment_score": "0.087605", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.165598", "ticker_sentiment_score": "0.220284", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.083251", "ticker_sentiment_score": "0.077199", "ticker_sentiment_label": "Neutral"}, {"ticker": "ECL", "relevance_score": "0.083251", "ticker_sentiment_score": "0.077199", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio  ( PACB )  and Form Bio to Boost AAV Industry Development", "url": "https://www.zacks.com/stock/news/2295819/pacbio-pacb-and-form-bio-to-boost-aav-industry-development", "time_published": "20240701T142600", "authors": ["Zacks Equity Research"], "summary": "PacBio (PACB) and Form Bio collaborate to form an expert AAV Working Group to introduce essential tools for AAV development and research professionals.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/604.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.229611, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UHS", "relevance_score": "0.235823", "ticker_sentiment_score": "0.105537", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.142847", "ticker_sentiment_score": "0.039319", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.142847", "ticker_sentiment_score": "0.104775", "ticker_sentiment_label": "Neutral"}, {"ticker": "ECL", "relevance_score": "0.142847", "ticker_sentiment_score": "0.082487", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Advances While Market Declines: Some Information for Investors", "url": "https://www.zacks.com/stock/news/2295299/pacific-biosciences-of-california-pacb-advances-while-market-declines-some-information-for-investors", "time_published": "20240628T221521", "authors": ["Zacks Equity Research"], "summary": "In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.37, indicating a +0.74% shift from the previous trading day.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default327.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.167797, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.448316", "ticker_sentiment_score": "0.211346", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pacific Biosciences of California  ( NASDAQ:PACB )  Upgraded to \"Sell\" at StockNews.com", "url": "https://www.defenseworld.net/2024/06/27/pacific-biosciences-of-california-nasdaqpacb-upgraded-to-sell-at-stocknews-com.html", "time_published": "20240627T100701", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of Pacific Biosciences of California ( NASDAQ:PACB - Free Report ) to a sell rating in a research report sent to investors on Wednesday. A number of other brokerages have also weighed in on PACB. Sanford C.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pacific-biosciences-of-california-inc-logo.png?v=20221123085851&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.692272"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.938238"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.266143, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "JEF", "relevance_score": "0.05387", "ticker_sentiment_score": "0.04096", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.05387", "ticker_sentiment_score": "0.04096", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENVX", "relevance_score": "0.05387", "ticker_sentiment_score": "0.083", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.844077", "ticker_sentiment_score": "0.439399", "ticker_sentiment_label": "Bullish"}, {"ticker": "MS", "relevance_score": "0.05387", "ticker_sentiment_score": "0.04096", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Stock Sinks As Market Gains: What You Should Know", "url": "https://www.zacks.com/stock/news/2290145/pacific-biosciences-of-california-pacb-stock-sinks-as-market-gains-what-you-should-know", "time_published": "20240618T221518", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences of California (PACB) closed the most recent trading day at $1.65, moving -1.5% from the previous trading session.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.194868, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.451494", "ticker_sentiment_score": "0.292977", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "DNA Sequencing Market size is set to grow by USD 17.34 billion from 2024-2028, Growing adoption of ngs to boost the ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/dna-sequencing-market-size-is-set-to-grow-by-usd-17-34-billion-from-2024-2028--growing-adoption-of-ngs-to-boost-the-market-growth-technavio-302165939.html", "time_published": "20240607T180000", "authors": [], "summary": "DNA Sequencing Market size is set to grow by USD 17.34 billion from 2024-2028, Growing adoption of ngs to boost the ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.2875, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.028833", "ticker_sentiment_score": "0.02218", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.028833", "ticker_sentiment_score": "0.02218", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.028833", "ticker_sentiment_score": "0.02218", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIO", "relevance_score": "0.028833", "ticker_sentiment_score": "0.02218", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.028833", "ticker_sentiment_score": "0.02218", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABT", "relevance_score": "0.028833", "ticker_sentiment_score": "0.02218", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.028833", "ticker_sentiment_score": "0.02218", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.028833", "ticker_sentiment_score": "0.02218", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.028833", "ticker_sentiment_score": "0.02218", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZTA", "relevance_score": "0.028833", "ticker_sentiment_score": "0.02218", "ticker_sentiment_label": "Neutral"}, {"ticker": "OUSZF", "relevance_score": "0.028833", "ticker_sentiment_score": "-0.027248", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.028833", "ticker_sentiment_score": "0.02218", "ticker_sentiment_label": "Neutral"}, {"ticker": "ERFSF", "relevance_score": "0.028833", "ticker_sentiment_score": "0.02218", "ticker_sentiment_label": "Neutral"}]}, {"title": "Reasons to Retain PacBio  ( PACB )  Stock in Your Portfolio", "url": "https://www.zacks.com/stock/news/2280860/reasons-to-retain-pacbio-pacb-stock-in-your-portfolio", "time_published": "20240529T170000", "authors": ["Zacks Equity Research"], "summary": "PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e0/1871.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.988787"}], "overall_sentiment_score": 0.212779, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALGN", "relevance_score": "0.165314", "ticker_sentiment_score": "0.049727", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.245752", "ticker_sentiment_score": "0.287507", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.165314", "ticker_sentiment_score": "0.024669", "ticker_sentiment_label": "Neutral"}, {"ticker": "ECL", "relevance_score": "0.124378", "ticker_sentiment_score": "0.075746", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Cathie Wood Thinks Stock Fears Are At 'Depression' Levels", "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-why-cathie-wood-thinks-stock-fears-are-at-depression-levels/", "time_published": "20240527T120000", "authors": ["MATT KRANTZ", "Investor's Business Daily"], "summary": "Why does Cathie Wood think investors' fear about stocks is at \"Great Depression\" levels? Because it is for her portfolio, unlike with the S&P 500. ARK Innovation ETF ( ARKK ) , Wood's flagship ETF, is down 16.73% this year, says an Investor's Business Daily analysis of data from Morningstar ...", "banner_image": "https://www.investors.com/wp-content/uploads/2021/11/Stock-CathieWoods-company.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.967645"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Blockchain", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.012422, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.160099", "ticker_sentiment_score": "-0.086295", "ticker_sentiment_label": "Neutral"}, {"ticker": "MORN", "relevance_score": "0.080458", "ticker_sentiment_score": "0.200071", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.160099", "ticker_sentiment_score": "0.051106", "ticker_sentiment_label": "Neutral"}]}, {"title": "Epigenetics Market size is set to grow by USD 1.47 billion from 2024-2028, Rising epigenetic applications in non ... - PR Newswire", "url": "https://www.prnewswire.com/news-releases/epigenetics-market-size-is-set-to-grow-by-usd-1-47-billion-from-2024-2028--rising-epigenetic-applications-in-non-oncology-diseases-to-boost-the-market-growth-technavio-302154241.html", "time_published": "20240524T180000", "authors": [], "summary": "Epigenetics Market size is set to grow by USD 1.47 billion from 2024-2028, Rising epigenetic applications in non ... PR ...", "banner_image": null, "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.090556, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.038162", "ticker_sentiment_score": "0.057527", "ticker_sentiment_label": "Neutral"}, {"ticker": "TECH", "relevance_score": "0.038162", "ticker_sentiment_score": "0.057527", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.038162", "ticker_sentiment_score": "0.057527", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.038162", "ticker_sentiment_score": "0.057527", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.038162", "ticker_sentiment_score": "0.057527", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIO", "relevance_score": "0.038162", "ticker_sentiment_score": "0.057527", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVS", "relevance_score": "0.038162", "ticker_sentiment_score": "0.057527", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.038162", "ticker_sentiment_score": "0.057527", "ticker_sentiment_label": "Neutral"}, {"ticker": "ERFSF", "relevance_score": "0.038162", "ticker_sentiment_score": "0.057527", "ticker_sentiment_label": "Neutral"}, {"ticker": "ESALF", "relevance_score": "0.038162", "ticker_sentiment_score": "0.057527", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California, Inc.  ( PACB )  Is a Trending Stock: Facts to Know Before Betting on It", "url": "https://www.zacks.com/stock/news/2277775/pacific-biosciences-of-california-inc-pacb-is-a-trending-stock-facts-to-know-before-betting-on-it", "time_published": "20240523T130011", "authors": ["Zacks Equity Research"], "summary": "Zacks.com users have recently been watching Pacific Biosciences (PACB) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default328.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.232911, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.100308", "ticker_sentiment_score": "0.036031", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( NASDAQ:PACB )  Upgraded to Sell at StockNews.com", "url": "https://www.defenseworld.net/2024/05/15/pacific-biosciences-of-california-nasdaqpacb-upgraded-to-sell-at-stocknews-com.html", "time_published": "20240515T092644", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of Pacific Biosciences of California ( NASDAQ:PACB - Free Report ) to a sell rating in a research note issued to investors on Tuesday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pacific-biosciences-of-california-inc-logo.png?v=20221123085851&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.839681"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.365926"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.25377, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.047278", "ticker_sentiment_score": "0.080666", "ticker_sentiment_label": "Neutral"}, {"ticker": "JACK", "relevance_score": "0.047278", "ticker_sentiment_score": "0.080666", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.807885", "ticker_sentiment_score": "0.41552", "ticker_sentiment_label": "Bullish"}, {"ticker": "BNS", "relevance_score": "0.047278", "ticker_sentiment_score": "0.066372", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday - Sony Group  ( NYSE:SONY ) ", "url": "https://www.benzinga.com/news/24/05/38819873/sony-group-posts-upbeat-earnings-joins-gamestop-paysafe-and-other-big-stocks-moving-higher-on-tuesda", "time_published": "20240514T150134", "authors": ["Avi Kapoor"], "summary": "U.S. stocks were higher, with the Dow Jones gaining around 20 points on Tuesday. Shares of Sony Group Corporation SONY rose sharply during Tuesday's session after the company reported better-than-expected quarterly financial results.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/14/Image47.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.360816, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "BB", "relevance_score": "0.118647", "ticker_sentiment_score": "-0.082136", "ticker_sentiment_label": "Neutral"}, {"ticker": "BE", "relevance_score": "0.059488", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FCEL", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOVA", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTZ", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BYND", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HROW", "relevance_score": "0.118647", "ticker_sentiment_score": "0.153595", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMC", "relevance_score": "0.118647", "ticker_sentiment_score": "0.188872", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SPCE", "relevance_score": "0.118647", "ticker_sentiment_score": "0.377305", "ticker_sentiment_label": "Bullish"}, {"ticker": "AGYS", "relevance_score": "0.118647", "ticker_sentiment_score": "0.266306", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GME", "relevance_score": "0.118647", "ticker_sentiment_score": "0.071964", "ticker_sentiment_label": "Neutral"}, {"ticker": "RENT", "relevance_score": "0.118647", "ticker_sentiment_score": "0.487398", "ticker_sentiment_label": "Bullish"}, {"ticker": "HKD", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIG", "relevance_score": "0.118647", "ticker_sentiment_score": "0.303814", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JBLU", "relevance_score": "0.118647", "ticker_sentiment_score": "0.387421", "ticker_sentiment_label": "Bullish"}, {"ticker": "MP", "relevance_score": "0.17715", "ticker_sentiment_score": "0.162702", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PSFE", "relevance_score": "0.118647", "ticker_sentiment_score": "0.362663", "ticker_sentiment_label": "Bullish"}, {"ticker": "RXRX", "relevance_score": "0.17715", "ticker_sentiment_score": "0.251476", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DCTH", "relevance_score": "0.118647", "ticker_sentiment_score": "0.283366", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TUP", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNEJF", "relevance_score": "0.234684", "ticker_sentiment_score": "0.232505", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LCID", "relevance_score": "0.118647", "ticker_sentiment_score": "0.387421", "ticker_sentiment_label": "Bullish"}, {"ticker": "PACB", "relevance_score": "0.118647", "ticker_sentiment_score": "0.306084", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALC", "relevance_score": "0.118647", "ticker_sentiment_score": "0.349119", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SMRT", "relevance_score": "0.118647", "ticker_sentiment_score": "0.208233", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOOD", "relevance_score": "0.118647", "ticker_sentiment_score": "0.220762", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JOBY", "relevance_score": "0.118647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:JPY", "relevance_score": "0.118647", "ticker_sentiment_score": "0.038257", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio  ( PACB )  Q1 Earnings In Line, Adjusted Gross Margin Up", "url": "https://www.zacks.com/stock/news/2272309/pacbio-pacb-q1-earnings-in-line-adjusted-gross-margin-up", "time_published": "20240510T151600", "authors": ["Zacks Equity Research"], "summary": "PacBio (PACB) reports growth in Product revenues in the first quarter of 2024. However, Instruments revenues decline year over year due to lower shipment of Revio units.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/54862.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.996718"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}], "overall_sentiment_score": -0.03127, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALGN", "relevance_score": "0.173958", "ticker_sentiment_score": "0.030094", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.216473", "ticker_sentiment_score": "0.253278", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.173958", "ticker_sentiment_score": "0.024127", "ticker_sentiment_label": "Neutral"}, {"ticker": "ECL", "relevance_score": "0.130926", "ticker_sentiment_score": "0.0776", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Reports Q1 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2271825/pacific-biosciences-of-california-pacb-reports-q1-loss-tops-revenue-estimates", "time_published": "20240509T221007", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default2.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999483"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.133071, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DRIO", "relevance_score": "0.20997", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.140896", "ticker_sentiment_score": "-0.005169", "ticker_sentiment_label": "Neutral"}]}, {"title": "Accelerate Diagnostics Reports Q1 Loss, Misses Revenue Estimates - Pacific Biosciences  ( NASDAQ:PACB ) , Accelerate Diagnostics  ( NASDAQ:AXDX ) ", "url": "https://www.benzinga.com/general/biotech/24/05/38719148/accelerate-diagnostics-reports-q1-loss-misses-revenue-estimates", "time_published": "20240509T181259", "authors": ["Zacks"], "summary": "Accelerate Diagnostics AXDX came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.70 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/05/09/wengang-zhai-bfb7ydn1-di-unsplash.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.092084, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AXDX", "relevance_score": "0.38489", "ticker_sentiment_score": "-0.029469", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.1331", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Accelerate Diagnostics  ( AXDX )  Reports Q1 Loss, Misses Revenue Estimates", "url": "https://www.zacks.com/stock/news/2270977/accelerate-diagnostics-axdx-reports-q1-loss-misses-revenue-estimates", "time_published": "20240508T222507", "authors": ["Zacks Equity Research"], "summary": "Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -22.22% and 2.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default351.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.077828, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AXDX", "relevance_score": "0.392948", "ticker_sentiment_score": "0.010895", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.136113", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Soft Instrument Orders Likely to Hurt PacBio's  ( PACB )  Q1 Earnings", "url": "https://www.zacks.com/stock/news/2269846/soft-instrument-orders-likely-to-hurt-pacbios-pacb-q1-earnings", "time_published": "20240507T161200", "authors": ["Zacks Equity Research"], "summary": "Despite strength in Revio and Onso platforms, an increasing number of customers delaying instrument purchases is likely to have dampened PacBio's (PACB) top line in the first quarter.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/66/49902.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999756"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.115837, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.137671", "ticker_sentiment_score": "0.074777", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.182851", "ticker_sentiment_score": "0.150458", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IGMS", "relevance_score": "0.182851", "ticker_sentiment_score": "0.053853", "ticker_sentiment_label": "Neutral"}, {"ticker": "ERAS", "relevance_score": "0.137671", "ticker_sentiment_score": "0.109971", "ticker_sentiment_label": "Neutral"}]}, {"title": "Only One ETF Is Doing Even Worse Than Cathie Wood's", "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-only-one-etf-is-doing-even-worse-than-cathie-woods/", "time_published": "20240507T120000", "authors": ["MATT KRANTZ", "Investor's Business Daily"], "summary": "Cathie Wood's ARK Innovation ( ARKK ) is having a terrible year vs. the S&P 500 - but it still has one thing going for it. At least it's not the absolute worst ETF. ARK Innovation is down 13.2% this year, says Morningstar Direct. That's an abysmal showing when the SPDR S&P 500 ETF Trust ( SPY ) ...", "banner_image": "https://www.investors.com/wp-content/uploads/2024/05/Sector-cathiewood-0506-news.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.875462"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.108855, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TXG", "relevance_score": "0.195814", "ticker_sentiment_score": "0.006456", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.380012", "ticker_sentiment_score": "-0.195296", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PACB", "relevance_score": "0.195814", "ticker_sentiment_score": "0.176074", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MORN", "relevance_score": "0.098659", "ticker_sentiment_score": "0.184286", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FLNC", "relevance_score": "0.195814", "ticker_sentiment_score": "0.376413", "ticker_sentiment_label": "Bullish"}, {"ticker": "VERV", "relevance_score": "0.195814", "ticker_sentiment_score": "0.006456", "ticker_sentiment_label": "Neutral"}, {"ticker": "IVZ", "relevance_score": "0.098659", "ticker_sentiment_score": "0.263986", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Investors Heavily Search Pacific Biosciences of California, Inc.  ( PACB ) : Here is What You Need to Know", "url": "https://www.zacks.com/stock/news/2266808/investors-heavily-search-pacific-biosciences-of-california-inc-pacb-here-is-what-you-need-to-know", "time_published": "20240502T130011", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences (PACB) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default4.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.213122, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.101797", "ticker_sentiment_score": "0.036179", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cigna  ( CI )  Q1 Earnings and Revenues Beat Estimates", "url": "https://www.zacks.com/stock/news/2266634/cigna-ci-q1-earnings-and-revenues-beat-estimates", "time_published": "20240502T111010", "authors": ["Zacks Equity Research"], "summary": "Cigna (CI) delivered earnings and revenue surprises of 4.86% and 1.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default217.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999992"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.15956, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.136888", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday - Tesla  ( NASDAQ:TSLA ) ", "url": "https://www.benzinga.com/news/24/04/38492833/tesla-deciphera-pharmaceuticals-heartland-financial-and-other-big-stocks-moving-higher-on-monday", "time_published": "20240429T144740", "authors": ["Avi Kapoor"], "summary": "U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday. Shares of Tesla, Inc. TSLA rose sharply during Monday's session on reports the company will partner with Baidu for mapping and navigation for Full Self-Driving in China. Tesla shares jumped 10.5% to $185.94 on ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/29/Tesla-logo_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.228997, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MPLN", "relevance_score": "0.221481", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ROKU", "relevance_score": "0.221481", "ticker_sentiment_score": "0.20041", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PARA", "relevance_score": "0.148731", "ticker_sentiment_score": "-0.027195", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIDU", "relevance_score": "0.074692", "ticker_sentiment_score": "0.007147", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAHC", "relevance_score": "0.221481", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MESO", "relevance_score": "0.148731", "ticker_sentiment_score": "0.106806", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.221481", "ticker_sentiment_score": "0.1128", "ticker_sentiment_label": "Neutral"}, {"ticker": "WFC", "relevance_score": "0.074692", "ticker_sentiment_score": "0.018481", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZTS", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FNLC", "relevance_score": "0.074692", "ticker_sentiment_score": "0.11105", "ticker_sentiment_label": "Neutral"}, {"ticker": "TNDM", "relevance_score": "0.148731", "ticker_sentiment_score": "0.023996", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTLF", "relevance_score": "0.148731", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DCPH", "relevance_score": "0.148731", "ticker_sentiment_score": "0.218908", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EAF", "relevance_score": "0.148731", "ticker_sentiment_score": "0.428867", "ticker_sentiment_label": "Bullish"}, {"ticker": "FRBK", "relevance_score": "0.074692", "ticker_sentiment_score": "0.11105", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.148731", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNA", "relevance_score": "0.148731", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FULT", "relevance_score": "0.221481", "ticker_sentiment_score": "0.183831", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALB", "relevance_score": "0.148731", "ticker_sentiment_score": "0.133889", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALTM", "relevance_score": "0.148731", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAI", "relevance_score": "0.148731", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TELLL", "relevance_score": "0.074692", "ticker_sentiment_score": "0.347222", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UMBF", "relevance_score": "0.074692", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLNO", "relevance_score": "0.148731", "ticker_sentiment_score": "0.177961", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IBRX", "relevance_score": "0.221481", "ticker_sentiment_score": "0.358618", "ticker_sentiment_label": "Bullish"}, {"ticker": "OPHLF", "relevance_score": "0.074692", "ticker_sentiment_score": "0.174934", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PRME", "relevance_score": "0.148731", "ticker_sentiment_score": "0.198629", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Skechers Reports Upbeat Earnings, Joins Tutor Perini, AppFolio, Newell Brands And Other Big Stocks Moving Higher On Friday - Skechers USA  ( NYSE:SKX ) , Newell Brands  ( NASDAQ:NWL ) , Tutor Perini  ( NYSE:TPC ) , AppFolio  ( NASDAQ:APPF ) ", "url": "https://www.benzinga.com/news/24/04/38462123/skechers-reports-upbeat-earnings-joins-tutor-perini-appfolio-newell-brands-and-other-big-stocks-movi", "time_published": "20240426T144517", "authors": ["Avi Kapoor"], "summary": "U.S. stocks were higher, with the Dow Jones jumping over 150 points on Friday. Shares of Skechers U.S.A., Inc. SKX rose sharply during Friday's session after the company reported better-than-expected first-quarter FY24 earnings.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/26/SKX--Skechers.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.999996"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.432267, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "RERE", "relevance_score": "0.178459", "ticker_sentiment_score": "0.27097", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GOOG", "relevance_score": "0.119532", "ticker_sentiment_score": "0.216868", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NWL", "relevance_score": "0.119532", "ticker_sentiment_score": "0.341073", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OUST", "relevance_score": "0.119532", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMCI", "relevance_score": "0.119532", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TPC", "relevance_score": "0.119532", "ticker_sentiment_score": "0.29675", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RMD", "relevance_score": "0.119532", "ticker_sentiment_score": "0.478784", "ticker_sentiment_label": "Bullish"}, {"ticker": "ROG", "relevance_score": "0.119532", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNAP", "relevance_score": "0.119532", "ticker_sentiment_score": "0.312684", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AN", "relevance_score": "0.059935", "ticker_sentiment_score": "0.245111", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KTOS", "relevance_score": "0.119532", "ticker_sentiment_score": "0.329728", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MTX", "relevance_score": "0.119532", "ticker_sentiment_score": "0.501825", "ticker_sentiment_label": "Bullish"}, {"ticker": "SKYW", "relevance_score": "0.119532", "ticker_sentiment_score": "0.267111", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ULH", "relevance_score": "0.119532", "ticker_sentiment_score": "0.367102", "ticker_sentiment_label": "Bullish"}, {"ticker": "EXPO", "relevance_score": "0.119532", "ticker_sentiment_score": "0.478784", "ticker_sentiment_label": "Bullish"}, {"ticker": "PACB", "relevance_score": "0.119532", "ticker_sentiment_score": "0.388526", "ticker_sentiment_label": "Bullish"}, {"ticker": "KB", "relevance_score": "0.119532", "ticker_sentiment_score": "0.278517", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "APPF", "relevance_score": "0.119532", "ticker_sentiment_score": "0.354665", "ticker_sentiment_label": "Bullish"}, {"ticker": "GERN", "relevance_score": "0.178459", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAH", "relevance_score": "0.178459", "ticker_sentiment_score": "0.112883", "ticker_sentiment_label": "Neutral"}, {"ticker": "RDFN", "relevance_score": "0.119532", "ticker_sentiment_score": "0.388526", "ticker_sentiment_label": "Bullish"}, {"ticker": "CSL", "relevance_score": "0.119532", "ticker_sentiment_score": "0.267111", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CGC", "relevance_score": "0.119532", "ticker_sentiment_score": "0.388526", "ticker_sentiment_label": "Bullish"}, {"ticker": "ZIM", "relevance_score": "0.119532", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why Pacific Biosciences  ( PACB )  is Poised for a Turnaround After Losing -63.44% in 4 Weeks", "url": "https://www.zacks.com/stock/news/2262172/heres-why-pacific-biosciences-pacb-is-poised-for-a-turnaround-after-losing--6344-in-4-weeks", "time_published": "20240425T133506", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences (PACB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the ...", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default97.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.990999"}], "overall_sentiment_score": 0.150143, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.489394", "ticker_sentiment_score": "0.165799", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pacific Biosciences  ( PACB )  Upgraded to Buy: Here's What You Should Know", "url": "https://www.zacks.com/stock/news/2260443/pacific-biosciences-pacb-upgraded-to-buy-heres-what-you-should-know", "time_published": "20240423T160010", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences (PACB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default134.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997845"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}], "overall_sentiment_score": 0.316021, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.124809", "ticker_sentiment_score": "0.203495", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pacific Biosciences of California  ( NASDAQ:PACB )  Upgraded to \"Sell\" at StockNews.com", "url": "https://www.defenseworld.net/2024/04/18/pacific-biosciences-of-california-nasdaqpacb-upgraded-to-sell-at-stocknews-com.html", "time_published": "20240418T095646", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of Pacific Biosciences of California ( NASDAQ:PACB - Free Report ) to a sell rating in a research report sent to investors on Wednesday. PACB has been the subject of a number of other research reports.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pacific-biosciences-of-california-inc-logo.png?v=20221123085851&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.215877, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BCS", "relevance_score": "0.045396", "ticker_sentiment_score": "-0.000978", "ticker_sentiment_label": "Neutral"}, {"ticker": "GS", "relevance_score": "0.045396", "ticker_sentiment_score": "-0.000978", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.789566", "ticker_sentiment_score": "0.35456", "ticker_sentiment_label": "Bullish"}, {"ticker": "CMA", "relevance_score": "0.045396", "ticker_sentiment_score": "0.170549", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio  ( PACB )  Preliminary Q1 Revenues Dampened by Purchase Delays", "url": "https://www.zacks.com/stock/news/2257154/pacbio-pacb-preliminary-q1-revenues-dampened-by-purchase-delays", "time_published": "20240417T170000", "authors": ["Zacks Equity Research"], "summary": "PacBio's (PACB) revenue growth in the first quarter is likely to have been hampered by an increasing number of customers delaying instrument purchases and softness in consumable shipments.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/45/26891.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.714479"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": 0.092726, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.09989", "ticker_sentiment_score": "0.166181", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.198221", "ticker_sentiment_score": "0.124442", "ticker_sentiment_label": "Neutral"}, {"ticker": "COR", "relevance_score": "0.198221", "ticker_sentiment_score": "0.09824", "ticker_sentiment_label": "Neutral"}, {"ticker": "ECL", "relevance_score": "0.198221", "ticker_sentiment_score": "0.059214", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket - INVO Bioscience  ( NASDAQ:INVO ) ", "url": "https://www.benzinga.com/news/24/04/38286501/why-invo-bioscience-shares-are-trading-higher-by-around-73-here-are-20-stocks-moving-premarket", "time_published": "20240417T101357", "authors": ["Avi Kapoor"], "summary": "Shares of INVO Bioscience, Inc. INVO rose sharply in today's pre-market trading after reporting fourth-quarter results. The company said quarterly revenue surged 397% year-over-year to $1,381,754, from $278,142 in the year-ago period, according to data from Benzinga Pro.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/17/image50.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.897321"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.905476"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.183098, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "DFLI", "relevance_score": "0.221481", "ticker_sentiment_score": "0.189448", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CXAI", "relevance_score": "0.148731", "ticker_sentiment_score": "0.27824", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MGAM", "relevance_score": "0.221481", "ticker_sentiment_score": "0.160549", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WISA", "relevance_score": "0.148731", "ticker_sentiment_score": "0.090638", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIAO", "relevance_score": "0.148731", "ticker_sentiment_score": "0.322069", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CNXA", "relevance_score": "0.074692", "ticker_sentiment_score": "-0.27674", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ASML", "relevance_score": "0.148731", "ticker_sentiment_score": "0.065402", "ticker_sentiment_label": "Neutral"}, {"ticker": "GPAK", "relevance_score": "0.148731", "ticker_sentiment_score": "0.483621", "ticker_sentiment_label": "Bullish"}, {"ticker": "SXTC", "relevance_score": "0.221481", "ticker_sentiment_score": "-0.049266", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXYZ", "relevance_score": "0.148731", "ticker_sentiment_score": "-0.015249", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.074692", "ticker_sentiment_score": "0.145096", "ticker_sentiment_label": "Neutral"}, {"ticker": "CLNN", "relevance_score": "0.148731", "ticker_sentiment_score": "0.103439", "ticker_sentiment_label": "Neutral"}, {"ticker": "UK", "relevance_score": "0.148731", "ticker_sentiment_score": "0.483621", "ticker_sentiment_label": "Bullish"}, {"ticker": "DYNT", "relevance_score": "0.148731", "ticker_sentiment_score": "-0.015249", "ticker_sentiment_label": "Neutral"}, {"ticker": "INVO", "relevance_score": "0.221481", "ticker_sentiment_score": "0.160241", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "IZM", "relevance_score": "0.148731", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "S&P 500 Edges Lower; PacBio Shares Plunge - Calidi Biotherapeutics  ( AMEX:CLDI ) , Barnes & Noble Education  ( NYSE:BNED ) ", "url": "https://www.benzinga.com/news/earnings/24/04/38278265/s-p-500-edges-lower-pacbio-shares-plunge", "time_published": "20240416T183045", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling around 0.3% on Tuesday. The Dow traded up 0.02% to 37,741.96 while the NASDAQ fell 0.20% to 15,853.39. The S&P 500 also fell, dropping, 0.28% to 5,047.76. Information technology shares rose by 0.4% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/16/image37.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.04364, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WISA", "relevance_score": "0.137278", "ticker_sentiment_score": "0.325554", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAGX", "relevance_score": "0.137278", "ticker_sentiment_score": "0.311138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PALI", "relevance_score": "0.204647", "ticker_sentiment_score": "0.299799", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNED", "relevance_score": "0.137278", "ticker_sentiment_score": "0.119515", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.137278", "ticker_sentiment_score": "-0.185889", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Gold Moves Higher; Morgan Stanley Earnings Top Views - Calidi Biotherapeutics  ( AMEX:CLDI ) , Barnes & Noble Education  ( NYSE:BNED ) ", "url": "https://www.benzinga.com/news/earnings/24/04/38275683/gold-moves-higher-morgan-stanley-earnings-top-views", "time_published": "20240416T161143", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 0.2% on Tuesday. The Dow traded up 0.13% to 37,784.21 while the NASDAQ fell 0.20% to 15,853.34. The S&P 500 also fell, dropping, 0.29% to 5,047.11. Health care shares rose by 0.2% on Tuesday.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/16/image13.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.714479"}], "overall_sentiment_score": 0.04617, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WISA", "relevance_score": "0.130571", "ticker_sentiment_score": "0.317802", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JAGX", "relevance_score": "0.130571", "ticker_sentiment_score": "0.303677", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PALI", "relevance_score": "0.194763", "ticker_sentiment_score": "0.289369", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNED", "relevance_score": "0.130571", "ticker_sentiment_score": "0.116501", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.130571", "ticker_sentiment_score": "-0.180825", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MS", "relevance_score": "0.130571", "ticker_sentiment_score": "0.392559", "ticker_sentiment_label": "Bullish"}]}, {"title": "Dow Gains Over 100 Points; Bank of America Posts Upbeat Profit", "url": "https://markets.businessinsider.com/news/stocks/dow-gains-over-100-points-bank-of-america-posts-upbeat-profit-1033253547", "time_published": "20240416T142237", "authors": [], "summary": "Dow Gains Over 100 Points. Bank of America Posts Upbeat Profit - Markets Insider ...", "banner_image": "https://cdn.benzinga.com/files/imagecache/1024x768xUP/images/story/2024/04/16/image39.jpeg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.891286"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": -0.009733, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TOL", "relevance_score": "0.06623", "ticker_sentiment_score": "-0.154378", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BAC", "relevance_score": "0.06623", "ticker_sentiment_score": "0.366041", "ticker_sentiment_label": "Bullish"}, {"ticker": "BNED", "relevance_score": "0.06623", "ticker_sentiment_score": "0.10419", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.06623", "ticker_sentiment_score": "-0.155539", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SMCI", "relevance_score": "0.06623", "ticker_sentiment_score": "0.107199", "ticker_sentiment_label": "Neutral"}, {"ticker": "WISA", "relevance_score": "0.06623", "ticker_sentiment_score": "0.279187", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DYNT", "relevance_score": "0.06623", "ticker_sentiment_score": "0.185925", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PALI", "relevance_score": "0.132004", "ticker_sentiment_score": "0.123084", "ticker_sentiment_label": "Neutral"}]}, {"title": "Dow Gains Over 100 Points; Bank of America Posts Upbeat Profit - Bank of America  ( NYSE:BAC ) , Barnes & Noble Education  ( NYSE:BNED ) ", "url": "https://www.benzinga.com/news/earnings/24/04/38271269/dow-gains-over-100-points-bank-of-america-posts-upbeat-profit", "time_published": "20240416T134851", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.35% to 37,865.71 while the NASDAQ fell 0.13% to 15,865.09. The S&P 500 also fell, dropping, 0.12% to 5,055.53.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/04/16/image39.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}, {"topic": "Economy - Monetary", "relevance_score": "0.310843"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.891286"}], "overall_sentiment_score": 0.038951, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "WISA", "relevance_score": "0.128135", "ticker_sentiment_score": "0.315074", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DYNT", "relevance_score": "0.128135", "ticker_sentiment_score": "0.212416", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PALI", "relevance_score": "0.19117", "ticker_sentiment_score": "0.147932", "ticker_sentiment_label": "Neutral"}, {"ticker": "BAC", "relevance_score": "0.128135", "ticker_sentiment_score": "0.389333", "ticker_sentiment_label": "Bullish"}, {"ticker": "BNED", "relevance_score": "0.128135", "ticker_sentiment_score": "0.115448", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.128135", "ticker_sentiment_score": "-0.179031", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Reasons to Retain PacBio  ( PACB )  Stock in Your Portfolio Now", "url": "https://www.zacks.com/stock/news/2249871/reasons-to-retain-pacbio-pacb-stock-in-your-portfolio-now", "time_published": "20240403T145400", "authors": ["Zacks Equity Research"], "summary": "PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/0e/879.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.330638, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WGS", "relevance_score": "0.047371", "ticker_sentiment_score": "0.111756", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.187827", "ticker_sentiment_score": "0.097258", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.233556", "ticker_sentiment_score": "0.224346", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.141448", "ticker_sentiment_score": "0.115299", "ticker_sentiment_label": "Neutral"}, {"ticker": "COR", "relevance_score": "0.141448", "ticker_sentiment_score": "0.083266", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( NASDAQ:PACB )  Stock Rating Upgraded by StockNews.com", "url": "https://www.defenseworld.net/2024/03/20/pacific-biosciences-of-california-nasdaqpacb-stock-rating-upgraded-by-stocknews-com.html", "time_published": "20240320T073043", "authors": ["Defense World Staff"], "summary": "Pacific Biosciences of California ( NASDAQ:PACB - Get Free Report ) was upgraded by equities research analysts at StockNews.com to a \"sell\" rating in a research report issued on Wednesday. PACB has been the topic of several other reports.", "banner_image": "https://www.marketbeat.com/logos/pacific-biosciences-of-california-inc-logo-1200x675.png?v=20221123085851", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.266991, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.082677", "ticker_sentiment_score": "0.217839", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XPEV", "relevance_score": "0.041394", "ticker_sentiment_score": "0.106658", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.041394", "ticker_sentiment_score": "0.106658", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.746491", "ticker_sentiment_score": "0.364822", "ticker_sentiment_label": "Bullish"}]}, {"title": "Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary  ( NASDAQ:IVP ) , Fractyl Health  ( NASDAQ:GUTS ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/03/37819071/top-5-health-care-stocks-which-could-rescue-your-portfolio-in-march", "time_published": "20240319T120840", "authors": ["Avi Kapoor"], "summary": "The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/19/image31.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.072592, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IVP", "relevance_score": "0.260189", "ticker_sentiment_score": "-0.21622", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "MTEM", "relevance_score": "0.260189", "ticker_sentiment_score": "-0.237864", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GUTS", "relevance_score": "0.260189", "ticker_sentiment_score": "-0.196596", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PACB", "relevance_score": "0.175221", "ticker_sentiment_score": "-0.070425", "ticker_sentiment_label": "Neutral"}, {"ticker": "OM", "relevance_score": "0.260189", "ticker_sentiment_score": "-0.106218", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio's  ( PACB )  New Panel to Aid Its Clinical Research Solution", "url": "https://www.zacks.com/stock/news/2240028/pacbios-pacb-new-panel-to-aid-its-clinical-research-solution", "time_published": "20240313T141700", "authors": ["Zacks Equity Research"], "summary": "PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.208246, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "0.208017", "ticker_sentiment_score": "0.105093", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.258351", "ticker_sentiment_score": "0.005828", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.1568", "ticker_sentiment_score": "0.122544", "ticker_sentiment_label": "Neutral"}, {"ticker": "COR", "relevance_score": "0.1568", "ticker_sentiment_score": "0.088515", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( NASDAQ:PACB )  Upgraded to Sell at StockNews.com", "url": "https://www.americanbankingnews.com/2024/03/12/pacific-biosciences-of-california-nasdaqpacb-upgraded-to-sell-at-stocknews-com.html", "time_published": "20240312T083018", "authors": ["ABMN Staff"], "summary": "Pacific Biosciences of California ( NASDAQ:PACB ) Upgraded to Sell at ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pacific-biosciences-of-california-inc-logo.png?v=20221123085851&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.americanbankingnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.95139"}, {"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.260767, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BLK", "relevance_score": "0.085022", "ticker_sentiment_score": "0.197059", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.737711", "ticker_sentiment_score": "0.412335", "ticker_sentiment_label": "Bullish"}, {"ticker": "COIN", "relevance_score": "0.042571", "ticker_sentiment_score": "0.140103", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( NASDAQ:PACB )  Lifted to Sell at StockNews.com", "url": "https://www.defenseworld.net/2024/03/12/pacific-biosciences-of-california-nasdaqpacb-lifted-to-sell-at-stocknews-com.html", "time_published": "20240312T082842", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of Pacific Biosciences of California ( NASDAQ:PACB - Free Report ) to a sell rating in a research note released on Monday. Other equities research analysts have also recently issued research reports about the stock.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pacific-biosciences-of-california-inc-logo.png?v=20221123085851&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.82617"}, {"topic": "Earnings", "relevance_score": "0.986564"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.266776, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PRU", "relevance_score": "0.086556", "ticker_sentiment_score": "0.199821", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ENV", "relevance_score": "0.086556", "ticker_sentiment_score": "0.199821", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.722944", "ticker_sentiment_score": "0.418172", "ticker_sentiment_label": "Bullish"}, {"ticker": "COIN", "relevance_score": "0.043342", "ticker_sentiment_score": "0.095441", "ticker_sentiment_label": "Neutral"}]}, {"title": "Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March - Ironwood Pharmaceuticals  ( NASDAQ:IRWD ) , Integra Lifesciences  ( NASDAQ:IART ) ", "url": "https://www.benzinga.com/trading-ideas/long-ideas/24/03/37531181/top-3-health-care-stocks-that-could-lead-to-your-biggest-gains-in-march", "time_published": "20240307T121846", "authors": ["Avi Kapoor"], "summary": "The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/03/07/image45_0.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.050789, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "IART", "relevance_score": "0.325924", "ticker_sentiment_score": "-0.413864", "ticker_sentiment_label": "Bearish"}, {"ticker": "IRWD", "relevance_score": "0.325924", "ticker_sentiment_score": "-0.212948", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PACB", "relevance_score": "0.220809", "ticker_sentiment_score": "-0.083772", "ticker_sentiment_label": "Neutral"}]}, {"title": "Epigenetics Market Research Report 2023-2030: DNA Methylation and Oncology Applications At the Forefront of Advancements", "url": "https://www.prnewswire.com/news-releases/epigenetics-market-research-report-2023-2030-dna-methylation-and-oncology-applications-at-the-forefront-of-advancements-302077372.html", "time_published": "20240301T194500", "authors": ["Research and Markets"], "summary": "Epigenetics Market Research Report 2023-2030: DNA Methylation and Oncology Applications At the Forefront of ... PR ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.07706, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.060541", "ticker_sentiment_score": "-0.016039", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio  ( PACB )  Q4 Earnings Beat, Adjusted Gross Margin Down", "url": "https://www.zacks.com/stock/news/2227448/pacbio-pacb-q4-earnings-beat-adjusted-gross-margin-down", "time_published": "20240216T155000", "authors": ["Zacks Equity Research"], "summary": "PacBio (PACB) witnesses strong revenue growth in the fourth quarter, partly aided by customers' continued product transition to the Revio system.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b1/44137.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Earnings", "relevance_score": "0.99986"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.04575, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CAH", "relevance_score": "0.156715", "ticker_sentiment_score": "0.023815", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.195182", "ticker_sentiment_score": "0.300203", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ELV", "relevance_score": "0.156715", "ticker_sentiment_score": "0.023825", "ticker_sentiment_label": "Neutral"}, {"ticker": "COR", "relevance_score": "0.156715", "ticker_sentiment_score": "0.075327", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Reports Q4 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2227162/pacific-biosciences-of-california-pacb-reports-q4-loss-tops-revenue-estimates", "time_published": "20240215T223008", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences (PACB) delivered earnings and revenue surprises of 12.90% and 0.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default89.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999892"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.109975, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.137278", "ticker_sentiment_score": "-0.063579", "ticker_sentiment_label": "Neutral"}, {"ticker": "TFX", "relevance_score": "0.137278", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medical Products Stocks' Earnings Due on Feb 15: WST, ITGR & More", "url": "https://www.zacks.com/stock/news/2226041/medical-products-stocks-earnings-due-on-feb-15-wst-itgr-more", "time_published": "20240214T135600", "authors": ["Debanjana Dey"], "summary": "Medical Products companies' quarterly results are likely to reflect strength in customer demand. Let's see how ITGR, WST, AMN and PACB are placed ahead of their earnings releases.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/54381.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.176182, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMN", "relevance_score": "0.303175", "ticker_sentiment_score": "0.315302", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITGR", "relevance_score": "0.366061", "ticker_sentiment_score": "0.319401", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.171363", "ticker_sentiment_score": "0.154863", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.03453", "ticker_sentiment_score": "-0.07478", "ticker_sentiment_label": "Neutral"}, {"ticker": "WST", "relevance_score": "0.204936", "ticker_sentiment_score": "0.177515", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.103331", "ticker_sentiment_score": "0.140792", "ticker_sentiment_label": "Neutral"}, {"ticker": "ECL", "relevance_score": "0.03453", "ticker_sentiment_score": "-0.07478", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cathie Wood's Ark Invest Sheds $2.8M Worth Of Nvidia Shares Amid AI Hype, Picks Up Robinhood Stock Worth $1.3M - NVIDIA  ( NASDAQ:NVDA ) ", "url": "https://www.benzinga.com/markets/equities/24/02/36998194/cathie-woods-ark-invest-sheds-2-8m-worth-of-nvidia-shares-amid-ai-hype-picks-up-robinhood-stock-", "time_published": "20240208T032040", "authors": ["Benzinga Neuro"], "summary": "In a move that caught the attention of investors, Cathie Wood-led Ark Invest offloaded over $2.8 million worth of Nvidia NVDA shares on Wednesday. This trade comes amid a flurry of discussions around Nvidia's valuation and its potential in the AI sector.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/Cathie-Wood--founder-of-Ark-Invest-_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Financial Markets", "relevance_score": "0.961735"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.25"}, {"topic": "Finance", "relevance_score": "0.25"}], "overall_sentiment_score": 0.385156, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "PATH", "relevance_score": "0.140896", "ticker_sentiment_score": "0.305553", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVDA", "relevance_score": "0.405651", "ticker_sentiment_score": "0.362527", "ticker_sentiment_label": "Bullish"}, {"ticker": "TXG", "relevance_score": "0.140896", "ticker_sentiment_score": "0.182816", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TWST", "relevance_score": "0.140896", "ticker_sentiment_score": "0.300677", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.140896", "ticker_sentiment_score": "0.300677", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.070725", "ticker_sentiment_score": "0.180189", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RXRX", "relevance_score": "0.140896", "ticker_sentiment_score": "0.182816", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOOD", "relevance_score": "0.20997", "ticker_sentiment_score": "0.286853", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio's  ( PACB )  New Kits to Boost Its Revio Sequencing System", "url": "https://www.zacks.com/stock/news/2221789/pacbios-pacb-new-kits-to-boost-its-revio-sequencing-system", "time_published": "20240206T144100", "authors": ["Zacks Equity Research"], "summary": "PacBio's (PACB) new library preparation kits are likely to boost Revio's long-read sequencing systems by reducing cost and workflow time.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.614606"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.20638, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UHS", "relevance_score": "0.172507", "ticker_sentiment_score": "0.122147", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.22861", "ticker_sentiment_score": "0.080856", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.283542", "ticker_sentiment_score": "0.203398", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ELV", "relevance_score": "0.22861", "ticker_sentiment_score": "0.033281", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio's  ( PACB )  New PanDNA Kit Ready to Boost DNA Extraction", "url": "https://www.zacks.com/stock/news/2210985/pacbios-pacb-new-pandna-kit-ready-to-boost-dna-extraction", "time_published": "20240116T171300", "authors": ["Zacks Equity Research"], "summary": "PacBio's (PACB) new offering, PanDNA kit, is likely to help researchers effectively extract DNA optimized for HiFi sequencing. This versatile Nanobind kit is expected to be available in February 2024.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/1076.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.158519"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.283812, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UHS", "relevance_score": "0.192183", "ticker_sentiment_score": "0.104941", "ticker_sentiment_label": "Neutral"}, {"ticker": "ACHC", "relevance_score": "0.192183", "ticker_sentiment_score": "0.067372", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.254307", "ticker_sentiment_score": "0.125779", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.31482", "ticker_sentiment_score": "0.278343", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "StockNews.com Upgrades Pacific Biosciences of California  ( NASDAQ:PACB )  to Sell", "url": "https://www.defenseworld.net/2024/01/13/stocknews-com-upgrades-pacific-biosciences-of-california-nasdaqpacb-to-sell.html", "time_published": "20240113T063446", "authors": ["Defense World Staff"], "summary": "Pacific Biosciences of California ( NASDAQ:PACB - Get Free Report ) was upgraded by StockNews.com to a \"sell\" rating in a report issued on Saturday.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pacific-biosciences-of-california-inc-logo.png?v=20221123085851&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.986564"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Blockchain", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.224841, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BCS", "relevance_score": "0.042048", "ticker_sentiment_score": "0.04293", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCORF", "relevance_score": "0.042048", "ticker_sentiment_score": "0.04293", "ticker_sentiment_label": "Neutral"}, {"ticker": "MET", "relevance_score": "0.08398", "ticker_sentiment_score": "0.214823", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.794264", "ticker_sentiment_score": "0.369172", "ticker_sentiment_label": "Bullish"}, {"ticker": "JPM", "relevance_score": "0.08398", "ticker_sentiment_score": "0.214823", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What's Going On With Pacific Biosciences Stock? - Pacific Biosciences  ( NASDAQ:PACB ) ", "url": "https://www.benzinga.com/news/24/01/36600287/whats-going-on-with-pacific-biosciences-stock", "time_published": "20240111T193227", "authors": ["Erica Kollmann"], "summary": "Pacific Biosciences of California, Inc. PACB shares are trading lower Thursday, and the stock is down more than 20% over the past five days. Here's a look at what's going on.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/laboratory-217041-1280.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.23478, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.507932", "ticker_sentiment_score": "0.25481", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Aspen Aerogels Issues Business Update, Joins Plug Power, SunPower And Other Big Stocks Moving Lower On Thursday - Applied Optoelectronics  ( NASDAQ:AAOI ) , C3.ai  ( NYSE:AI ) ", "url": "https://www.benzinga.com/news/24/01/36596069/aspen-aerogels-issues-business-update-joins-plug-power-sunpower-and-other-big-stocks-moving-lower-on", "time_published": "20240111T153232", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded lower, with the Dow Jones index falling over 150 points on Thursday. Shares of Aspen Aerogels, Inc. ASPN fell sharply during Thursday's session after the company issued a business update. Aspen Aerogels clocked preliminary fourth-quarter revenue of $84 million.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/11/image20.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": -0.214174, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "RDZN", "relevance_score": "0.325924", "ticker_sentiment_score": "-0.08717", "ticker_sentiment_label": "Neutral"}, {"ticker": "AAOI", "relevance_score": "0.220809", "ticker_sentiment_score": "-0.582579", "ticker_sentiment_label": "Bearish"}, {"ticker": "ETWO", "relevance_score": "0.220809", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SANA", "relevance_score": "0.220809", "ticker_sentiment_score": "-0.582579", "ticker_sentiment_label": "Bearish"}, {"ticker": "OPI", "relevance_score": "0.220809", "ticker_sentiment_score": "0.113383", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLUG", "relevance_score": "0.325924", "ticker_sentiment_score": "0.072122", "ticker_sentiment_label": "Neutral"}, {"ticker": "WB", "relevance_score": "0.325924", "ticker_sentiment_score": "-0.279505", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ASPN", "relevance_score": "0.42503", "ticker_sentiment_score": "-0.03487", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTZ", "relevance_score": "0.220809", "ticker_sentiment_score": "-0.582579", "ticker_sentiment_label": "Bearish"}, {"ticker": "CYTK", "relevance_score": "0.220809", "ticker_sentiment_score": "-0.582579", "ticker_sentiment_label": "Bearish"}, {"ticker": "PACB", "relevance_score": "0.220809", "ticker_sentiment_score": "-0.291304", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RELL", "relevance_score": "0.220809", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "U", "relevance_score": "0.220809", "ticker_sentiment_score": "-0.582579", "ticker_sentiment_label": "Bearish"}, {"ticker": "AMRN", "relevance_score": "0.220809", "ticker_sentiment_score": "-0.526857", "ticker_sentiment_label": "Bearish"}, {"ticker": "GCT", "relevance_score": "0.220809", "ticker_sentiment_score": "-0.582579", "ticker_sentiment_label": "Bearish"}, {"ticker": "UPST", "relevance_score": "0.325924", "ticker_sentiment_score": "-0.050793", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio  ( PACB )  Preliminary Q4 Revenues Boosted by Revio Sales", "url": "https://www.zacks.com/stock/news/2207537/pacbio-pacb-preliminary-q4-revenues-boosted-by-revio-sales", "time_published": "20240109T154300", "authors": ["Zacks Equity Research"], "summary": "PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/45/26891.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.818451"}], "overall_sentiment_score": 0.251683, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MMSI", "relevance_score": "0.116348", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.230235", "ticker_sentiment_score": "0.150062", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.116348", "ticker_sentiment_score": "0.216778", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.230235", "ticker_sentiment_score": "0.177523", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Boeing, Pacific Biosciences of California And Other Big Stocks Moving Lower On Monday - AAR  ( NYSE:AIR ) , Boeing  ( NYSE:BA ) ", "url": "https://www.benzinga.com/news/24/01/36538431/boeing-pacific-biosciences-of-california-and-other-big-stocks-moving-lower-on-monday", "time_published": "20240108T164604", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded mixed, with the Dow Jones index falling around 80 points on Monday. Shares of The Boeing Company BA fell during Friday's session after an exit door blew out of a 737 aircraft during a commercial flight.", "banner_image": "https://cdn.benzinga.com/files/images/story/2024/01/08/boeing_-_logo.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.25"}, {"topic": "Manufacturing", "relevance_score": "0.25"}, {"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Energy & Transportation", "relevance_score": "0.25"}, {"topic": "Technology", "relevance_score": "0.25"}], "overall_sentiment_score": -0.320075, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "ALK", "relevance_score": "0.108958", "ticker_sentiment_score": "-0.143227", "ticker_sentiment_label": "Neutral"}, {"ticker": "DADA", "relevance_score": "0.318897", "ticker_sentiment_score": "-0.026747", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZJYL", "relevance_score": "0.215894", "ticker_sentiment_score": "-0.575095", "ticker_sentiment_label": "Bearish"}, {"ticker": "PRTA", "relevance_score": "0.215894", "ticker_sentiment_score": "-0.244975", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DTC", "relevance_score": "0.215894", "ticker_sentiment_score": "-0.213268", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SPR", "relevance_score": "0.318897", "ticker_sentiment_score": "-0.358068", "ticker_sentiment_label": "Bearish"}, {"ticker": "PACB", "relevance_score": "0.318897", "ticker_sentiment_score": "-0.364155", "ticker_sentiment_label": "Bearish"}, {"ticker": "FNA", "relevance_score": "0.318897", "ticker_sentiment_score": "-0.31477", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RGNX", "relevance_score": "0.318897", "ticker_sentiment_score": "-0.597191", "ticker_sentiment_label": "Bearish"}, {"ticker": "MTC", "relevance_score": "0.215894", "ticker_sentiment_score": "-0.575095", "ticker_sentiment_label": "Bearish"}, {"ticker": "BA", "relevance_score": "0.41627", "ticker_sentiment_score": "-0.250705", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RVNC", "relevance_score": "0.215894", "ticker_sentiment_score": "-0.233714", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ZIM", "relevance_score": "0.215894", "ticker_sentiment_score": "-0.575095", "ticker_sentiment_label": "Bearish"}]}, {"title": "PacBio Announces Record Preliminary Fourth Quarter and Full Year Revenue Growing 113% and 56%, respectively", "url": "https://www.prnewswire.com/news-releases/pacbio-announces-record-preliminary-fourth-quarter-and-full-year-revenue-growing-113-and-56-respectively-302028151.html", "time_published": "20240108T130000", "authors": ["Inc.", "Pacific Biosciences of California"], "summary": "Ships a record number of PacBio sequencers in 2023, including 173 Revio\u2122 systems, and announces record fourth quarter preliminary consumable revenue of $18.9 million as demand for long-read sequencing grows and increased capacity from the Revio system drives sample elasticity", "banner_image": "https://mma.prnewswire.com/media/1861430/PacBio_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}, {"topic": "Earnings", "relevance_score": "0.999987"}], "overall_sentiment_score": 0.101562, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.090021", "ticker_sentiment_score": "0.169907", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pacific Biosciences of California  ( NASDAQ:PACB )  Upgraded by StockNews.com to \"Sell\"", "url": "https://www.defenseworld.net/2023/12/29/pacific-biosciences-of-california-nasdaqpacb-upgraded-by-stocknews-com-to-sell.html", "time_published": "20231229T074046", "authors": ["Defense World Staff"], "summary": "StockNews.com upgraded shares of Pacific Biosciences of California ( NASDAQ:PACB - Free Report ) to a sell rating in a report issued on Thursday. Other equities analysts have also recently issued research reports about the company.", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pacific-biosciences-of-california-inc-logo.png?v=20221123085851&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.999998"}, {"topic": "Earnings", "relevance_score": "0.972476"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.161794, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CCORF", "relevance_score": "0.052455", "ticker_sentiment_score": "0.009964", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.811755", "ticker_sentiment_score": "0.271543", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CMA", "relevance_score": "0.052455", "ticker_sentiment_score": "0.158804", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.052455", "ticker_sentiment_score": "0.009964", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Illumina  ( ILMN )  Stock for Now", "url": "https://www.zacks.com/stock/news/2203319/heres-why-you-should-retain-illumina-ilmn-stock-for-now", "time_published": "20231228T180200", "authors": ["Zacks Equity Research"], "summary": "Investors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/4c/2710.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.99489"}], "overall_sentiment_score": 0.264288, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.046184", "ticker_sentiment_score": "0.233216", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.046184", "ticker_sentiment_score": "0.233216", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ILMN", "relevance_score": "0.356865", "ticker_sentiment_score": "0.316312", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.046184", "ticker_sentiment_score": "0.233216", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PODD", "relevance_score": "0.137934", "ticker_sentiment_score": "0.054256", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.046184", "ticker_sentiment_score": "0.233216", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HAE", "relevance_score": "0.227859", "ticker_sentiment_score": "0.157356", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.137934", "ticker_sentiment_score": "0.054256", "ticker_sentiment_label": "Neutral"}]}, {"title": "CVRx  ( CVRX )  Moves 24.2% Higher: Will This Strength Last?", "url": "https://www.zacks.com/stock/news/2202455/cvrx-cvrx-moves-242-higher-will-this-strength-last", "time_published": "20231227T121800", "authors": ["Zacks Equity Research"], "summary": "CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default144.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.241165, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.333257", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVRX", "relevance_score": "0.610896", "ticker_sentiment_score": "0.38778", "ticker_sentiment_label": "Bullish"}]}, {"title": "Reasons to Retain PacBio  ( PACB )  Stock in Your Portfolio Now", "url": "https://www.zacks.com/stock/news/2202089/reasons-to-retain-pacbio-pacb-stock-in-your-portfolio-now", "time_published": "20231226T132400", "authors": ["Zacks Equity Research"], "summary": "PacBio's (PACB) product development activities raise optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c2/53795.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.682689"}], "overall_sentiment_score": 0.321452, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BDSX", "relevance_score": "0.155786", "ticker_sentiment_score": "0.047546", "ticker_sentiment_label": "Neutral"}, {"ticker": "HQY", "relevance_score": "0.155786", "ticker_sentiment_score": "0.089457", "ticker_sentiment_label": "Neutral"}, {"ticker": "WGS", "relevance_score": "0.155786", "ticker_sentiment_score": "0.101184", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.155786", "ticker_sentiment_score": "0.112918", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.256719", "ticker_sentiment_score": "0.241463", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "What's Up With Pacific Biosciences Stock? - Pacific Biosciences  ( NASDAQ:PACB ) ", "url": "https://www.benzinga.com/general/biotech/23/12/36316766/whats-up-with-pacific-biosciences-stock", "time_published": "20231219T225236", "authors": ["Ryan Gustafson"], "summary": "Pacific Biosciences of California Inc PACB shares traded higher on Tuesday. A few significant analyst upgrades over the past several weeks have helped to lift the stock out of its prolonged downtrend. What To Know: Shares of the stock had been in an extended downtrend throughout the summer and ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/19/medications-1853400_12806.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.127369, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.644033", "ticker_sentiment_score": "0.585786", "ticker_sentiment_label": "Bullish"}]}, {"title": "Why Is Pacific Biosciences of California Stock Soaring Today? - Pacific Biosciences  ( NASDAQ:PACB ) ", "url": "https://www.benzinga.com/news/23/12/36242414/why-is-pacific-biosciences-of-california-stock-soaring-today", "time_published": "20231214T204109", "authors": ["Vandana Singh"], "summary": "Stephens initiated coverage on Pacific Biosciences of California Inc PACB, noting a solid management team, the market opportunity of long-read, and refraining from taking over the short-read market. PACB offers next-generation sequencing ( NGS ) products and solutions.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/14/pacbio_rsii_2.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.212698, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.639616", "ticker_sentiment_score": "0.515486", "ticker_sentiment_label": "Bullish"}]}, {"title": "Jabil Posts Upbeat Earnings, Joins Moderna, Rivian Automotive And Other Big Stocks Moving Higher On Thursday - Alcoa  ( NYSE:AA ) , Alector  ( NASDAQ:ALEC ) ", "url": "https://www.benzinga.com/news/23/12/36239155/jabil-posts-upbeat-earnings-joins-moderna-rivian-automotive-and-other-big-stocks-moving-higher-on-th", "time_published": "20231214T151520", "authors": ["Avi Kapoor"], "summary": "U.S. stocks traded higher, with the Nasdaq Composite gaining around 75 points on Thursday. Shares of Jabil Inc. JBL rose during Thursday's session after the company reported first-quarter earnings. Jabil reported quarterly revenue of $8.39 billion, down by 13% year-on-year, beating the consensus ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/14/jabil_-_logo_0.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.210657, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AA", "relevance_score": "0.290033", "ticker_sentiment_score": "0.366527", "ticker_sentiment_label": "Bullish"}, {"ticker": "ENPH", "relevance_score": "0.195814", "ticker_sentiment_score": "0.501186", "ticker_sentiment_label": "Bullish"}, {"ticker": "CG", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CFG", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOVA", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RIVN", "relevance_score": "0.195814", "ticker_sentiment_score": "0.303754", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GFI", "relevance_score": "0.195814", "ticker_sentiment_score": "0.129246", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALGN", "relevance_score": "0.290033", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OPEN", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LCID", "relevance_score": "0.290033", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FSLR", "relevance_score": "0.195814", "ticker_sentiment_score": "0.501186", "ticker_sentiment_label": "Bullish"}, {"ticker": "RF", "relevance_score": "0.195814", "ticker_sentiment_score": "0.501186", "ticker_sentiment_label": "Bullish"}, {"ticker": "JBL", "relevance_score": "0.380012", "ticker_sentiment_score": "0.178746", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.195814", "ticker_sentiment_score": "0.006443", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALEC", "relevance_score": "0.290033", "ticker_sentiment_score": "0.257527", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "POOL", "relevance_score": "0.195814", "ticker_sentiment_score": "0.501186", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.290033", "ticker_sentiment_score": "0.076997", "ticker_sentiment_label": "Neutral"}, {"ticker": "RDFN", "relevance_score": "0.195814", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Shockwave Medical  ( SWAV )  Down 1% Since Last Earnings Report: Can It Rebound?", "url": "https://www.zacks.com/stock/news/2194331/shockwave-medical-swav-down-1-since-last-earnings-report-can-it-rebound", "time_published": "20231206T163034", "authors": ["Zacks Equity Research"], "summary": "Shockwave Medical (SWAV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default294.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.990786"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.128682, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.050465", "ticker_sentiment_score": "0.061485", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.431065", "ticker_sentiment_score": "0.134248", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is IQVIA  ( IQV )  Up 12.4% Since Last Earnings Report?", "url": "https://www.zacks.com/stock/news/2192443/why-is-iqvia-iqv-up-124-since-last-earnings-report", "time_published": "20231201T163143", "authors": ["Zacks Equity Research"], "summary": "IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default129.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.998645"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.056607, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.062271", "ticker_sentiment_score": "0.062007", "ticker_sentiment_label": "Neutral"}, {"ticker": "IQV", "relevance_score": "0.360752", "ticker_sentiment_score": "0.170596", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday - Adaptive Biotechnologies  ( NASDAQ:ADPT ) , Accolade  ( NASDAQ:ACCD ) ", "url": "https://www.benzinga.com/news/23/11/35779972/azenta-reports-upbeat-earnings-joins-talis-biomedical-sally-beauty-and-other-big-stocks-moving-highe", "time_published": "20231114T153913", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. AZTA rose on Tuesday after the company reported better-than-expected fourth-quarter financial results. Azenta posted adjusted earnings of 13 cents per share, beating market estimates of 2 ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/14/image40.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.333893, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PCT", "relevance_score": "0.202366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMRC", "relevance_score": "0.202366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "JANX", "relevance_score": "0.202366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNIT", "relevance_score": "0.202366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGTI", "relevance_score": "0.299478", "ticker_sentiment_score": "0.341199", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TLIS", "relevance_score": "0.202366", "ticker_sentiment_score": "0.264012", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PSFE", "relevance_score": "0.202366", "ticker_sentiment_score": "0.422837", "ticker_sentiment_label": "Bullish"}, {"ticker": "NOVA", "relevance_score": "0.202366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZIONL", "relevance_score": "0.102013", "ticker_sentiment_score": "0.291681", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PLUG", "relevance_score": "0.202366", "ticker_sentiment_score": "0.511259", "ticker_sentiment_label": "Bullish"}, {"ticker": "SNAP", "relevance_score": "0.202366", "ticker_sentiment_score": "0.370202", "ticker_sentiment_label": "Bullish"}, {"ticker": "SLG", "relevance_score": "0.202366", "ticker_sentiment_score": "0.511259", "ticker_sentiment_label": "Bullish"}, {"ticker": "CMPS", "relevance_score": "0.202366", "ticker_sentiment_score": "0.511259", "ticker_sentiment_label": "Bullish"}, {"ticker": "PACB", "relevance_score": "0.202366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VNO", "relevance_score": "0.202366", "ticker_sentiment_score": "0.511259", "ticker_sentiment_label": "Bullish"}, {"ticker": "ARVN", "relevance_score": "0.202366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AX", "relevance_score": "0.202366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZTA", "relevance_score": "0.391923", "ticker_sentiment_score": "0.402693", "ticker_sentiment_label": "Bullish"}, {"ticker": "SBH", "relevance_score": "0.202366", "ticker_sentiment_score": "0.376038", "ticker_sentiment_label": "Bullish"}, {"ticker": "ADPT", "relevance_score": "0.299478", "ticker_sentiment_score": "-0.347995", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "Z", "relevance_score": "0.299478", "ticker_sentiment_score": "0.365484", "ticker_sentiment_label": "Bullish"}, {"ticker": "ACCD", "relevance_score": "0.202366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AFRM", "relevance_score": "0.202366", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cathie Wood's Ark Invest Purchases $9.5M Worth Of Robinhood Shares, Downsizes Holdings Of Grayscale Bitcoin Investment Trust - ARK Fintech Innovation ETF  ( ARCA:ARKF ) , ARK Innovation ETF  ( ARCA:ARKK ) ", "url": "https://www.benzinga.com/markets/equities/23/11/35692174/cathie-woods-ark-invest-purchases-9-5m-worth-of-robinhood-shares-downsizes-holdings-of-grayscale", "time_published": "20231109T044247", "authors": ["Benzinga Neuro"], "summary": "On Wednesday, in a significant move, Cathie Wood-led Ark Invest purchased over $9.5 million worth of shares in Robinhood Markets Inc HOOD, signaling a bullish stance on the brokerage firm despite its mixed third-quarter earnings report.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Cathie-Wood-Photo-courtesy-Benzinga-YouT.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.94762"}, {"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.422537, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.120431", "ticker_sentiment_score": "0.379496", "ticker_sentiment_label": "Bullish"}, {"ticker": "ROKU", "relevance_score": "0.238133", "ticker_sentiment_score": "0.315001", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SSTK", "relevance_score": "0.120431", "ticker_sentiment_score": "0.379496", "ticker_sentiment_label": "Bullish"}, {"ticker": "TXG", "relevance_score": "0.238133", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOOD", "relevance_score": "0.238133", "ticker_sentiment_score": "0.425744", "ticker_sentiment_label": "Bullish"}, {"ticker": "PACB", "relevance_score": "0.238133", "ticker_sentiment_score": "0.262305", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.120431", "ticker_sentiment_score": "0.353449", "ticker_sentiment_label": "Bullish"}]}, {"title": "Global Precision Medicine Market Size Demonstrates Consistent Growth with a CAGR of 11.12%, with North America Taking a Leading Role - Illumina  ( NASDAQ:ILMN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ", "url": "https://www.benzinga.com/pressreleases/23/11/g35674541/global-precision-medicine-market-size-demonstrates-consistent-growth-with-a-cagr-of-11-12-with-nor", "time_published": "20231108T145000", "authors": ["Globe Newswire"], "summary": "New York, United States, Nov. 08, 2023 ( GLOBE NEWSWIRE ) -- Precision medicine is a new approach to treating and preventing disease that considers each individual's genetic, environmental, and lifestyle differences. Giving the proper treatment to the right patient at the right time is the goal ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.145794, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.039353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.039353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.039353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.194868", "ticker_sentiment_score": "0.144939", "ticker_sentiment_label": "Neutral"}, {"ticker": "JNJ", "relevance_score": "0.039353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.039353", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BMY", "relevance_score": "0.156461", "ticker_sentiment_score": "0.115839", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( NASDAQ:PACB )  Upgraded to Sell by StockNews.com", "url": "https://www.defenseworld.net/2023/11/07/pacific-biosciences-of-california-nasdaqpacb-upgraded-to-sell-by-stocknews-com.html", "time_published": "20231107T094645", "authors": ["Defense World Staff"], "summary": "Pacific Biosciences of California ( NASDAQ:PACB ) Upgraded to Sell ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pacific-biosciences-of-california-inc-logo.png?v=20221123085851&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "1.0"}, {"topic": "Earnings", "relevance_score": "0.988915"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.220363, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BK", "relevance_score": "0.085324", "ticker_sentiment_score": "0.154809", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.127682", "ticker_sentiment_score": "0.107785", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.801457", "ticker_sentiment_score": "0.363412", "ticker_sentiment_label": "Bullish"}, {"ticker": "MS", "relevance_score": "0.042723", "ticker_sentiment_score": "0.050806", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio  ( PACB )  Tops on Q3 Earnings, Raises FY23 Revenue View", "url": "https://www.zacks.com/stock/news/2175683/pacbio-pacb-tops-on-q3-earnings-raises-fy23-revenue-view", "time_published": "20231031T153500", "authors": ["Zacks Equity Research"], "summary": "PacBio (PACB) witnesses strong revenue growth in the third quarter, partly aided by customers' continued product transition to the Revio system.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/dd/52606.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.999691"}], "overall_sentiment_score": 0.064889, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.081552", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.162255", "ticker_sentiment_score": "0.024365", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.202028", "ticker_sentiment_score": "0.30258", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.162255", "ticker_sentiment_score": "-0.006828", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cathie Wood Just Added $5 Million of This Stock After It Had a Steep Pullback. Is It a No-Brainer Buy?", "url": "https://www.fool.com/investing/2023/10/18/cathie-wood-just-added-million-of-this-stock-pacp/", "time_published": "20231018T095200", "authors": ["Keith Speights"], "summary": "This innovator is targeting a huge, rapidly growing market.", "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.999921"}], "overall_sentiment_score": 0.316047, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.123844", "ticker_sentiment_score": "-0.003517", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.06211", "ticker_sentiment_score": "0.121041", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio's  ( PACB )  New Offering to Boost WGS Data Analysis", "url": "https://www.zacks.com/stock/news/2167258/pacbios-pacb-new-offering-to-boost-wgs-data-analysis", "time_published": "20231017T140400", "authors": ["Zacks Equity Research"], "summary": "PacBio's (PACB) latest software pipeline is likely to provide standardization to HiFi WGS analysis.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.26654, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.098255", "ticker_sentiment_score": "0.130248", "ticker_sentiment_label": "Neutral"}, {"ticker": "HQY", "relevance_score": "0.195025", "ticker_sentiment_score": "0.043495", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.195025", "ticker_sentiment_score": "0.156206", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.195025", "ticker_sentiment_score": "0.094153", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.098255", "ticker_sentiment_score": "0.103657", "ticker_sentiment_label": "Neutral"}]}, {"title": "Merit Medical's  ( MMSI )  New Launch to Expand Its Product Suite", "url": "https://www.zacks.com/stock/news/2165038/merit-medicals-mmsi-new-launch-to-expand-its-product-suite", "time_published": "20231012T155500", "authors": ["Zacks Equity Research"], "summary": "Merit Medical's (MMSI) latest addition to its Vascular portfolio is expected to significantly improve patient outcomes.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/07/49005.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.714479"}], "overall_sentiment_score": 0.316512, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MMSI", "relevance_score": "0.12546", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.247838", "ticker_sentiment_score": "0.153571", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.247838", "ticker_sentiment_score": "0.120992", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.12546", "ticker_sentiment_score": "0.092266", "ticker_sentiment_label": "Neutral"}]}, {"title": "Three Reasons to Add PacBio  ( PACB )  Stock to Your Portfolio", "url": "https://www.zacks.com/stock/news/2161714/three-reasons-to-add-pacbio-pacb-stock-to-your-portfolio", "time_published": "20231006T161100", "authors": ["Zacks Equity Research"], "summary": "PacBio's (PACB) product development activities raise optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.682689"}], "overall_sentiment_score": 0.273579, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "WGS", "relevance_score": "0.059488", "ticker_sentiment_score": "0.184019", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITGR", "relevance_score": "0.234684", "ticker_sentiment_score": "0.1576", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.234684", "ticker_sentiment_score": "0.062372", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.118647", "ticker_sentiment_score": "0.167497", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.234684", "ticker_sentiment_score": "0.088765", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cathie Wood's Ark Invest Sells Over $25M Worth Of Tesla Shares Amid Boost In Price - NVIDIA  ( NASDAQ:NVDA ) , ARK Genomic Revolution ETF  ( BATS:ARKG ) , ARK Next Generation Internet ETF  ( ARCA:ARKW ) , CRISPR Therapeutics  ( NASDAQ:CRSP ) ", "url": "https://www.benzinga.com/markets/equities/23/10/35100076/cathie-woods-ark-invest-sells-over-25m-worth-of-tesla-shares-amid-boost-in-price", "time_published": "20231005T015433", "authors": ["Benzinga Neuro"], "summary": "On Wednesday, October 4, 2023, Cathie Wood-led Ark Invest made a significant move by selling over $25 million worth of Tesla Inc TSLA shares. This divestment is a notable shift, given Ark's previous bullish stance on the electric car maker, indicating a nuanced approach to portfolio management ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Cathie_Wood_Ark_Photo_courtesy_Benzinga_YouTube_and_Unsplash_36.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.938793"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.371374, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.12165", "ticker_sentiment_score": "0.381013", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVDA", "relevance_score": "0.240489", "ticker_sentiment_score": "0.274654", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRSP", "relevance_score": "0.240489", "ticker_sentiment_score": "0.344201", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSLA", "relevance_score": "0.641573", "ticker_sentiment_score": "0.610855", "ticker_sentiment_label": "Bullish"}, {"ticker": "PACB", "relevance_score": "0.240489", "ticker_sentiment_score": "0.344201", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DNA", "relevance_score": "0.240489", "ticker_sentiment_score": "0.295239", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Genomics Market reach USD 72.67 Bn by 2029 size to grow at a CAGR of 15.35 percent - says Maximize Market Research", "url": "https://www.benzinga.com/pressreleases/23/09/g34788962/genomics-market-reach-usd-72-67-bn-by-2029-size-to-grow-at-a-cagr-of-15-35-percent-says-maximize-m", "time_published": "20230921T114400", "authors": ["Globe Newswire"], "summary": "Pune, Sept. 21, 2023 ( GLOBE NEWSWIRE ) -- Maximize Market Research a leading Healthcare research firm has published a market intelligence report on the Global Genomics Market.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.250081, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.029545", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIO", "relevance_score": "0.029545", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTTF", "relevance_score": "0.029545", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.029545", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYGN", "relevance_score": "0.029545", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.029545", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Strength Seen in Pacific Biosciences  ( PACB ) : Can Its 8.9% Jump Turn into More Strength?", "url": "https://www.zacks.com/stock/news/2148734/strength-seen-in-pacific-biosciences-pacb-can-its-89-jump-turn-into-more-strength", "time_published": "20230914T113000", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences (PACB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default233.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.95493"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.289897, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ISRG", "relevance_score": "0.53784", "ticker_sentiment_score": "0.110138", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.340915", "ticker_sentiment_score": "0.36407", "ticker_sentiment_label": "Bullish"}]}, {"title": "Pacific Biosciences of California Stock Clears Key Benchmark, Hitting 80-Plus RS Rating", "url": "https://www.investors.com/research/pacific-biosciences-of-california-clears-key-benchmark-hitting-80-plus-rs-rating/", "time_published": "20230913T164800", "authors": ["Investor's Business Daily", "JULIE MAK", "INVESTOR'S BUSINESS DAILY"], "summary": "Pacific Biosciences of California Stock Clears Key Benchmark ... Investor's Business Daily ...", "banner_image": "https://www.investors.com/wp-content/uploads/2017/05/IRU4.jpg", "source": "Investors Business Daily", "category_within_source": "n/a", "source_domain": "www.investors.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.325847, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HAE", "relevance_score": "0.308891", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IDXX", "relevance_score": "0.308891", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.573213", "ticker_sentiment_score": "0.14417", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cathie Wood's Buying These 3 Stocks Hand Over Fist", "url": "https://www.fool.com/investing/2023/09/08/cathie-woods-buying-these-3-stocks-hand-over-fist/", "time_published": "20230908T112300", "authors": ["Cory Renauer"], "summary": "A drugmaker, a gene sequencer, and a streaming business all made deep impressions on Ark Invest's stock-picking team.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F746792%2Finvestor-with-stock-chart-getty.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.980716"}, {"topic": "Earnings", "relevance_score": "0.995973"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.228712, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BEAM", "relevance_score": "0.204936", "ticker_sentiment_score": "0.264927", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AAPL", "relevance_score": "0.051774", "ticker_sentiment_score": "0.121756", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERV", "relevance_score": "0.051774", "ticker_sentiment_score": "0.113498", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPOT", "relevance_score": "0.303175", "ticker_sentiment_score": "0.195224", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.154455", "ticker_sentiment_score": "0.082774", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.154455", "ticker_sentiment_score": "0.065401", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain PacBio  ( PACB )  Stock for Now", "url": "https://www.zacks.com/stock/news/2144992/heres-why-you-should-retain-pacbio-pacb-stock-for-now", "time_published": "20230905T162500", "authors": ["Zacks Equity Research"], "summary": "PacBio's (PACB) product development activities raise optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.288332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.218325", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WGS", "relevance_score": "0.055236", "ticker_sentiment_score": "0.183911", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ITGR", "relevance_score": "0.218325", "ticker_sentiment_score": "0.153795", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.110209", "ticker_sentiment_score": "0.183387", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DVA", "relevance_score": "0.218325", "ticker_sentiment_score": "0.082083", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.055236", "ticker_sentiment_score": "0.08798", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( NASDAQ:PACB )  Upgraded to Sell at StockNews.com", "url": "https://www.defenseworld.net/2023/08/31/pacific-biosciences-of-california-nasdaqpacb-upgraded-to-sell-at-stocknews-com.html", "time_published": "20230831T082442", "authors": ["Defense World Staff"], "summary": "Pacific Biosciences of California ( NASDAQ:PACB ) Upgraded to Sell ... Defense World ...", "banner_image": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pacific-biosciences-of-california-inc-logo.png?v=20221123085851&w=240&h=240&zc=2", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "www.defenseworld.net", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.998962"}, {"topic": "Earnings", "relevance_score": "0.99246"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.263208, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AB", "relevance_score": "0.114956", "ticker_sentiment_score": "0.242985", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCS", "relevance_score": "0.057628", "ticker_sentiment_score": "0.052957", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.830401", "ticker_sentiment_score": "0.433171", "ticker_sentiment_label": "Bullish"}, {"ticker": "MS", "relevance_score": "0.057628", "ticker_sentiment_score": "0.052957", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rising Fuel Costs Lead To Win For Energy, Cathie Wood's Biotech Play Loses Big - ETF Winners And Losers: Medium-Cap Returns - ARK Genomic Revolution ETF  ( BATS:ARKG ) , SPDR S&P Oil & Gas Explor & Product  ( ARCA:XOP ) ", "url": "https://www.benzinga.com/news/23/08/33842374/rising-fuel-costs-lead-to-win-for-energy-cathie-woods-biotech-play-loses-big-etf-winners-and-losers", "time_published": "20230814T201437", "authors": ["Johnny Rice"], "summary": "We performed a screening of medium-cap ETFs, defined as having Assets Under Management ( AUM ) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on the week, according to data from etfdb.com. Only non-leveraged funds were considered.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/08/14/arvind-vallabh-rqwwhkzvcau-unsplash.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Energy & Transportation", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.190363, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BABA", "relevance_score": "0.09989", "ticker_sentiment_score": "0.019608", "ticker_sentiment_label": "Neutral"}, {"ticker": "APA", "relevance_score": "0.198221", "ticker_sentiment_score": "0.181096", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CVX", "relevance_score": "0.198221", "ticker_sentiment_score": "0.181096", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EXAS", "relevance_score": "0.198221", "ticker_sentiment_score": "0.190267", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.198221", "ticker_sentiment_score": "0.190267", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "XOM", "relevance_score": "0.198221", "ticker_sentiment_score": "0.181096", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SM", "relevance_score": "0.198221", "ticker_sentiment_score": "0.181096", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TCTZF", "relevance_score": "0.09989", "ticker_sentiment_score": "0.019608", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought", "url": "https://www.fool.com/investing/2023/08/09/cathie-wood-goes-bargain-hunting-3-stocks-she-just/", "time_published": "20230809T140000", "authors": ["Rick Munarriz"], "summary": "The growth-focused money manager is making moves, with her ETFs beating the market again in 2023 after terrible returns the two previous years.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F743392%2Fgettycash-fan.jpg&op=resize&w=700", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}, {"topic": "Earnings", "relevance_score": "0.998682"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.19352, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GLBE", "relevance_score": "0.132368", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.197413", "ticker_sentiment_score": "0.02983", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLTR", "relevance_score": "0.132368", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio  ( PACB )  Inks Research Collaboration for Genome Sequencing", "url": "https://www.zacks.com/stock/news/2134275/pacbio-pacb-inks-research-collaboration-for-genome-sequencing", "time_published": "20230809T121600", "authors": ["Zacks Equity Research"], "summary": "PacBio (PACB) and GeneDx sign a deal with the University of Washington to study long-read sequencing in rare diseases. The study will use PacBio's Revio system to explore novel variants.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/7b/850.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.220373, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GOOG", "relevance_score": "0.120733", "ticker_sentiment_score": "0.095128", "ticker_sentiment_label": "Neutral"}, {"ticker": "WGS", "relevance_score": "0.552443", "ticker_sentiment_score": "0.240095", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.295867", "ticker_sentiment_score": "0.210311", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DXCM", "relevance_score": "0.180236", "ticker_sentiment_score": "0.146051", "ticker_sentiment_label": "Neutral"}]}, {"title": "Palantir Post Q2 Earnings Share Price Dip Doesn't Deter Cathie Wood - Ark Invest Buys $14M Worth Of Shares - DraftKings  ( NASDAQ:DKNG ) , Roku  ( NASDAQ:ROKU ) , ARK Fintech Innovation ETF  ( ARCA:ARKF ) , ARK Genomic Revolution ETF  ( BATS:ARKG ) , ARK Next Generation Internet ETF  ( ARCA:ARKW ) , Pacific Biosciences  ( NASDAQ:PACB ) , ARK Innovation ETF  ( ARCA:ARKK ) , Palantir Technologies  ( NYSE:PLTR ) ", "url": "https://www.benzinga.com/markets/equities/23/08/33651868/palantir-post-q2-earnings-share-price-dip-doesnt-deter-cathie-wood-ark-invest-buys-14m-worth-of-", "time_published": "20230809T030338", "authors": ["Benzinga Neuro"], "summary": "On Tuesday, August 8, 2023, Cathie Wood-led Ark Invest made headlines by purchasing nearly $14 million worth of shares in Palantir Technologies Inc PLTR. This significant acquisition comes in the wake of Palantir's recent second-quarter earnings report, which aligned with estimates and included ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Cathie_Wood_Ark_Photo_courtesy_Benzinga_YouTube_and_Unsplash_25.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.938238"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.428666, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.228073", "ticker_sentiment_score": "0.593465", "ticker_sentiment_label": "Bullish"}, {"ticker": "ROKU", "relevance_score": "0.228073", "ticker_sentiment_score": "0.327781", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.228073", "ticker_sentiment_score": "0.445124", "ticker_sentiment_label": "Bullish"}, {"ticker": "PLTR", "relevance_score": "0.228073", "ticker_sentiment_score": "0.288575", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports - DraftKings  ( NASDAQ:DKNG ) , 10x Genomics  ( NASDAQ:TXG ) , ARK Genomic Revolution ETF  ( BATS:ARKG ) , ARK Next Generation Internet ETF  ( ARCA:ARKW ) , Pacific Biosciences  ( NASDAQ:PACB ) , Quantum-Si  ( NASDAQ:QSI ) , Genius Sports  ( NYSE:GENI ) , Ionis Pharmaceuticals  ( NASDAQ:IONS ) , Recursion Pharmaceuticals  ( NASDAQ:RXRX ) , Accolade  ( NASDAQ:ACCD ) , ARK Innovation ETF  ( ARCA:ARKK ) ", "url": "https://www.benzinga.com/markets/equities/23/08/33613338/cathie-wood-buys-shares-of-pacific-biosciences-reduces-exposure-to-draftkings-and-genius-sports", "time_published": "20230808T020005", "authors": ["Benzinga Neuro"], "summary": "On Monday, August 7, 2023, Cathie Wood-led Ark Invest made significant trades, with the most notable being a substantial acquisition of shares in Pacific Biosciences of California PACB. This move comes shortly after PACB announced its impressive second-quarter financial results, showcasing a 34% ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Cathie_Wood_Ark_Photo_courtesy_Benzinga_YouTube_and_Unsplash_24.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.796627"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}], "overall_sentiment_score": 0.442158, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "DKNG", "relevance_score": "0.473208", "ticker_sentiment_score": "0.728909", "ticker_sentiment_label": "Bullish"}, {"ticker": "TXG", "relevance_score": "0.199859", "ticker_sentiment_score": "0.405845", "ticker_sentiment_label": "Bullish"}, {"ticker": "PACB", "relevance_score": "0.473208", "ticker_sentiment_score": "0.44845", "ticker_sentiment_label": "Bullish"}, {"ticker": "GENI", "relevance_score": "0.295867", "ticker_sentiment_score": "0.368032", "ticker_sentiment_label": "Bullish"}, {"ticker": "IONS", "relevance_score": "0.199859", "ticker_sentiment_score": "0.405845", "ticker_sentiment_label": "Bullish"}, {"ticker": "RXRX", "relevance_score": "0.199859", "ticker_sentiment_score": "0.364141", "ticker_sentiment_label": "Bullish"}, {"ticker": "ACCD", "relevance_score": "0.199859", "ticker_sentiment_score": "0.300722", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio Reports Equity Incentive Awards to New Employees Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ", "url": "https://www.prnewswire.com/news-releases/pacbio-reports-equity-incentive-awards-to-new-employees-under-nasdaq-listing-rule-5635c4-301894034.html", "time_published": "20230804T232000", "authors": ["Pacific Biosciences of California", "Inc."], "summary": "MENLO PARK, Calif., Aug. 4, 2023 /PRNewswire/ -- PacBio ( NASDAQ: PACB ) , a leading developer of high-quality, highly accurate sequencing solutions, today announced that PacBio's Compensation Committee of the Board of Directors granted non-qualified stock options covering an aggregate of ...", "banner_image": "https://mma.prnewswire.com/media/1861430/PacBio_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.99393"}], "overall_sentiment_score": 0.343232, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.276909", "ticker_sentiment_score": "0.319203", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cathie Wood's Ark Invest Acquires $5.5M of Robinhood Shares Following Platform's First Profitable Quarter - Teradyne  ( NASDAQ:TER ) , ARK Fintech Innovation ETF  ( ARCA:ARKF ) , ARK Genomic Revolution ETF  ( BATS:ARKG ) , ARK Next Generation Internet ETF  ( ARCA:ARKW ) , Pacific Biosciences  ( NASDAQ:PACB ) , ARK Autonomous Technology & Robotics ETF  ( BATS:ARKQ ) , Accolade  ( NASDAQ:ACCD ) , Robinhood Markets  ( NASDAQ:HOOD ) , ARK Innovation ETF  ( ARCA:ARKK ) , Intellia Therapeutics  ( NASDAQ:NTLA ) ", "url": "https://www.benzinga.com/markets/equities/23/08/33565298/cathie-woods-ark-invest-acquires-5-5m-of-robinhood-shares-following-platforms-first-profitable-q", "time_published": "20230804T020757", "authors": ["Benzinga Neuro"], "summary": "On Thursday, Cathie Wood-led Ark Invest made several trades, the most prominent being a substantial purchase of Robinhood Markets Inc HOOD shares. This move comes in the wake of Robinhood's recent Q2 earnings report that beat Street estimates and marked the company's first profitable quarter.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/Cathie_Wood_Ark_Photo_courtesy_Benzinga_YouTube_and_Unsplash_23.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Markets", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.875462"}, {"topic": "Earnings", "relevance_score": "0.818451"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.41631, "overall_sentiment_label": "Bullish", "ticker_sentiment": [{"ticker": "TER", "relevance_score": "0.240489", "ticker_sentiment_score": "0.382134", "ticker_sentiment_label": "Bullish"}, {"ticker": "ADPT", "relevance_score": "0.240489", "ticker_sentiment_score": "0.317332", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACCD", "relevance_score": "0.240489", "ticker_sentiment_score": "0.360799", "ticker_sentiment_label": "Bullish"}, {"ticker": "HOOD", "relevance_score": "0.240489", "ticker_sentiment_score": "0.476607", "ticker_sentiment_label": "Bullish"}, {"ticker": "PACB", "relevance_score": "0.240489", "ticker_sentiment_score": "0.461355", "ticker_sentiment_label": "Bullish"}, {"ticker": "NTLA", "relevance_score": "0.240489", "ticker_sentiment_score": "0.360799", "ticker_sentiment_label": "Bullish"}]}, {"title": "PacBio  ( PACB )  Tops on Q2 Earnings, Raises FY23 Revenue View", "url": "https://www.zacks.com/stock/news/2132189/pacbio-pacb-tops-on-q2-earnings-raises-fy23-revenue-view", "time_published": "20230803T171600", "authors": ["Zacks Equity Research"], "summary": "PacBio (PACB) witnesses strong revenue growth in the second quarter, partly aided by customers' product transition to the Revio system.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3c/35363.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.998663"}], "overall_sentiment_score": 0.03357, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ABT", "relevance_score": "0.088472", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.175859", "ticker_sentiment_score": "0.025754", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.175859", "ticker_sentiment_score": "-0.007221", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.218817", "ticker_sentiment_score": "0.352451", "ticker_sentiment_label": "Bullish"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Reports Q2 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2131426/pacific-biosciences-of-california-pacb-reports-q2-loss-tops-revenue-estimates", "time_published": "20230802T221518", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences (PACB) delivered earnings and revenue surprises of 23.53% and 17.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default168.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.128375, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VCYT", "relevance_score": "0.138066", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.138066", "ticker_sentiment_score": "-0.063787", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California, Inc. Q2 Loss Decreases, beats estimates", "url": "https://markets.businessinsider.com/news/stocks/pacific-biosciences-of-california-inc-q2-loss-decreases-beats-estimates-1032508560", "time_published": "20230802T221506", "authors": ["markets.businessinsider.com"], "summary": "( RTTNews ) - Pacific Biosciences of California, Inc. ( PACB ) reported Loss for second quarter that decreased from the same period last year and beat the Street estimates. The company's bottom line totaled -$69.33 million, or -$0.28 per share.", "banner_image": "https://markets.businessinsider.com/Images/FacebookIcon.jpg", "source": "Business Insider", "category_within_source": "GoogleRSS", "source_domain": "markets.businessinsider.com", "topics": [{"topic": "Earnings", "relevance_score": "0.938793"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.117087, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.769861", "ticker_sentiment_score": "-0.007911", "ticker_sentiment_label": "Neutral"}, {"ticker": "TRI", "relevance_score": "0.235823", "ticker_sentiment_score": "0.19842", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Is a Beat Likely for DENTSPLY SIRONA  ( XRAY )  in Q2 Earnings?", "url": "https://www.zacks.com/stock/news/2130463/is-a-beat-likely-for-dentsply-sirona-xray-in-q2-earnings", "time_published": "20230801T131100", "authors": ["Zacks Equity Research"], "summary": "DENTSPLY SIRONA's (XRAY) second-quarter 2023 results are likely to reflect recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999996"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.118679, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.139669", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.139669", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "XRAY", "relevance_score": "0.402403", "ticker_sentiment_score": "0.271554", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Revvity  ( RVTY )  to Report Q2 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2129877/revvity-rvty-to-report-q2-earnings-whats-in-the-cards", "time_published": "20230731T124000", "authors": ["Zacks Equity Research"], "summary": "Revvity's (RVTY) second-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/e7/2307.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999973"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}], "overall_sentiment_score": 0.085886, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AZN", "relevance_score": "0.049221", "ticker_sentiment_score": "0.222138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.098255", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.098255", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVTY", "relevance_score": "0.421485", "ticker_sentiment_score": "0.239061", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "McKesson  ( MCK )  to Report Q1 Earnings: Is a Beat in Store?", "url": "https://www.zacks.com/stock/news/2129879/mckesson-mck-to-report-q1-earnings-is-a-beat-in-store", "time_published": "20230731T123700", "authors": ["Zacks Equity Research"], "summary": "McKesson's (MCK) fiscal first-quarter 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.999997"}], "overall_sentiment_score": 0.228311, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MCK", "relevance_score": "0.414559", "ticker_sentiment_score": "0.355081", "ticker_sentiment_label": "Bullish"}, {"ticker": "PACB", "relevance_score": "0.123844", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.123844", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Expected to Beat Earnings Estimates: Can the Stock Move Higher?", "url": "https://www.zacks.com/stock/news/2127960/pacific-biosciences-of-california-pacb-expected-to-beat-earnings-estimates-can-the-stock-move-higher", "time_published": "20230726T140202", "authors": ["Zacks Equity Research"], "summary": "Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default168.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.142465, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.087503", "ticker_sentiment_score": "0.079308", "ticker_sentiment_label": "Neutral"}, {"ticker": "KIDS", "relevance_score": "0.173958", "ticker_sentiment_score": "0.023904", "ticker_sentiment_label": "Neutral"}]}, {"title": "Is a Beat Likely for AmerisourceBergen  ( ABC )  in Q3 Earnings?", "url": "https://www.zacks.com/stock/news/2127575/is-a-beat-likely-for-amerisourcebergen-abc-in-q3-earnings", "time_published": "20230726T110400", "authors": ["Zacks Equity Research"], "summary": "AmerisourceBergen's (ABC) fiscal third-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.999989"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.210953, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AVNS", "relevance_score": "0.172097", "ticker_sentiment_score": "-0.066873", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.115232", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.115232", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Stryker  ( SYK )  to Report Q2 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2126933/stryker-syk-to-report-q2-earnings-whats-in-the-cards", "time_published": "20230725T125900", "authors": ["Zacks Equity Research"], "summary": "Stryker's (SYK) second-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.999973"}], "overall_sentiment_score": 0.237993, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AVNS", "relevance_score": "0.170075", "ticker_sentiment_score": "-0.066325", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.113866", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SYK", "relevance_score": "0.433215", "ticker_sentiment_score": "0.405278", "ticker_sentiment_label": "Bullish"}, {"ticker": "PACB", "relevance_score": "0.113866", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "DexCom  ( DXCM )  to Report Q2 Earnings: What's in the Cards?", "url": "https://www.zacks.com/stock/news/2126187/dexcom-dxcm-to-report-q2-earnings-whats-in-the-cards", "time_published": "20230724T131500", "authors": ["Zacks Equity Research"], "summary": "DexCom's (DXCM) second-quarter 2023 results are likely to reflect rising volumes across all channels.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "1.0"}], "overall_sentiment_score": 0.248635, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AVNS", "relevance_score": "0.153797", "ticker_sentiment_score": "-0.062044", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.102888", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.102888", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DXCM", "relevance_score": "0.349153", "ticker_sentiment_score": "0.21529", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Baxter  ( BAX )  to Post Q2 Earnings: What's in the Offing?", "url": "https://www.zacks.com/stock/news/2125454/baxter-bax-to-post-q2-earnings-whats-in-the-offing", "time_published": "20230721T135700", "authors": ["Zacks Equity Research"], "summary": "Baxter's (BAX) second-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/09/2677.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.173006, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "BAX", "relevance_score": "0.305058", "ticker_sentiment_score": "0.303456", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVNS", "relevance_score": "0.116914", "ticker_sentiment_score": "-0.004651", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.116914", "ticker_sentiment_score": "0.07603", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.039096", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.078099", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Intuitive Surgical  ( ISRG )  to Post Q2 Earnings: What's in Store?", "url": "https://www.zacks.com/stock/news/2123858/intuitive-surgical-isrg-to-post-q2-earnings-whats-in-store", "time_published": "20230719T140200", "authors": ["Zacks Investment Research"], "summary": "Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/15/2078.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}, {"topic": "Earnings", "relevance_score": "0.999937"}], "overall_sentiment_score": 0.199577, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MASI", "relevance_score": "0.047465", "ticker_sentiment_score": "-0.077905", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVNS", "relevance_score": "0.141726", "ticker_sentiment_score": "-0.06291", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.047465", "ticker_sentiment_score": "0.031001", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.141726", "ticker_sentiment_score": "0.094448", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.323078", "ticker_sentiment_score": "0.021006", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.094762", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Reasons to Retain PacBio  ( PACB )  Stock in Your Portfolio", "url": "https://www.zacks.com/stock/news/2118221/3-reasons-to-retain-pacbio-pacb-stock-in-your-portfolio", "time_published": "20230707T160400", "authors": ["Zacks Investment Research"], "summary": "PacBio's (PACB) product development activities raise optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.769861"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.259934, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HQY", "relevance_score": "0.213988", "ticker_sentiment_score": "0.040703", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.213988", "ticker_sentiment_score": "0.133512", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.107978", "ticker_sentiment_score": "0.166055", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.213988", "ticker_sentiment_score": "0.04064", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:USD", "relevance_score": "0.054114", "ticker_sentiment_score": "0.075984", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio  ( PACB )  Gets New Order for Revio System From Bioscientia", "url": "https://www.zacks.com/stock/news/2115395/pacbio-pacb-gets-new-order-for-revio-system-from-bioscientia", "time_published": "20230630T131400", "authors": ["Zacks Investment Research"], "summary": "PacBio (PACB) receives new order for its Revio system from Bioscientia that will boost the latter's services. Here's how Revio can help Bioscientia improve diagnosis and treatment for monogenic disorders.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.576289"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.234838, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ALC", "relevance_score": "0.146618", "ticker_sentiment_score": "0.103831", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.146618", "ticker_sentiment_score": "0.106346", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.194632", "ticker_sentiment_score": "0.232786", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PRGO", "relevance_score": "0.098054", "ticker_sentiment_score": "0.053776", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio Announces a Private Convertible Exchange Transaction of $441 Million Principal Amount of 1.375% Convertible Senior Notes due 2030", "url": "https://www.prnewswire.com/news-releases/pacbio-announces-a-private-convertible-exchange-transaction-of-441-million-principal-amount-of-1-375-convertible-senior-notes-due-2030--301861431.html", "time_published": "20230626T100000", "authors": ["Pacific Biosciences of California", "Inc."], "summary": "PacBio Announces a Private Convertible Exchange Transaction of $441 Million Principal Amount of 1.375 ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1861430/PacBio_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.997874"}], "overall_sentiment_score": 0.256151, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GS", "relevance_score": "0.047371", "ticker_sentiment_score": "0.084914", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.141448", "ticker_sentiment_score": "0.122413", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio's  ( PACB )  New Tie-Up to Boost Rare Disease Research", "url": "https://www.zacks.com/stock/news/2110759/pacbios-pacb-new-tie-up-to-boost-rare-disease-research", "time_published": "20230620T154100", "authors": ["Zacks Investment Research"], "summary": "PacBio's (PACB) latest collaboration is expected to highlight the feasibility and cost-effectiveness of using its HiFi sequencing technology.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.247116, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HOLX", "relevance_score": "0.223866", "ticker_sentiment_score": "0.140024", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMSI", "relevance_score": "0.113062", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTVA", "relevance_score": "0.056674", "ticker_sentiment_score": "0.135948", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.113062", "ticker_sentiment_score": "0.055119", "ticker_sentiment_label": "Neutral"}, {"ticker": "BSX", "relevance_score": "0.223866", "ticker_sentiment_score": "0.042116", "ticker_sentiment_label": "Neutral"}]}, {"title": "Genomics Market Size to Grow by USD 18,244.34 million from 2022 to 2027, North America is estimated to contribute 37% to the global market growth - Technavio", "url": "https://www.prnewswire.com/news-releases/genomics-market-size-to-grow-by-usd-18-244-34-million-from-2022-to-2027--north-america-is-estimated-to-contribute-37-to-the-global-market-growth---technavio-301853361.html", "time_published": "20230619T071500", "authors": ["Technavio"], "summary": "Genomics Market Size to Grow by USD 18,244.34 million from 2022 to 2027, North America is estimated to contribute ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2104227/Technavio_Logo_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.194272, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.078354", "ticker_sentiment_score": "0.045313", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.052283", "ticker_sentiment_score": "-0.044004", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.052283", "ticker_sentiment_score": "0.044", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIO", "relevance_score": "0.052283", "ticker_sentiment_score": "0.044", "ticker_sentiment_label": "Neutral"}, {"ticker": "LAB", "relevance_score": "0.026155", "ticker_sentiment_score": "-0.041644", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.026155", "ticker_sentiment_score": "-0.041644", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABCM", "relevance_score": "0.052283", "ticker_sentiment_score": "-0.044004", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.026155", "ticker_sentiment_score": "-0.041644", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.026155", "ticker_sentiment_score": "-0.041644", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYGN", "relevance_score": "0.026155", "ticker_sentiment_score": "-0.041644", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.052283", "ticker_sentiment_score": "0.044", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTTF", "relevance_score": "0.026155", "ticker_sentiment_score": "-0.041644", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.026155", "ticker_sentiment_score": "-0.041644", "ticker_sentiment_label": "Neutral"}]}, {"title": "Epigenetics Market size to grow by USD 1,148.2 million from 2022-2027 with 40% of the market growth originate from North America - Technavio", "url": "https://www.prnewswire.com/news-releases/epigenetics-market-size-to-grow-by-usd-1-148-2-million-from-2022-2027-with-40-of-the-market-growth-originate-from-north-america---technavio-301852330.html", "time_published": "20230616T141500", "authors": ["Technavio"], "summary": "Epigenetics Market size to grow by USD 1,148.2 million from 2022-2027 with 40% of the market growth originate from ... PR ...", "banner_image": "https://mma.prnewswire.com/media/2103157/Technavio_Logo_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.093069, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ENZ", "relevance_score": "0.033098", "ticker_sentiment_score": "0.02861", "ticker_sentiment_label": "Neutral"}, {"ticker": "A", "relevance_score": "0.033098", "ticker_sentiment_score": "0.02861", "ticker_sentiment_label": "Neutral"}, {"ticker": "TECH", "relevance_score": "0.033098", "ticker_sentiment_score": "0.02861", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.033098", "ticker_sentiment_score": "0.02861", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABCM", "relevance_score": "0.033098", "ticker_sentiment_score": "0.02861", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.033098", "ticker_sentiment_score": "0.02861", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.033098", "ticker_sentiment_score": "0.02861", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.033098", "ticker_sentiment_score": "0.02861", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIO", "relevance_score": "0.033098", "ticker_sentiment_score": "0.02861", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.033098", "ticker_sentiment_score": "0.02861", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain Illumina  ( ILMN )  Stock for Now", "url": "https://www.zacks.com/stock/news/2108381/heres-why-you-should-retain-illumina-ilmn-stock-for-now", "time_published": "20230614T152200", "authors": ["Zacks Investment Research"], "summary": "Investors are optimistic about Illumina (ILMN) on solid long-term growth potential in the oncology space.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/c0/2297.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999813"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.283695, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.045139", "ticker_sentiment_score": "0.232975", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOLX", "relevance_score": "0.179121", "ticker_sentiment_score": "0.11826", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMSI", "relevance_score": "0.090134", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.045139", "ticker_sentiment_score": "0.232975", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.179121", "ticker_sentiment_score": "0.035512", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.349329", "ticker_sentiment_score": "0.448947", "ticker_sentiment_label": "Bullish"}, {"ticker": "MYGN", "relevance_score": "0.045139", "ticker_sentiment_score": "0.047419", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.045139", "ticker_sentiment_score": "0.232975", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QGEN", "relevance_score": "0.045139", "ticker_sentiment_score": "0.232975", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Here's Why You Should Retain PacBio  ( PACB )  Stock for Now", "url": "https://www.zacks.com/stock/news/2103412/heres-why-you-should-retain-pacbio-pacb-stock-for-now", "time_published": "20230602T160800", "authors": ["Zacks Investment Research"], "summary": "PacBio's (PACB) product development activities raise optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.838487"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.334271, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HOLX", "relevance_score": "0.206685", "ticker_sentiment_score": "0.169537", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MMSI", "relevance_score": "0.104228", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.104228", "ticker_sentiment_score": "0.212474", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.206685", "ticker_sentiment_score": "0.039551", "ticker_sentiment_label": "Neutral"}]}, {"title": "Inari Medical, Inc.  ( NARI )  Down 0.6% Since Last Earnings Report: Can It Rebound?", "url": "https://www.zacks.com/stock/news/2103326/inari-medical-inc-nari-down-06-since-last-earnings-report-can-it-rebound", "time_published": "20230602T153131", "authors": ["Zacks Investment Research"], "summary": "Inari Medical, Inc. (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default230.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.980509"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980922"}], "overall_sentiment_score": 0.096534, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.055881", "ticker_sentiment_score": "0.061889", "ticker_sentiment_label": "Neutral"}, {"ticker": "NARI", "relevance_score": "0.42503", "ticker_sentiment_score": "0.194759", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Cathie Wood Buys AMD Stock Amid 9% Drop - ARK Next Generation Internet ETF  ( ARCA:ARKW ) , Pacific Biosciences  ( NASDAQ:PACB ) , Advanced Micro Devices  ( NASDAQ:AMD ) ", "url": "https://www.benzinga.com/markets/equities/23/05/32204379/cathie-wood-scoops-up-amd-stock-on-a-day-when-it-tanks-over-9-also-raises-stake-in-this-biotech-", "time_published": "20230504T023523", "authors": ["Bhavik Nair"], "summary": "Cathie Wood-led ARK Investment Management bought over 26,200 shares of Advanced Micro Devices, Inc. AMD on Wednesday when the stock tanked over 9%, dragged by weak guidance and a slump in PC revenue.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/ARK_Photo_by_Ira_Lichi_on_Shutterstock_0.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.684621"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.413559"}], "overall_sentiment_score": -0.165519, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "AMD", "relevance_score": "0.832201", "ticker_sentiment_score": "-0.356757", "ticker_sentiment_label": "Bearish"}, {"ticker": "PACB", "relevance_score": "0.269776", "ticker_sentiment_score": "0.152861", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio  ( PACB )  Tops on Q1 Earnings, Raises FY23 Revenue View", "url": "https://www.zacks.com/stock/news/2089182/pacbio-pacb-tops-on-q1-earnings-raises-fy23-revenue-view", "time_published": "20230503T153500", "authors": ["Zacks Investment Research"], "summary": "PacBio (PACB) witnesses strong revenue growth in the first quarter. This is partly aided by customers' product transition to the Revio system.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d9/554.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999691"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}], "overall_sentiment_score": 0.009651, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "EW", "relevance_score": "0.161982", "ticker_sentiment_score": "-0.001376", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMSI", "relevance_score": "0.081414", "ticker_sentiment_score": "0.048832", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTVA", "relevance_score": "0.04076", "ticker_sentiment_score": "0.114939", "ticker_sentiment_label": "Neutral"}, {"ticker": "ISRG", "relevance_score": "0.161982", "ticker_sentiment_score": "0.038916", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.201691", "ticker_sentiment_score": "0.196327", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Reports Q1 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2088502/pacific-biosciences-of-california-pacb-reports-q1-loss-tops-revenue-estimates", "time_published": "20230502T211509", "authors": ["Zacks Investment Research"], "summary": "Pacific Biosciences (PACB) delivered earnings and revenue surprises of 6.06% and 10.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default294.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.114626, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.137671", "ticker_sentiment_score": "-0.063683", "ticker_sentiment_label": "Neutral"}, {"ticker": "DYNT", "relevance_score": "0.205225", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Genomics Market to be Worth $72.62 Billion by 2030 - Exclusive Report by Meticulous Research\u00ae", "url": "https://www.benzinga.com/pressreleases/23/04/g31790465/genomics-market-to-be-worth-72-62-billion-by-2030-exclusive-report-by-meticulous-research", "time_published": "20230413T150000", "authors": ["Globe Newswire"], "summary": "Redding, California, April 13, 2023 ( GLOBE NEWSWIRE ) -- According to a new market research report titled, 'Genomics Market by Offering ( Systems, Consumables, Software, Services ) , Technology ( Sequencing, Microarray, PCR ) , Application ( Diagnostics, Life Science Research ) , End User ( ...", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.160332, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.022686", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.022686", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.045353", "ticker_sentiment_score": "0.090479", "ticker_sentiment_label": "Neutral"}, {"ticker": "MYGN", "relevance_score": "0.022686", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.022686", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIO", "relevance_score": "0.022686", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTTF", "relevance_score": "0.022686", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.022686", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DHR", "relevance_score": "0.022686", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday - Allogene Therapeutics  ( NASDAQ:ALLO ) , AlloVir  ( NASDAQ:ALVR ) ", "url": "https://www.benzinga.com/news/23/04/31789935/consolidated-communications-crispr-therapeutics-and-other-big-stocks-moving-higher-on-thursday", "time_published": "20230413T143842", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today's session. Consolidated Communications Holdings, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/04/13/image_4.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}, {"topic": "Real Estate & Construction", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.23297, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MARA", "relevance_score": "0.277433", "ticker_sentiment_score": "0.616912", "ticker_sentiment_label": "Bullish"}, {"ticker": "WW", "relevance_score": "0.277433", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BANL", "relevance_score": "0.277433", "ticker_sentiment_score": "-0.460934", "ticker_sentiment_label": "Bearish"}, {"ticker": "SANA", "relevance_score": "0.277433", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EDIT", "relevance_score": "0.277433", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CCORF", "relevance_score": "0.277433", "ticker_sentiment_score": "0.114391", "ticker_sentiment_label": "Neutral"}, {"ticker": "CIFR", "relevance_score": "0.277433", "ticker_sentiment_score": "0.616912", "ticker_sentiment_label": "Bullish"}, {"ticker": "ALLO", "relevance_score": "0.277433", "ticker_sentiment_score": "0.616912", "ticker_sentiment_label": "Bullish"}, {"ticker": "MGNI", "relevance_score": "0.277433", "ticker_sentiment_score": "-0.040164", "ticker_sentiment_label": "Neutral"}, {"ticker": "CRSP", "relevance_score": "0.277433", "ticker_sentiment_score": "0.008521", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCM", "relevance_score": "0.277433", "ticker_sentiment_score": "-0.374915", "ticker_sentiment_label": "Bearish"}, {"ticker": "PACB", "relevance_score": "0.277433", "ticker_sentiment_score": "0.616912", "ticker_sentiment_label": "Bullish"}, {"ticker": "KPTI", "relevance_score": "0.277433", "ticker_sentiment_score": "0.616912", "ticker_sentiment_label": "Bullish"}, {"ticker": "SCLX", "relevance_score": "0.277433", "ticker_sentiment_score": "0.616912", "ticker_sentiment_label": "Bullish"}, {"ticker": "CNSL", "relevance_score": "0.405651", "ticker_sentiment_score": "0.335493", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VERV", "relevance_score": "0.277433", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "IBRX", "relevance_score": "0.277433", "ticker_sentiment_score": "0.616912", "ticker_sentiment_label": "Bullish"}, {"ticker": "NTLA", "relevance_score": "0.277433", "ticker_sentiment_score": "0.219579", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Next-Generation Sequencing Data Analysis Market to Reach USD 5.4 Bn by 2032 | Transparency Market Research", "url": "https://www.benzinga.com/pressreleases/23/04/g31770310/next-generation-sequencing-data-analysis-market-to-reach-usd-5-4-bn-by-2032-transparency-market-re", "time_published": "20230412T143000", "authors": ["Globe Newswire"], "summary": "Wilmington, Delaware, United States, April 12, 2023 ( GLOBE NEWSWIRE ) -- The global next-generation sequencing data analysis market was valued at USD 610.6 Mn in 2021 and is projected to reach USD 5.4 Bn by 2032 growing at a CAGR of 16.6%.", "banner_image": "https://www.benzinga.com/next-assets/images/schema-image-default.png", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.360215"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.08163, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.03878", "ticker_sentiment_score": "0.066392", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.03878", "ticker_sentiment_score": "0.066392", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.03878", "ticker_sentiment_score": "0.066392", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.03878", "ticker_sentiment_score": "0.066392", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIO", "relevance_score": "0.03878", "ticker_sentiment_score": "0.066392", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.03878", "ticker_sentiment_score": "0.066392", "ticker_sentiment_label": "Neutral"}, {"ticker": "ERFSF", "relevance_score": "0.03878", "ticker_sentiment_score": "0.066392", "ticker_sentiment_label": "Neutral"}]}, {"title": "All You Need to Know About Pacific Biosciences  ( PACB )  Rating Upgrade to Buy", "url": "https://www.zacks.com/stock/news/2077089/all-you-need-to-know-about-pacific-biosciences-pacb-rating-upgrade-to-buy", "time_published": "20230411T160007", "authors": ["Zacks Investment Research"], "summary": "Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default353.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.997845"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.658903"}], "overall_sentiment_score": 0.305727, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.122269", "ticker_sentiment_score": "0.107269", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio's  ( PACB )  New Offering to Enable High-Throughput Workflows", "url": "https://www.zacks.com/stock/news/2077016/pacbios-pacb-new-offering-to-enable-high-throughput-workflows", "time_published": "20230411T151400", "authors": ["Zacks Investment Research"], "summary": "PacBio's (PACB) latest launch is expected to combine the power of HiFi sequencing and Nanobind technology to optimize sample preparation workflows for its high-volume customers.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/2337.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.168426, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "MASI", "relevance_score": "0.217834", "ticker_sentiment_score": "0.045657", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLX", "relevance_score": "0.217834", "ticker_sentiment_score": "0.085923", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTVA", "relevance_score": "0.055109", "ticker_sentiment_score": "0.135854", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSIC", "relevance_score": "0.217834", "ticker_sentiment_score": "-0.052152", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.109956", "ticker_sentiment_score": "0.014363", "ticker_sentiment_label": "Neutral"}]}, {"title": "PACB: RIP to These 3 Dying Medical Stocks", "url": "https://stocknews.com/news/pacb-dmtk-gene-rip-to-these-3-dying-medical-stocks/", "time_published": "20230410T133023", "authors": [], "summary": "While investors anticipate the Fed to turn dovish in light of the banking crisis, rising oil prices might lead to inflation remaining high in the foreseeable future.", "banner_image": "https://stocknews.com/wp-content/uploads/2022/06/StockDowntrend_1200x630.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.769861"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.962106"}, {"topic": "Earnings", "relevance_score": "0.998311"}], "overall_sentiment_score": -0.184923, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "DMTK", "relevance_score": "0.175539", "ticker_sentiment_score": "-0.144948", "ticker_sentiment_label": "Neutral"}, {"ticker": "GENE", "relevance_score": "0.260652", "ticker_sentiment_score": "-0.024284", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.30211", "ticker_sentiment_score": "-0.004575", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.044222", "ticker_sentiment_score": "-0.150012", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "Carl Icahn says Illumina's appeal of FTC order to divest Grail is 'an almost impossible battle'", "url": "https://www.cnbc.com/2023/04/05/carl-icahn-illumina-appeal-of-ftc-grail-order-is-an-almost-impossible-battle.html", "time_published": "20230405T203358", "authors": ["Annika Kim Constantino"], "summary": "Carl Icahn shares common ground with the FTC, which argued that Illumina's acquisition of cancer test developer Grail would stifle competition and innovation.", "banner_image": "https://image.cnbcfm.com/api/v1/image/101140453-1680725617243-GettyImages-141972353rr.jpg?v=1680726838&w=1920&h=1080", "source": "CNBC", "category_within_source": "Top News", "source_domain": "www.cnbc.com", "topics": [{"topic": "Mergers & Acquisitions", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.002433, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.076602", "ticker_sentiment_score": "-0.126559", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.709804", "ticker_sentiment_score": "0.007767", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Reasons to Retain PacBio  ( PACB )  Stock in Your Portfolio", "url": "https://www.zacks.com/stock/news/2073864/3-reasons-to-retain-pacbio-pacb-stock-in-your-portfolio", "time_published": "20230403T160700", "authors": ["Zacks Investment Research"], "summary": "PacBio's (PACB) product development activities raise optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.857896"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.250694, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HOLX", "relevance_score": "0.215894", "ticker_sentiment_score": "0.043611", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTVA", "relevance_score": "0.054607", "ticker_sentiment_score": "0.0868", "ticker_sentiment_label": "Neutral"}, {"ticker": "AVNS", "relevance_score": "0.162802", "ticker_sentiment_score": "0.055902", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSIC", "relevance_score": "0.215894", "ticker_sentiment_score": "-0.051812", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.108958", "ticker_sentiment_score": "0.213461", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pacific Biosciences  ( PACB )  Stock Jumps 18.7%: Will It Continue to Soar?", "url": "https://www.zacks.com/stock/news/2073663/pacific-biosciences-pacb-stock-jumps-187-will-it-continue-to-soar", "time_published": "20230403T132100", "authors": ["Zacks Investment Research"], "summary": "Pacific Biosciences (PACB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default60.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983783"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.25811, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.316168", "ticker_sentiment_score": "0.371965", "ticker_sentiment_label": "Bullish"}, {"ticker": "SWAV", "relevance_score": "0.502693", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CTVA", "relevance_score": "0.107978", "ticker_sentiment_score": "0.140592", "ticker_sentiment_label": "Neutral"}]}, {"title": "Rumble, TORM And Other Big Stocks Moving Higher In Friday's Pre-Market Session - Digital World Acq  ( NASDAQ:DWAC ) , IonQ  ( NYSE:IONQ ) ", "url": "https://www.benzinga.com/news/23/03/31604716/rumble-torm-and-other-big-stocks-moving-higher-in-fridays-pre-market-session", "time_published": "20230331T103355", "authors": ["Lisa Levin"], "summary": "U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today's pre-market trading session. Rumble Inc. RUM shares climbed 14.7% to $10.73 in pre-market trading after the company reported better-than-expected Q4 results and a 142% year-over-year increase in ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/03/31/image_7.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Energy & Transportation", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Financial Markets", "relevance_score": "0.54554"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.744043"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}], "overall_sentiment_score": 0.138021, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "TRMD", "relevance_score": "0.282234", "ticker_sentiment_score": "0.014841", "ticker_sentiment_label": "Neutral"}, {"ticker": "DWAC", "relevance_score": "0.282234", "ticker_sentiment_score": "0.256946", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.282234", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KSFTF", "relevance_score": "0.282234", "ticker_sentiment_score": "-0.313973", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KC", "relevance_score": "0.412298", "ticker_sentiment_score": "-0.405728", "ticker_sentiment_label": "Bearish"}, {"ticker": "IONQ", "relevance_score": "0.412298", "ticker_sentiment_score": "-0.125231", "ticker_sentiment_label": "Neutral"}, {"ticker": "RUM", "relevance_score": "0.282234", "ticker_sentiment_score": "0.528941", "ticker_sentiment_label": "Bullish"}, {"ticker": "WB", "relevance_score": "0.282234", "ticker_sentiment_score": "0.666911", "ticker_sentiment_label": "Bullish"}, {"ticker": "PKX", "relevance_score": "0.282234", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio  ( PACB )  New Revio Workflows to Boost Agricultural Output", "url": "https://www.zacks.com/stock/news/2072613/pacbio-pacb-new-revio-workflows-to-boost-agricultural-output", "time_published": "20230330T173600", "authors": ["Zacks Investment Research"], "summary": "PacBio (PACB), in collaboration with Corteva Agriscience, is likely to enable groundbreaking plant and microbial long-read sequencing workflow on Revio system.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.310843"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.185054, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "CTVA", "relevance_score": "0.27838", "ticker_sentiment_score": "0.243646", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HSIC", "relevance_score": "0.169279", "ticker_sentiment_score": "0.105451", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.224383", "ticker_sentiment_score": "0.199104", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BDX", "relevance_score": "0.169279", "ticker_sentiment_score": "0.109577", "ticker_sentiment_label": "Neutral"}]}, {"title": "Does Pacific Biosciences  ( PACB )  Have the Potential to Rally 30.15% as Wall Street Analysts Expect?", "url": "https://www.zacks.com/stock/news/2071353/does-pacific-biosciences-pacb-have-the-potential-to-rally-3015-as-wall-street-analysts-expect", "time_published": "20230328T135504", "authors": ["Zacks Investment Research"], "summary": "The mean of analysts' price targets for Pacific Biosciences (PACB) points to a 30.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default196.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.217836, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.286193", "ticker_sentiment_score": "0.291496", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio's  ( PACB )  Latest Offering to Enhance Genome Analysis", "url": "https://www.zacks.com/stock/news/2066232/pacbios-pacb-latest-offering-to-enhance-genome-analysis", "time_published": "20230315T145700", "authors": ["Zacks Investment Research"], "summary": "PacBio's (PACB) new informatics analysis method, Paraphase, will enable researchers to genotype gene paralogs and pseudogenes with high accuracy.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.135095, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "COO", "relevance_score": "0.200134", "ticker_sentiment_score": "-0.025782", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWST", "relevance_score": "0.067347", "ticker_sentiment_score": "0.055102", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSIC", "relevance_score": "0.200134", "ticker_sentiment_score": "0.106656", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.264658", "ticker_sentiment_score": "0.140917", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.200134", "ticker_sentiment_score": "0.111303", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio  ( PACB )  Q4 Earnings Match Estimates, Revenues Top", "url": "https://www.zacks.com/stock/news/2055976/pacbio-pacb-q4-earnings-match-estimates-revenues-top", "time_published": "20230217T161700", "authors": ["Zacks Investment Research"], "summary": "Despite robust Consumables revenues, PacBio (PACB) witnesses overall soft performance in the fourth quarter.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/03/1257.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.999953"}], "overall_sentiment_score": -0.026323, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HOLX", "relevance_score": "0.14131", "ticker_sentiment_score": "0.048532", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.14131", "ticker_sentiment_score": "0.003749", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.14131", "ticker_sentiment_score": "0.004935", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.14131", "ticker_sentiment_score": "0.059206", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:GBP", "relevance_score": "0.035502", "ticker_sentiment_score": "-0.108095", "ticker_sentiment_label": "Neutral"}, {"ticker": "FOREX:EUR", "relevance_score": "0.035502", "ticker_sentiment_score": "-0.108095", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Reports Q4 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/2055580/pacific-biosciences-of-california-pacb-reports-q4-loss-tops-revenue-estimates", "time_published": "20230216T221505", "authors": ["Zacks Investment Research"], "summary": "Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 3.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default114.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999483"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.130457, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.139265", "ticker_sentiment_score": "-0.005134", "ticker_sentiment_label": "Neutral"}, {"ticker": "SILK", "relevance_score": "0.139265", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Medical Device Stocks' Q4 Earnings on Feb 16: WST, SWAV & More", "url": "https://www.zacks.com/stock/news/2054626/medical-device-stocks-q4-earnings-on-feb-16-wst-swav-more", "time_published": "20230215T143300", "authors": ["Zacks Investment Research"], "summary": "Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat macro headwinds. Let's see how WST, SWAV, AMN, ITGR and PACB are likely to fare this time.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/dc/1107.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Economy - Macro", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.097802, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CURN", "relevance_score": "0.026444", "ticker_sentiment_score": "0.054237", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMN", "relevance_score": "0.284621", "ticker_sentiment_score": "0.083483", "ticker_sentiment_label": "Neutral"}, {"ticker": "ITGR", "relevance_score": "0.183496", "ticker_sentiment_score": "0.135831", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.131643", "ticker_sentiment_score": "0.035996", "ticker_sentiment_label": "Neutral"}, {"ticker": "WST", "relevance_score": "0.157655", "ticker_sentiment_score": "0.066688", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.105488", "ticker_sentiment_score": "0.017829", "ticker_sentiment_label": "Neutral"}, {"ticker": "SWAV", "relevance_score": "0.209139", "ticker_sentiment_score": "0.119417", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week", "url": "https://www.fool.com/investing/2023/02/10/why-bionano-genomics-stock-crumbled-this-week/", "time_published": "20230210T160135", "authors": ["George Budwell"], "summary": "These cutting-edge biotech companies quickly fell out of favor with investors this week.", "banner_image": "https://media.ycharts.com/charts/07e2c4c8fe5c99a6a9e4927d81b94f29.png", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}], "overall_sentiment_score": 0.092882, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "SGMO", "relevance_score": "0.463792", "ticker_sentiment_score": "0.033799", "ticker_sentiment_label": "Neutral"}, {"ticker": "SPGI", "relevance_score": "0.082111", "ticker_sentiment_score": "-0.010375", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNGO", "relevance_score": "0.463792", "ticker_sentiment_score": "0.033799", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.52949", "ticker_sentiment_score": "0.105883", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio's  ( PACB )  Preliminary Q4 Revenues Dampened by Lower Sales", "url": "https://www.zacks.com/stock/news/2038656/pacbios-pacb-preliminary-q4-revenues-dampened-by-lower-sales", "time_published": "20230112T172900", "authors": ["Zacks Investment Research"], "summary": "PacBio's (PACB) revenue growth in the fourth quarter is likely to have been dampened by the displacement of previously-anticipated Sequel IIe sales.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/45/26891.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.839681"}], "overall_sentiment_score": 0.087387, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMN", "relevance_score": "0.210274", "ticker_sentiment_score": "0.006514", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMSI", "relevance_score": "0.10607", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CAH", "relevance_score": "0.210274", "ticker_sentiment_score": "0.053805", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.10607", "ticker_sentiment_score": "0.128865", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.053153", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global Long Read Sequencing Market Report to 2031 - Featuring Agilent Technologies, BaseClear, Cantata Bio and F. Hoffmann-La Roche Among Others", "url": "https://www.prnewswire.com/news-releases/global-long-read-sequencing-market-report-to-2031---featuring-agilent-technologies-baseclear-cantata-bio-and-f-hoffmann-la-roche-among-others-301717264.html", "time_published": "20230110T124500", "authors": ["Research and Markets"], "summary": "Global Long Read Sequencing Market Report to 2031 - Featuring ... PR ...", "banner_image": "https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.227069, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.034039", "ticker_sentiment_score": "0.060357", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTTF", "relevance_score": "0.068016", "ticker_sentiment_score": "0.054163", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.034039", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.034039", "ticker_sentiment_score": "0.060357", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.034039", "ticker_sentiment_score": "0.060357", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Pacific Biosciences Of California Shares Are Trading Higher Today - Pacific Biosciences  ( NASDAQ:PACB ) ", "url": "https://www.benzinga.com/trading-ideas/movers/23/01/30336689/why-pacific-biosciences-of-california-shares-are-trading-higher-today", "time_published": "20230109T174722", "authors": ["Sean Torres"], "summary": "Pacific Biosciences of California ( PacBio ) PACB shares are trading higher today after the company announced it received orders for 76 Revio systems in the fourth quarter of 2022. The company also issued preliminary fourth-quarter revenue results.", "banner_image": "https://cdn.benzinga.com/files/images/story/2023/01/09/screen_shot_2022-04-25_at_10.45.02_am_0.png?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.161647"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.083403, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.507932", "ticker_sentiment_score": "0.003241", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio Announces Record Orders, Including Orders for 76 Revio Systems Received in the Fourth Quarter of 2022", "url": "https://www.prnewswire.com/news-releases/pacbio-announces-record-orders-including-orders-for-76-revio-systems-received-in-the-fourth-quarter-of-2022-301716154.html", "time_published": "20230109T120500", "authors": ["Inc.", "Pacific Biosciences of California"], "summary": "PacBio Announces Record Orders, Including Orders for 76 Revio ... PR ...", "banner_image": "https://mma.prnewswire.com/media/1861430/PacBio_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.614606"}, {"topic": "Earnings", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.078334, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.100835", "ticker_sentiment_score": "0.171862", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CTVA", "relevance_score": "0.025272", "ticker_sentiment_score": "0.12881", "ticker_sentiment_label": "Neutral"}]}, {"title": "Here's Why You Should Retain PacBio  ( PACB )  Stock for Now", "url": "https://www.zacks.com/stock/news/2035314/heres-why-you-should-retain-pacbio-pacb-stock-for-now", "time_published": "20230104T173400", "authors": ["Zacks Investment Research"], "summary": "PacBio's (PACB) strength in its Sequel system raises optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/bc/379.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.904684"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.270892, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMN", "relevance_score": "0.214462", "ticker_sentiment_score": "-0.05154", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMSI", "relevance_score": "0.108222", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWST", "relevance_score": "0.054236", "ticker_sentiment_score": "-0.086772", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.108222", "ticker_sentiment_score": "0.256407", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BSX", "relevance_score": "0.214462", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.054236", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cancer researchers question antitrust arguments against Illumina-Grail deal", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/cancer-researchers-question-antitrust-arguments-against-illumina-grail-deal-2022-12-16/", "time_published": "20221216T120636", "authors": ["Deena Beasley", "Julie Steenhuysen"], "summary": "Cancer researchers question antitrust arguments against Illumina ... ...", "banner_image": "https://cloudfront-us-east-2.images.arcpublishing.com/reuters/SRHDDO3IOBLYZE4C2QRYTA52MA.jpg", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.157014, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "GH", "relevance_score": "0.043738", "ticker_sentiment_score": "-0.055779", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.043738", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXAS", "relevance_score": "0.043738", "ticker_sentiment_score": "0.028657", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.043738", "ticker_sentiment_score": "-0.122505", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.378412", "ticker_sentiment_score": "-0.253919", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TMO", "relevance_score": "0.043738", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Non-Invasive Prenatal Testing Market Size is projected to reach USD 7.96 billion by 2031, growing at a CAGR of 9.2%: Straits Research", "url": "https://www.benzinga.com/pressreleases/22/12/g29924559/non-invasive-prenatal-testing-market-size-is-projected-to-reach-usd-7-96-billion-by-2031-growing-a", "time_published": "20221201T143000", "authors": ["Globe Newswire"], "summary": "New York, United States, Dec. 01, 2022 ( GLOBE NEWSWIRE ) -- Prenatal non-invasive testing is used to check for genetic diseases such as Down syndrome, Edwards syndrome, and Patau syndrome in the developing fetus. This test examines the tiny DNA fragments that are circulating in a pregnant ...", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.113435, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.029951", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GENE", "relevance_score": "0.029951", "ticker_sentiment_score": "0.026888", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.029951", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.029951", "ticker_sentiment_score": "0.096037", "ticker_sentiment_label": "Neutral"}, {"ticker": "RYLPF", "relevance_score": "0.029951", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.029951", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Sea, UiPath, J&J Snack Foods And Other Big Gainers From Tuesday - Evoqua Water Technologies  ( NYSE:AQUA ) , Azenta  ( NASDAQ:AZTA ) ", "url": "https://www.benzinga.com/news/22/11/29742456/sea-uipath-j-j-snack-foods-and-other-big-gainers-from-tuesday", "time_published": "20221116T073308", "authors": ["Lisa Levin"], "summary": "U.S. stocks closed higher on Tuesday, with the Nasdaq Composite gaining more than 150 points. Here is the list of some big stocks recording gains in the previous session. 4D Molecular Therapeutics, Inc. FDMT jumped 38.6% to close at $18.69 after Goldman Sachs upgraded the stock from Neutral to ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/11/16/image26.jpeg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}, {"topic": "Finance", "relevance_score": "0.2"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Earnings", "relevance_score": "0.983783"}], "overall_sentiment_score": 0.276778, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PATH", "relevance_score": "0.137278", "ticker_sentiment_score": "0.152322", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FDMT", "relevance_score": "0.137278", "ticker_sentiment_score": "0.145028", "ticker_sentiment_label": "Neutral"}, {"ticker": "TTD", "relevance_score": "0.137278", "ticker_sentiment_score": "0.296687", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NU", "relevance_score": "0.137278", "ticker_sentiment_score": "0.107378", "ticker_sentiment_label": "Neutral"}, {"ticker": "LU", "relevance_score": "0.137278", "ticker_sentiment_score": "0.327953", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WB", "relevance_score": "0.137278", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWKS", "relevance_score": "0.204647", "ticker_sentiment_score": "0.111648", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCTZF", "relevance_score": "0.068896", "ticker_sentiment_score": "0.215182", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NTES", "relevance_score": "0.137278", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SE", "relevance_score": "0.137278", "ticker_sentiment_score": "0.248955", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "LPX", "relevance_score": "0.137278", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "U", "relevance_score": "0.137278", "ticker_sentiment_score": "0.327953", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WTII", "relevance_score": "0.068896", "ticker_sentiment_score": "0.374112", "ticker_sentiment_label": "Bullish"}, {"ticker": "EDU", "relevance_score": "0.137278", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GDS", "relevance_score": "0.137278", "ticker_sentiment_score": "-0.232547", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "QH", "relevance_score": "0.137278", "ticker_sentiment_score": "0.242596", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MNSO", "relevance_score": "0.204647", "ticker_sentiment_score": "0.16742", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BILI", "relevance_score": "0.204647", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BABA", "relevance_score": "0.137278", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AQUA", "relevance_score": "0.137278", "ticker_sentiment_score": "0.446136", "ticker_sentiment_label": "Bullish"}, {"ticker": "BRK-A", "relevance_score": "0.137278", "ticker_sentiment_score": "-0.058948", "ticker_sentiment_label": "Neutral"}, {"ticker": "IQ", "relevance_score": "0.137278", "ticker_sentiment_score": "0.327953", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GS", "relevance_score": "0.068896", "ticker_sentiment_score": "0.120463", "ticker_sentiment_label": "Neutral"}, {"ticker": "TME", "relevance_score": "0.137278", "ticker_sentiment_score": "0.259223", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TSM", "relevance_score": "0.137278", "ticker_sentiment_score": "-0.109804", "ticker_sentiment_label": "Neutral"}, {"ticker": "JJSF", "relevance_score": "0.137278", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.137278", "ticker_sentiment_score": "0.327953", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DAVA", "relevance_score": "0.137278", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZTA", "relevance_score": "0.137278", "ticker_sentiment_score": "0.406403", "ticker_sentiment_label": "Bullish"}, {"ticker": "YMM", "relevance_score": "0.137278", "ticker_sentiment_score": "0.327953", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SHLS", "relevance_score": "0.137278", "ticker_sentiment_score": "0.242254", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TRUP", "relevance_score": "0.137278", "ticker_sentiment_score": "0.327953", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio's  ( PACB )  Q3 Earnings Top Estimates, Revenues Lag", "url": "https://www.zacks.com/stock/news/2015503/pacbios-pacb-q3-earnings-top-estimates-revenues-lag", "time_published": "20221108T150000", "authors": ["Zacks Investment Research"], "summary": "PacBio (PACB) witnesses strength in Service and other revenues, along with robust consumable sales, in the third quarter.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/79/359.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999691"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}], "overall_sentiment_score": -0.024024, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "MEDP", "relevance_score": "0.163078", "ticker_sentiment_score": "0.037264", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMN", "relevance_score": "0.163078", "ticker_sentiment_score": "0.065329", "ticker_sentiment_label": "Neutral"}, {"ticker": "MMSI", "relevance_score": "0.08197", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.163078", "ticker_sentiment_score": "-0.038826", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.041039", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Reports Q3 Loss, Misses Revenue Estimates", "url": "https://www.zacks.com/stock/news/2015046/pacific-biosciences-of-california-pacb-reports-q3-loss-misses-revenue-estimates", "time_published": "20221107T225512", "authors": ["Zacks Investment Research"], "summary": "Pacific Biosciences (PACB) delivered earnings and revenue surprises of 8.57% and 8.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default14.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.051989, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.136888", "ticker_sentiment_score": "-0.063476", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday - Aeglea BioTherapeutics  ( NASDAQ:AGLE ) , Avista Public Acquisition  ( NASDAQ:AHPA ) ", "url": "https://www.benzinga.com/news/22/10/29474596/why-pinterest-shares-jumped-around-14-here-are-69-biggest-movers-from-friday", "time_published": "20221031T081300", "authors": ["Lisa Levin"], "summary": "Quanergy Systems, Inc. QNGY jumped 153.9% to close at $3.30 on Friday. Aeglea BioTherapeutics, Inc. AGLE surged 61.4% to close at $0.92 after jumping 15% on Thursday. Nuvalent, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/10/31/image-pinterest.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.918141"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.083971, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "XPEV", "relevance_score": "0.084922", "ticker_sentiment_score": "-0.061442", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGLE", "relevance_score": "0.056674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FBC", "relevance_score": "0.056674", "ticker_sentiment_score": "0.208993", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BHSE", "relevance_score": "0.056674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBBY", "relevance_score": "0.056674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CZOO", "relevance_score": "0.084922", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GNLN", "relevance_score": "0.056674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SOBR", "relevance_score": "0.056674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "EGHT", "relevance_score": "0.056674", "ticker_sentiment_score": "0.189984", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PHAS", "relevance_score": "0.056674", "ticker_sentiment_score": "-0.300019", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TBBK", "relevance_score": "0.056674", "ticker_sentiment_score": "0.271004", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GDS", "relevance_score": "0.056674", "ticker_sentiment_score": "-0.412204", "ticker_sentiment_label": "Bearish"}, {"ticker": "FRGT", "relevance_score": "0.084922", "ticker_sentiment_score": "-0.015835", "ticker_sentiment_label": "Neutral"}, {"ticker": "NUVL", "relevance_score": "0.056674", "ticker_sentiment_score": "0.194987", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HSCS", "relevance_score": "0.056674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LOPE", "relevance_score": "0.056674", "ticker_sentiment_score": "0.230999", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NMRK", "relevance_score": "0.056674", "ticker_sentiment_score": "-0.149958", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATHX", "relevance_score": "0.056674", "ticker_sentiment_score": "0.271004", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KMB", "relevance_score": "0.028355", "ticker_sentiment_score": "-0.014439", "ticker_sentiment_label": "Neutral"}, {"ticker": "OBLG", "relevance_score": "0.056674", "ticker_sentiment_score": "0.271004", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVA", "relevance_score": "0.028355", "ticker_sentiment_score": "-0.202481", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DRTS", "relevance_score": "0.056674", "ticker_sentiment_score": "-0.300019", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EQOS", "relevance_score": "0.056674", "ticker_sentiment_score": "-0.412204", "ticker_sentiment_label": "Bearish"}, {"ticker": "EW", "relevance_score": "0.056674", "ticker_sentiment_score": "-0.085109", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCS", "relevance_score": "0.028355", "ticker_sentiment_score": "-0.168261", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NGM", "relevance_score": "0.056674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NRBO", "relevance_score": "0.056674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.056674", "ticker_sentiment_score": "0.271004", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TESS", "relevance_score": "0.056674", "ticker_sentiment_score": "0.337055", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VERB", "relevance_score": "0.084922", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVSN", "relevance_score": "0.056674", "ticker_sentiment_score": "0.271004", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "C", "relevance_score": "0.028355", "ticker_sentiment_score": "-0.054938", "ticker_sentiment_label": "Neutral"}, {"ticker": "NEXA", "relevance_score": "0.056674", "ticker_sentiment_score": "-0.135948", "ticker_sentiment_label": "Neutral"}, {"ticker": "KCDMF", "relevance_score": "0.028355", "ticker_sentiment_score": "-0.014439", "ticker_sentiment_label": "Neutral"}, {"ticker": "SND", "relevance_score": "0.056674", "ticker_sentiment_score": "0.271004", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NNWWF", "relevance_score": "0.056674", "ticker_sentiment_score": "-0.12294", "ticker_sentiment_label": "Neutral"}, {"ticker": "MAAQU", "relevance_score": "0.028355", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PERF", "relevance_score": "0.028355", "ticker_sentiment_score": "0.176052", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "INT", "relevance_score": "0.056674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTCT", "relevance_score": "0.084922", "ticker_sentiment_score": "-0.162414", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BX", "relevance_score": "0.028355", "ticker_sentiment_score": "-0.147903", "ticker_sentiment_label": "Neutral"}, {"ticker": "LMAT", "relevance_score": "0.056674", "ticker_sentiment_score": "0.058924", "ticker_sentiment_label": "Neutral"}, {"ticker": "VTEX", "relevance_score": "0.084922", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HTCR", "relevance_score": "0.084922", "ticker_sentiment_score": "0.121114", "ticker_sentiment_label": "Neutral"}, {"ticker": "PINS", "relevance_score": "0.056674", "ticker_sentiment_score": "0.221997", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CSL", "relevance_score": "0.056674", "ticker_sentiment_score": "-0.175976", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "DXCM", "relevance_score": "0.056674", "ticker_sentiment_score": "0.221997", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BWMX", "relevance_score": "0.056674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DUO", "relevance_score": "0.056674", "ticker_sentiment_score": "0.271004", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KNSL", "relevance_score": "0.056674", "ticker_sentiment_score": "0.189984", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCRB", "relevance_score": "0.056674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FNHC", "relevance_score": "0.056674", "ticker_sentiment_score": "-0.142953", "ticker_sentiment_label": "Neutral"}, {"ticker": "COHU", "relevance_score": "0.056674", "ticker_sentiment_score": "0.189984", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UFCS", "relevance_score": "0.056674", "ticker_sentiment_score": "-0.137949", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFSI", "relevance_score": "0.056674", "ticker_sentiment_score": "0.337055", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QNGY", "relevance_score": "0.056674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLNA", "relevance_score": "0.056674", "ticker_sentiment_score": "-0.067116", "ticker_sentiment_label": "Neutral"}, {"ticker": "EGO", "relevance_score": "0.056674", "ticker_sentiment_score": "-0.149958", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.056674", "ticker_sentiment_score": "-0.085109", "ticker_sentiment_label": "Neutral"}, {"ticker": "VIOT", "relevance_score": "0.056674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRRX", "relevance_score": "0.056674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEI", "relevance_score": "0.056674", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "INTC", "relevance_score": "0.084922", "ticker_sentiment_score": "0.154131", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TIL", "relevance_score": "0.056674", "ticker_sentiment_score": "0.271004", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TRCLF", "relevance_score": "0.028355", "ticker_sentiment_score": "0.109526", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZLAB", "relevance_score": "0.084922", "ticker_sentiment_score": "-0.211079", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GILD", "relevance_score": "0.056674", "ticker_sentiment_score": "0.221997", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RBSPF", "relevance_score": "0.028355", "ticker_sentiment_score": "-0.038918", "ticker_sentiment_label": "Neutral"}, {"ticker": "LI", "relevance_score": "0.084922", "ticker_sentiment_score": "-0.184141", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SRRK", "relevance_score": "0.056674", "ticker_sentiment_score": "0.271004", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TAL", "relevance_score": "0.056674", "ticker_sentiment_score": "0.337055", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DBGI", "relevance_score": "0.084922", "ticker_sentiment_score": "-0.089187", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Bio Pushes Back at Illumina With New No-Compromise Gene Readers", "url": "https://www.barrons.com/articles/pacific-bio-illumina-gene-sequencing-51666807868", "time_published": "20221026T181200", "authors": ["Bill Alpert"], "summary": "Gene-sequencing giant Illumina tried acquiring Pacific BioSciences of California a few years ago, because PacBio's technology can decode parts of our DNA that elude Illumina. The deal didn't survive antitrust scrutiny, so PacBio continued alone in its high-end niche of the sequencing market.", "banner_image": "https://images.barrons.com/im-652148/social", "source": "Barrons", "category_within_source": "n/a", "source_domain": "www.barrons.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.060969, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.724687", "ticker_sentiment_score": "-0.099422", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.970877", "ticker_sentiment_score": "-0.110479", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio To Launch New Gene-Sequencing Systems - Pacific Biosciences  ( NASDAQ:PACB ) ", "url": "https://www.benzinga.com/news/22/10/29411000/pacbio-to-launch-new-gene-sequencing-systems", "time_published": "20221026T104300", "authors": ["Vandana Singh"], "summary": "Pacific BioSciences of California Inc PACB announced the launch of the Revio long-read sequencing system. The company said its new Revio long-read sequencing system, with a list price of $779,000, offers a 15-fold increase in throughput, enabling customers to sequence up to 1,300 whole human ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/10/26/aapharma_0.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.018718, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.426225", "ticker_sentiment_score": "0.261157", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio to launch new gene-sequencing systems", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pacbio-launch-new-gene-sequencing-systems-2022-10-26/", "time_published": "20221026T024800", "authors": ["Deena Beasley"], "summary": "Oct 25 ( Reuters ) - Gene-sequencing company Pacific BioSciences of California Inc ( PACB.O ) on Tuesday announced the launch of a new, more affordable, higher-throughput \"long-read\" sequencer as well as customer testing of its first \"short-read\" sequencer aimed at emerging markets such as ...", "banner_image": "https://www.reuters.com/pf/resources/images/reuters/reuters-default.png?d=117", "source": "Reuters", "category_within_source": "Business", "source_domain": "www.reuters.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.068342, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.126119", "ticker_sentiment_score": "0.122748", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.249106", "ticker_sentiment_score": "-0.12933", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio's  ( PACB )  Latest Offering to Enhance Genome Sequencing", "url": "https://www.zacks.com/stock/news/1996240/pacbios-pacb-latest-offering-to-enhance-genome-sequencing", "time_published": "20221024T141000", "authors": ["Zacks Investment Research"], "summary": "PacBio's (PACB) latest sequencing panels are expected to simplify the study of the difficult-to-sequence or accurately map genomes, thereby aiding researchers.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/bc/379.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.131611, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QGEN", "relevance_score": "0.170576", "ticker_sentiment_score": "0.068123", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWST", "relevance_score": "0.212301", "ticker_sentiment_score": "0.061411", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZN", "relevance_score": "0.085782", "ticker_sentiment_score": "0.066685", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.085782", "ticker_sentiment_score": "0.105543", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.170576", "ticker_sentiment_score": "0.127332", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.128363", "ticker_sentiment_score": "0.260252", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio's  ( PACB )  Latest Offering to Enhance Disease Discoveries", "url": "https://www.zacks.com/stock/news/1996135/pacbios-pacb-latest-offering-to-enhance-disease-discoveries", "time_published": "20221024T132000", "authors": ["Zacks Investment Research"], "summary": "PacBio's (PACB) latest sequencing kit is expected to help generate insights into how single-cell research can power new disease discoveries and the identification of therapeutic targets across many categories.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/08/595.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.205673, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "QGEN", "relevance_score": "0.208017", "ticker_sentiment_score": "0.07891", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.208017", "ticker_sentiment_score": "0.255407", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TWST", "relevance_score": "0.05257", "ticker_sentiment_score": "0.057918", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.104911", "ticker_sentiment_score": "0.183907", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.1568", "ticker_sentiment_score": "0.294658", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday - Amprius Technologies  ( NYSE:AMPX ) , ALFI  ( NASDAQ:ALF ) ", "url": "https://www.benzinga.com/news/22/10/29374553/why-huntington-bancshares-shares-surged-around-10-here-are-72-biggest-movers-from-friday", "time_published": "20221024T093702", "authors": ["Lisa Levin"], "summary": "Huadi International Group Co., Ltd. HUDI jumped 89.3% to close at $58.92 on Friday. Altamira Therapeutics Ltd. CYTO climbed 58.6% to close at $0.5197 on Friday after the company announced divestiture of its inner ear development assets. Missfresh Limited MF gained 57.5% to close at $2.52.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/10/24/image_4.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "IPO", "relevance_score": "0.310843"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "0.999816"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.045872, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "ERNA", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HBAN", "relevance_score": "0.062761", "ticker_sentiment_score": "0.320759", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SLB", "relevance_score": "0.062761", "ticker_sentiment_score": "0.214385", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRE", "relevance_score": "0.062761", "ticker_sentiment_score": "0.095034", "ticker_sentiment_label": "Neutral"}, {"ticker": "COMS", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.300643", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "KPLT", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.031405", "ticker_sentiment_score": "0.186052", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "KLR", "relevance_score": "0.062761", "ticker_sentiment_score": "0.271494", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCTI", "relevance_score": "0.062761", "ticker_sentiment_score": "0.271494", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "YJ", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZVO", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.353975", "ticker_sentiment_label": "Bearish"}, {"ticker": "CYH", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LITM", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MF", "relevance_score": "0.062761", "ticker_sentiment_score": "0.062492", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVPH", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.300643", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "EFOI", "relevance_score": "0.09402", "ticker_sentiment_score": "0.126739", "ticker_sentiment_label": "Neutral"}, {"ticker": "RKLY", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.192201", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SIVB", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RBT", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.300643", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HCA", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.16714", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LEJU", "relevance_score": "0.062761", "ticker_sentiment_score": "0.062492", "ticker_sentiment_label": "Neutral"}, {"ticker": "SRCE", "relevance_score": "0.062761", "ticker_sentiment_score": "0.271494", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AMPX", "relevance_score": "0.09402", "ticker_sentiment_score": "0.230324", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ILAG", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUPH", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.142549", "ticker_sentiment_label": "Neutral"}, {"ticker": "BTOG", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.300643", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PACB", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "KAL", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.174156", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ASTI", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVSN", "relevance_score": "0.062761", "ticker_sentiment_score": "0.271494", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HOOB", "relevance_score": "0.031405", "ticker_sentiment_score": "0.11302", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATRA", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.062761", "ticker_sentiment_score": "0.100038", "ticker_sentiment_label": "Neutral"}, {"ticker": "SGRY", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SAM", "relevance_score": "0.062761", "ticker_sentiment_score": "0.160125", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NLSP", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MGNX", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "FFIN", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZTEK", "relevance_score": "0.062761", "ticker_sentiment_score": "0.271494", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "THC", "relevance_score": "0.062761", "ticker_sentiment_score": "0.069016", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "STRY", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.052026", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUID", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLL", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RHI", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.200337", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BTCY", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NMTR", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.300643", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SIEN", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.184795", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVAX", "relevance_score": "0.062761", "ticker_sentiment_score": "0.195209", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PINS", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.120622", "ticker_sentiment_label": "Neutral"}, {"ticker": "SLGG", "relevance_score": "0.062761", "ticker_sentiment_score": "0.271494", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NXTP", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.016269", "ticker_sentiment_label": "Neutral"}, {"ticker": "FNHC", "relevance_score": "0.062761", "ticker_sentiment_score": "0.16714", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STAB", "relevance_score": "0.09402", "ticker_sentiment_score": "0.125686", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMUX", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.002018", "ticker_sentiment_label": "Neutral"}, {"ticker": "TWTR", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.070556", "ticker_sentiment_label": "Neutral"}, {"ticker": "KALA", "relevance_score": "0.09402", "ticker_sentiment_score": "-0.292915", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "QNGY", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.300643", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SNAP", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.020057", "ticker_sentiment_label": "Neutral"}, {"ticker": "CYTO", "relevance_score": "0.062761", "ticker_sentiment_score": "0.078021", "ticker_sentiment_label": "Neutral"}, {"ticker": "MVST", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNES", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.190902", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "TC", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.192201", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HUDI", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEI", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CADL", "relevance_score": "0.062761", "ticker_sentiment_score": "0.271494", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CALT", "relevance_score": "0.062761", "ticker_sentiment_score": "0.178165", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HA", "relevance_score": "0.062761", "ticker_sentiment_score": "0.37815", "ticker_sentiment_label": "Bullish"}, {"ticker": "APCX", "relevance_score": "0.062761", "ticker_sentiment_score": "0.271494", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ALF", "relevance_score": "0.062761", "ticker_sentiment_score": "-0.300643", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "UCL", "relevance_score": "0.062761", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Moderna, Amazon, Tesla, And Other Big Gainers From Friday - Atara Biotherapeutics  ( NASDAQ:ATRA ) , Amazon.com  ( NASDAQ:AMZN ) ", "url": "https://www.benzinga.com/news/22/10/29372471/moderna-amazon-tesla-and-other-big-gainers-from-friday", "time_published": "20221024T081911", "authors": ["Lisa Levin"], "summary": "U.S. stocks closed higher on Friday, with the Dow Jones gaining around 750 points. Here is the list of some big stocks recording gains in the previous session. Huadi International Group Co., Ltd. HUDI shares climbed 89.3% to close at $58.92 on Friday. Veris Residential, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/10/24/image-moderna.gif?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Finance", "relevance_score": "0.166667"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "IPO", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": 0.340042, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HBAN", "relevance_score": "0.179788", "ticker_sentiment_score": "0.447904", "ticker_sentiment_label": "Bullish"}, {"ticker": "SRCE", "relevance_score": "0.179788", "ticker_sentiment_score": "0.382798", "ticker_sentiment_label": "Bullish"}, {"ticker": "SLB", "relevance_score": "0.179788", "ticker_sentiment_score": "0.322302", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VRE", "relevance_score": "0.179788", "ticker_sentiment_score": "0.276549", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BANF", "relevance_score": "0.179788", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MVST", "relevance_score": "0.179788", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.090474", "ticker_sentiment_score": "0.203148", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BNTX", "relevance_score": "0.179788", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HUDI", "relevance_score": "0.179788", "ticker_sentiment_score": "0.256844", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PLL", "relevance_score": "0.179788", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.179788", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.179788", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "HA", "relevance_score": "0.179788", "ticker_sentiment_score": "0.447904", "ticker_sentiment_label": "Bullish"}, {"ticker": "NVAX", "relevance_score": "0.179788", "ticker_sentiment_score": "0.277953", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ATRA", "relevance_score": "0.179788", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "MRNA", "relevance_score": "0.179788", "ticker_sentiment_score": "0.142929", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMZN", "relevance_score": "0.179788", "ticker_sentiment_score": "0.275144", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SAM", "relevance_score": "0.179788", "ticker_sentiment_score": "0.228543", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STLD", "relevance_score": "0.179788", "ticker_sentiment_score": "0.361071", "ticker_sentiment_label": "Bullish"}]}, {"title": "Moderna, BioNTech And Some Other Big Stocks Moving Higher On Wednesday - AZZ  ( NYSE:AZZ ) , BioNTech  ( NASDAQ:BNTX ) ", "url": "https://www.benzinga.com/news/22/10/29237483/moderna-biontech-and-some-other-big-stocks-moving-higher-on-wednesday", "time_published": "20221012T142846", "authors": ["Lisa Levin"], "summary": "U.S. stocks traded mostly higher, with the Dow Jones gaining more than 100 points on Wednesday. Here are some big stocks recording gains in today's session. FLJ Group Limited FLJ shares jumped 69% to $2.59. Cango Inc. CANG climbed 13.1% to $2.5550 after the company declared a special cash ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/10/12/image-moderna.gif?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.2"}, {"topic": "Retail & Wholesale", "relevance_score": "0.2"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Manufacturing", "relevance_score": "0.2"}, {"topic": "Real Estate & Construction", "relevance_score": "0.2"}, {"topic": "Technology", "relevance_score": "0.2"}], "overall_sentiment_score": 0.247279, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "HKD", "relevance_score": "0.252987", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AZZ", "relevance_score": "0.371523", "ticker_sentiment_score": "0.453633", "ticker_sentiment_label": "Bullish"}, {"ticker": "KNBE", "relevance_score": "0.252987", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.252987", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOTE", "relevance_score": "0.252987", "ticker_sentiment_score": "0.584954", "ticker_sentiment_label": "Bullish"}, {"ticker": "CANG", "relevance_score": "0.252987", "ticker_sentiment_score": "0.421155", "ticker_sentiment_label": "Bullish"}, {"ticker": "QK", "relevance_score": "0.128135", "ticker_sentiment_score": "0.039154", "ticker_sentiment_label": "Neutral"}, {"ticker": "LOCO", "relevance_score": "0.252987", "ticker_sentiment_score": "0.553948", "ticker_sentiment_label": "Bullish"}, {"ticker": "MRNA", "relevance_score": "0.481177", "ticker_sentiment_score": "0.01262", "ticker_sentiment_label": "Neutral"}, {"ticker": "PFE", "relevance_score": "0.252987", "ticker_sentiment_score": "0.005889", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNTX", "relevance_score": "0.481177", "ticker_sentiment_score": "0.009451", "ticker_sentiment_label": "Neutral"}, {"ticker": "RLX", "relevance_score": "0.371523", "ticker_sentiment_score": "-0.334702", "ticker_sentiment_label": "Somewhat-Bearish"}]}, {"title": "PacBio's  ( PACB )  New Method for TR Profiling Now Available", "url": "https://www.zacks.com/stock/news/1986188/pacbios-pacb-new-method-for-tr-profiling-now-available", "time_published": "20220928T170800", "authors": ["Zacks Investment Research"], "summary": "PacBio's (PACB) latest tool is expected to enable scientists to better understand the role of known TRs in human disease, which could also lead to the discovery of novel disease-causing TRs.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/eb/4111.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.451494"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.183041, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMN", "relevance_score": "0.230235", "ticker_sentiment_score": "0.196733", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.230235", "ticker_sentiment_score": "0.191323", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.116348", "ticker_sentiment_score": "0.096085", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.05833", "ticker_sentiment_score": "0.236023", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SWAV", "relevance_score": "0.230235", "ticker_sentiment_score": "0.250783", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "3 Reasons to Retain PacBio  ( PACB )  Stock in Your Portfolio", "url": "https://www.zacks.com/stock/news/1983014/3-reasons-to-retain-pacbio-pacb-stock-in-your-portfolio", "time_published": "20220921T120200", "authors": ["Zacks Investment Research"], "summary": "PacBio's (PACB) strength in its Sequel system raises optimism about the stock.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.682689"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.309105, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "AMN", "relevance_score": "0.215894", "ticker_sentiment_score": "0.187192", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MCK", "relevance_score": "0.215894", "ticker_sentiment_score": "0.182026", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.108958", "ticker_sentiment_score": "0.239185", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "HCSG", "relevance_score": "0.054607", "ticker_sentiment_score": "0.235931", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SWAV", "relevance_score": "0.215894", "ticker_sentiment_score": "0.238805", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "U.S. Market Faces Worst Meltdown Since 2020: Here's Why", "url": "https://www.zacks.com/stock/news/1980566/us-market-faces-worst-meltdown-since-2020-heres-why", "time_published": "20220914T164500", "authors": ["Zacks Investment Research"], "summary": "Major U.S. indices nosedived on Sep 14 following the inflation report for the month of August.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/bf/21076.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.999682"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.744043"}, {"topic": "Earnings", "relevance_score": "0.891286"}], "overall_sentiment_score": -0.096402, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AVTR", "relevance_score": "0.201105", "ticker_sentiment_score": "0.123668", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.151539", "ticker_sentiment_score": "0.148707", "ticker_sentiment_label": "Neutral"}, {"ticker": "PKI", "relevance_score": "0.201105", "ticker_sentiment_score": "-0.071762", "ticker_sentiment_label": "Neutral"}]}, {"title": "DNA Sequencing Market to Generate Revenue of $29.89 Billion By 2028 | Demand for DNA Sequencing to Increase 1200% if Per Genome Sequencing Goes Down to $100", "url": "https://www.benzinga.com/pressreleases/22/09/g28832059/dna-sequencing-market-to-generate-revenue-of-29-89-billion-by-2028-demand-for-dna-sequencing-to-in", "time_published": "20220912T150953", "authors": ["Globe Newswire"], "summary": "Westford, USA, Sept. 12, 2022 ( GLOBE NEWSWIRE ) -- As the world becomes increasingly digitized, so too does the legality of DNA sequencing market. What once was considered a fringe practice is now bustling with high-tech firms and scientists alike, thanks to advancements in technology and ...", "banner_image": "", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.196103, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.035502", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTTF", "relevance_score": "0.035502", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": " ( AGRI ) , Amplify YieldShares Oil Hedged MLP Income ETF  ( AMLX )  - Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday", "url": "https://www.benzinga.com/news/22/09/28751095/why-polypid-dipped-over-73-here-are-60-biggest-movers-from-friday", "time_published": "20220906T065525", "authors": ["Lisa Levin"], "summary": "Venus Concept Inc. VERO jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results. PaxMedica, Inc. PXMD climbed 47.7% to settle at $5.17 on Friday. PaxMedica Executive Chairman, Director Michael Derby reported in Form4 filing the purchase of 95,000 ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/09/06/image_1.jpg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.166667"}, {"topic": "Energy & Transportation", "relevance_score": "0.166667"}, {"topic": "Technology", "relevance_score": "0.166667"}, {"topic": "IPO", "relevance_score": "0.576289"}, {"topic": "Retail & Wholesale", "relevance_score": "0.166667"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Manufacturing", "relevance_score": "0.166667"}, {"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Real Estate & Construction", "relevance_score": "0.166667"}], "overall_sentiment_score": -0.029117, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "CRTD", "relevance_score": "0.091046", "ticker_sentiment_score": "-0.04823", "ticker_sentiment_label": "Neutral"}, {"ticker": "DRUG", "relevance_score": "0.091046", "ticker_sentiment_score": "-0.090339", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERO", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.150028", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HP", "relevance_score": "0.060771", "ticker_sentiment_score": "0.110202", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARQT", "relevance_score": "0.091046", "ticker_sentiment_score": "-0.082001", "ticker_sentiment_label": "Neutral"}, {"ticker": "FEAM", "relevance_score": "0.060771", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VANI", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.300343", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NCNO", "relevance_score": "0.060771", "ticker_sentiment_score": "0.171047", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PYPD", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.022051", "ticker_sentiment_label": "Neutral"}, {"ticker": "RVPH", "relevance_score": "0.060771", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "USEA", "relevance_score": "0.060771", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "AUR", "relevance_score": "0.060771", "ticker_sentiment_score": "0.187066", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PETZ", "relevance_score": "0.091046", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OCGN", "relevance_score": "0.060771", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PIXY", "relevance_score": "0.091046", "ticker_sentiment_score": "-0.122703", "ticker_sentiment_label": "Neutral"}, {"ticker": "HKD", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.300343", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "META", "relevance_score": "0.091046", "ticker_sentiment_score": "0.072628", "ticker_sentiment_label": "Neutral"}, {"ticker": "DBVT", "relevance_score": "0.091046", "ticker_sentiment_score": "-0.004288", "ticker_sentiment_label": "Neutral"}, {"ticker": "INAB", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.028114", "ticker_sentiment_label": "Neutral"}, {"ticker": "AMLX", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.166042", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ARRY", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.300343", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "REUN", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.300343", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SHPH", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.357594", "ticker_sentiment_label": "Bearish"}, {"ticker": "DRTS", "relevance_score": "0.091046", "ticker_sentiment_score": "-0.005382", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMAR", "relevance_score": "0.060771", "ticker_sentiment_score": "0.320422", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MDJH", "relevance_score": "0.060771", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAIN", "relevance_score": "0.060771", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIAF", "relevance_score": "0.060771", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "SXTC", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.300343", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PACB", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.300343", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "VERA", "relevance_score": "0.091046", "ticker_sentiment_score": "-0.14235", "ticker_sentiment_label": "Neutral"}, {"ticker": "PXMD", "relevance_score": "0.091046", "ticker_sentiment_score": "0.145721", "ticker_sentiment_label": "Neutral"}, {"ticker": "CVGW", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.200085", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "HOWL", "relevance_score": "0.060771", "ticker_sentiment_score": "0.120011", "ticker_sentiment_label": "Neutral"}, {"ticker": "WHLR", "relevance_score": "0.060771", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NBEV", "relevance_score": "0.060771", "ticker_sentiment_score": "0.00811", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPK", "relevance_score": "0.060771", "ticker_sentiment_score": "0.271245", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PEAR", "relevance_score": "0.060771", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTON", "relevance_score": "0.091046", "ticker_sentiment_score": "-0.183465", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "CMCM", "relevance_score": "0.060771", "ticker_sentiment_score": "0.233577", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MSFT", "relevance_score": "0.030408", "ticker_sentiment_score": "0.177516", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BORR", "relevance_score": "0.060771", "ticker_sentiment_score": "0.04229", "ticker_sentiment_label": "Neutral"}, {"ticker": "FRZA", "relevance_score": "0.060771", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TCRX", "relevance_score": "0.091046", "ticker_sentiment_score": "-0.00537", "ticker_sentiment_label": "Neutral"}, {"ticker": "HPCO", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.357594", "ticker_sentiment_label": "Bearish"}, {"ticker": "QCOM", "relevance_score": "0.030408", "ticker_sentiment_score": "0.064952", "ticker_sentiment_label": "Neutral"}, {"ticker": "VRAX", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.290307", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LQDA", "relevance_score": "0.091046", "ticker_sentiment_score": "0.110165", "ticker_sentiment_label": "Neutral"}, {"ticker": "HOLI", "relevance_score": "0.060771", "ticker_sentiment_score": "0.053", "ticker_sentiment_label": "Neutral"}, {"ticker": "KUKE", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.259211", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "OKTA", "relevance_score": "0.060771", "ticker_sentiment_score": "0.301347", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "RIBT", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.300343", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LULU", "relevance_score": "0.060771", "ticker_sentiment_score": "0.236153", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EPOW", "relevance_score": "0.060771", "ticker_sentiment_score": "0.224128", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NIO", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.102519", "ticker_sentiment_label": "Neutral"}, {"ticker": "APE", "relevance_score": "0.060771", "ticker_sentiment_score": "0.271245", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "GCT", "relevance_score": "0.060771", "ticker_sentiment_score": "-0.300343", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "LE", "relevance_score": "0.091046", "ticker_sentiment_score": "-0.044861", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATXG", "relevance_score": "0.091046", "ticker_sentiment_score": "-0.162544", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RUBY", "relevance_score": "0.060771", "ticker_sentiment_score": "0.015133", "ticker_sentiment_label": "Neutral"}]}, {"title": "With 19.4% CAGR, Genomics Market Size to Reach USD 94.65 Billion [2021-2028]", "url": "https://www.benzinga.com/pressreleases/22/09/g28747260/with-19-4-cagr-genomics-market-size-to-reach-usd-94-65-billion-2021-2028", "time_published": "20220905T114946", "authors": ["Globe Newswire"], "summary": "Pune, India, Sept. 05, 2022 ( GLOBE NEWSWIRE ) -- The global genomics market size is projected to reach USD 94.65 billion by 2028, exhibiting a CAGR of 19.4% during the forecast period. Fortune Business Insights\u2122 shares this information in its report, titled \"Genomics Market, 2021-2028\".", "banner_image": "", "source": "Benzinga", "category_within_source": "Mergers", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.650727"}, {"topic": "Manufacturing", "relevance_score": "0.5"}], "overall_sentiment_score": 0.174081, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.046633", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTTF", "relevance_score": "0.046633", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.046633", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GE", "relevance_score": "0.046633", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.046633", "ticker_sentiment_score": "0.125531", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.046633", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Array Biopharma  ( ARRY ) ,  ( ATXG )  - Calavo Growers And Some Other Big Stocks Moving Lower On Friday", "url": "https://www.benzinga.com/news/22/09/28735013/calavo-growers-and-some-other-big-stocks-moving-lower-on-friday", "time_published": "20220902T145325", "authors": ["Lisa Levin"], "summary": "Shuttle Pharmaceuticals Holdings, Inc. SHPH shares tumbled 63.3% to $19.25 amid post-IPO volatility. Addentax Group Corp. ATXG dipped 46.6% to $16.03. Addentax shares tumbled 95% on Thursday following the company's uplisting and IPO. Calavo Growers, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/09/02/image27.jpeg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "IPO", "relevance_score": "0.451494"}, {"topic": "Manufacturing", "relevance_score": "0.5"}, {"topic": "Earnings", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.34634, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "GCT", "relevance_score": "0.727604", "ticker_sentiment_score": "-0.161501", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NVX", "relevance_score": "0.535653", "ticker_sentiment_score": "-0.66139", "ticker_sentiment_label": "Bearish"}, {"ticker": "CVGW", "relevance_score": "0.535653", "ticker_sentiment_score": "-0.871603", "ticker_sentiment_label": "Bearish"}, {"ticker": "PACB", "relevance_score": "0.535653", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ARRY", "relevance_score": "0.535653", "ticker_sentiment_score": "-0.849075", "ticker_sentiment_label": "Bearish"}, {"ticker": "PTON", "relevance_score": "0.727604", "ticker_sentiment_score": "-0.625326", "ticker_sentiment_label": "Bearish"}]}, {"title": "Genomic Data Analysis and Interpretation Market Size is projected to reach USD 2.15 Billion by 2030, growing at a CAGR of 10.25%: Straits Research", "url": "https://www.benzinga.com/pressreleases/22/08/g28521252/genomic-data-analysis-and-interpretation-market-size-is-projected-to-reach-usd-2-15-billion-by-203", "time_published": "20220816T161000", "authors": ["Globe Newswire"], "summary": "New York, United States, Aug. 16, 2022 ( GLOBE NEWSWIRE ) -- The term \"NGS,\" for \"high throughput sequencing,\" describes a wide range of cutting-edge sequencing methods. Researchers can study biological processes in great detail thanks to the high throughput, scalability, and speed of ...", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Manufacturing", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.198764, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.029802", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.029802", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NVDA", "relevance_score": "0.029802", "ticker_sentiment_score": "0.152725", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.029802", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.029802", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BIO", "relevance_score": "0.029802", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTTF", "relevance_score": "0.029802", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday", "url": "https://www.benzinga.com/news/22/08/28488766/why-embark-technology-jumped-around-85-here-are-108-biggest-movers-from-friday", "time_published": "20220815T074324", "authors": ["Lisa Levin"], "summary": "Embark Technology, Inc. EMBK jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. Twin Vee Powercats Co. VEEE shares climbed 77.5% to close at $7.10 on Friday after the company said Q2 sales results were up year over year. AN2 Therapeutics, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/08/15/image29.jpeg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "IPO", "relevance_score": "0.576289"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Financial Markets", "relevance_score": "0.998682"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.062856, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "VMAR", "relevance_score": "0.033942", "ticker_sentiment_score": "0.263294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VUZI", "relevance_score": "0.033942", "ticker_sentiment_score": "0.096801", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAWN", "relevance_score": "0.033942", "ticker_sentiment_score": "0.102485", "ticker_sentiment_label": "Neutral"}, {"ticker": "PALI", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.129786", "ticker_sentiment_label": "Neutral"}, {"ticker": "MOHO", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.405438", "ticker_sentiment_label": "Bearish"}, {"ticker": "FRSX", "relevance_score": "0.033942", "ticker_sentiment_score": "0.263294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NVTA", "relevance_score": "0.050894", "ticker_sentiment_score": "0.336765", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OLO", "relevance_score": "0.033942", "ticker_sentiment_score": "0.044399", "ticker_sentiment_label": "Neutral"}, {"ticker": "TSLA", "relevance_score": "0.033942", "ticker_sentiment_score": "0.110176", "ticker_sentiment_label": "Neutral"}, {"ticker": "SMSI", "relevance_score": "0.033942", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "UPST", "relevance_score": "0.033942", "ticker_sentiment_score": "0.263294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CODX", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.142853", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.132334", "ticker_sentiment_label": "Neutral"}, {"ticker": "ASLN", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.10647", "ticker_sentiment_label": "Neutral"}, {"ticker": "SURG", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.168963", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PACB", "relevance_score": "0.033942", "ticker_sentiment_score": "0.263294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CHPT", "relevance_score": "0.033942", "ticker_sentiment_score": "0.263294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EAR", "relevance_score": "0.050894", "ticker_sentiment_score": "0.125363", "ticker_sentiment_label": "Neutral"}, {"ticker": "TGL", "relevance_score": "0.050894", "ticker_sentiment_score": "0.208437", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SMRT", "relevance_score": "0.033942", "ticker_sentiment_score": "0.082352", "ticker_sentiment_label": "Neutral"}, {"ticker": "CERT", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.031266", "ticker_sentiment_label": "Neutral"}, {"ticker": "TOST", "relevance_score": "0.033942", "ticker_sentiment_score": "0.396319", "ticker_sentiment_label": "Bullish"}, {"ticker": "ZFOX", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.292368", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RKLB", "relevance_score": "0.033942", "ticker_sentiment_score": "0.283334", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TERN", "relevance_score": "0.033942", "ticker_sentiment_score": "0.109376", "ticker_sentiment_label": "Neutral"}, {"ticker": "BGRY", "relevance_score": "0.033942", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAPT", "relevance_score": "0.050894", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "GWH", "relevance_score": "0.033942", "ticker_sentiment_score": "0.125889", "ticker_sentiment_label": "Neutral"}, {"ticker": "MEGL", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.405438", "ticker_sentiment_label": "Bearish"}, {"ticker": "SIEN", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.077523", "ticker_sentiment_label": "Neutral"}, {"ticker": "MSC", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.405438", "ticker_sentiment_label": "Bearish"}, {"ticker": "USIO", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.113255", "ticker_sentiment_label": "Neutral"}, {"ticker": "PSHG", "relevance_score": "0.033942", "ticker_sentiment_score": "0.054349", "ticker_sentiment_label": "Neutral"}, {"ticker": "CNFR", "relevance_score": "0.050894", "ticker_sentiment_score": "0.172378", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "UBX", "relevance_score": "0.033942", "ticker_sentiment_score": "0.169947", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ANTX", "relevance_score": "0.050894", "ticker_sentiment_score": "-0.005003", "ticker_sentiment_label": "Neutral"}, {"ticker": "GOCO", "relevance_score": "0.033942", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "OSCR", "relevance_score": "0.033942", "ticker_sentiment_score": "0.312478", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AIRS", "relevance_score": "0.033942", "ticker_sentiment_score": "0.255293", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AVCT", "relevance_score": "0.033942", "ticker_sentiment_score": "0.263294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EVGO", "relevance_score": "0.033942", "ticker_sentiment_score": "0.263294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "JOBY", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.126863", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCW", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.109239", "ticker_sentiment_label": "Neutral"}, {"ticker": "PEGY", "relevance_score": "0.033942", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ETNB", "relevance_score": "0.050894", "ticker_sentiment_score": "-0.005003", "ticker_sentiment_label": "Neutral"}, {"ticker": "LAW", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.064793", "ticker_sentiment_label": "Neutral"}, {"ticker": "BBBY", "relevance_score": "0.033942", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "LRMR", "relevance_score": "0.033942", "ticker_sentiment_score": "0.049858", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALT", "relevance_score": "0.050894", "ticker_sentiment_score": "0.086432", "ticker_sentiment_label": "Neutral"}, {"ticker": "LU", "relevance_score": "0.050894", "ticker_sentiment_score": "-0.129361", "ticker_sentiment_label": "Neutral"}, {"ticker": "AQST", "relevance_score": "0.050894", "ticker_sentiment_score": "0.124364", "ticker_sentiment_label": "Neutral"}, {"ticker": "APYX", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.160116", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "GMBL", "relevance_score": "0.050894", "ticker_sentiment_score": "-0.025998", "ticker_sentiment_label": "Neutral"}, {"ticker": "NTCO", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.120052", "ticker_sentiment_label": "Neutral"}, {"ticker": "INOD", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.168963", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FORG", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.042054", "ticker_sentiment_label": "Neutral"}, {"ticker": "PIXY", "relevance_score": "0.033942", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DKNG", "relevance_score": "0.033942", "ticker_sentiment_score": "0.120052", "ticker_sentiment_label": "Neutral"}, {"ticker": "HKD", "relevance_score": "0.033942", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VEEE", "relevance_score": "0.033942", "ticker_sentiment_score": "0.086199", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILAG", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.292368", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "SWIM", "relevance_score": "0.033942", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "POSH", "relevance_score": "0.033942", "ticker_sentiment_score": "0.078511", "ticker_sentiment_label": "Neutral"}, {"ticker": "IMV", "relevance_score": "0.033942", "ticker_sentiment_score": "0.126863", "ticker_sentiment_label": "Neutral"}, {"ticker": "KORE", "relevance_score": "0.033942", "ticker_sentiment_score": "0.203529", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AEY", "relevance_score": "0.033942", "ticker_sentiment_score": "0.20452", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MRAM", "relevance_score": "0.033942", "ticker_sentiment_score": "0.141499", "ticker_sentiment_label": "Neutral"}, {"ticker": "BNSO", "relevance_score": "0.033942", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REAL", "relevance_score": "0.033942", "ticker_sentiment_score": "0.043267", "ticker_sentiment_label": "Neutral"}, {"ticker": "ATRA", "relevance_score": "0.050894", "ticker_sentiment_score": "0.119369", "ticker_sentiment_label": "Neutral"}, {"ticker": "SNPO", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.317512", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ERAS", "relevance_score": "0.033942", "ticker_sentiment_score": "0.114225", "ticker_sentiment_label": "Neutral"}, {"ticker": "ZEAL", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.129786", "ticker_sentiment_label": "Neutral"}, {"ticker": "NN", "relevance_score": "0.033942", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTE", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.345747", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "PEAR", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.151287", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "FDMT", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.032973", "ticker_sentiment_label": "Neutral"}, {"ticker": "PTON", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.047959", "ticker_sentiment_label": "Neutral"}, {"ticker": "ADCT", "relevance_score": "0.050894", "ticker_sentiment_score": "-0.005002", "ticker_sentiment_label": "Neutral"}, {"ticker": "EMBK", "relevance_score": "0.033942", "ticker_sentiment_score": "0.18276", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PLL", "relevance_score": "0.033942", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PLXP", "relevance_score": "0.050894", "ticker_sentiment_score": "-0.14518", "ticker_sentiment_label": "Neutral"}, {"ticker": "TVPC", "relevance_score": "0.016975", "ticker_sentiment_score": "0.078215", "ticker_sentiment_label": "Neutral"}, {"ticker": "CSSE", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.282331", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "RIDE", "relevance_score": "0.033942", "ticker_sentiment_score": "0.263294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NEPT", "relevance_score": "0.050894", "ticker_sentiment_score": "0.114374", "ticker_sentiment_label": "Neutral"}, {"ticker": "LQDA", "relevance_score": "0.033942", "ticker_sentiment_score": "0.168963", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "OPAD", "relevance_score": "0.050894", "ticker_sentiment_score": "0.096406", "ticker_sentiment_label": "Neutral"}, {"ticker": "PAYO", "relevance_score": "0.033942", "ticker_sentiment_score": "0.294377", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "AGL", "relevance_score": "0.050894", "ticker_sentiment_score": "-0.138128", "ticker_sentiment_label": "Neutral"}, {"ticker": "EXFY", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.363933", "ticker_sentiment_label": "Bearish"}, {"ticker": "XPOF", "relevance_score": "0.033942", "ticker_sentiment_score": "0.223385", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "APDN", "relevance_score": "0.033942", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "WETG", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.109808", "ticker_sentiment_label": "Neutral"}, {"ticker": "DMS", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.123943", "ticker_sentiment_label": "Neutral"}, {"ticker": "AGS", "relevance_score": "0.033942", "ticker_sentiment_score": "0.263294", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "APTX", "relevance_score": "0.033942", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DAVE", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.308453", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "ACRX", "relevance_score": "0.033942", "ticker_sentiment_score": "-0.043482", "ticker_sentiment_label": "Neutral"}, {"ticker": "BACK", "relevance_score": "0.033942", "ticker_sentiment_score": "0.045175", "ticker_sentiment_label": "Neutral"}, {"ticker": "APCX", "relevance_score": "0.050894", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "REKR", "relevance_score": "0.033942", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "Disney, Inotiv, Warby Parker And Some Other Big Stocks Moving Higher On Thursday", "url": "https://www.benzinga.com/news/22/08/28459146/disney-inotiv-warby-parker-and-some-other-big-stocks-moving-higher-on-thursday", "time_published": "20220811T161540", "authors": ["Lisa Levin"], "summary": "Absci Corporation ABSI jumped 38.8% to $5.83 after the company reported a narrower Q2 loss. Veru Inc VERU shares gained 30.5% to $15.36 after the company reported Q3 earnings results. Enovix Corporation ENVX rose 28.6% to $20.81 following Q2 results. AST SpaceMobile, Inc.", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/08/11/image30_0.jpeg?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.142857"}, {"topic": "Energy & Transportation", "relevance_score": "0.142857"}, {"topic": "Technology", "relevance_score": "0.142857"}, {"topic": "Finance", "relevance_score": "0.142857"}, {"topic": "Retail & Wholesale", "relevance_score": "0.142857"}, {"topic": "Manufacturing", "relevance_score": "0.142857"}, {"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Real Estate & Construction", "relevance_score": "0.142857"}], "overall_sentiment_score": 0.319073, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "UAL", "relevance_score": "0.047559", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "VZIO", "relevance_score": "0.09495", "ticker_sentiment_score": "0.091186", "ticker_sentiment_label": "Neutral"}, {"ticker": "WKME", "relevance_score": "0.09495", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ENVX", "relevance_score": "0.09495", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "NOAH", "relevance_score": "0.09495", "ticker_sentiment_score": "0.084999", "ticker_sentiment_label": "Neutral"}, {"ticker": "BFLY", "relevance_score": "0.09495", "ticker_sentiment_score": "0.361673", "ticker_sentiment_label": "Bullish"}, {"ticker": "QTRX", "relevance_score": "0.142005", "ticker_sentiment_score": "0.178651", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "VCSA", "relevance_score": "0.09495", "ticker_sentiment_score": "0.361673", "ticker_sentiment_label": "Bullish"}, {"ticker": "AOSL", "relevance_score": "0.09495", "ticker_sentiment_score": "0.108855", "ticker_sentiment_label": "Neutral"}, {"ticker": "VERU", "relevance_score": "0.09495", "ticker_sentiment_score": "0.302116", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "WRBY", "relevance_score": "0.09495", "ticker_sentiment_score": "0.252125", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "SYBX", "relevance_score": "0.047559", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "STKL", "relevance_score": "0.142005", "ticker_sentiment_score": "0.386806", "ticker_sentiment_label": "Bullish"}, {"ticker": "HUT", "relevance_score": "0.09495", "ticker_sentiment_score": "0.319138", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NOTV", "relevance_score": "0.09495", "ticker_sentiment_score": "0.247873", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "STAA", "relevance_score": "0.09495", "ticker_sentiment_score": "0.168278", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ABSI", "relevance_score": "0.09495", "ticker_sentiment_score": "-0.278712", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "BROS", "relevance_score": "0.09495", "ticker_sentiment_score": "0.375484", "ticker_sentiment_label": "Bullish"}, {"ticker": "AIT", "relevance_score": "0.09495", "ticker_sentiment_score": "0.286158", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ASTS", "relevance_score": "0.142005", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BRCC", "relevance_score": "0.09495", "ticker_sentiment_score": "0.258505", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DIS", "relevance_score": "0.09495", "ticker_sentiment_score": "0.222371", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ACHR", "relevance_score": "0.142005", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "RAD", "relevance_score": "0.09495", "ticker_sentiment_score": "0.361673", "ticker_sentiment_label": "Bullish"}, {"ticker": "SOND", "relevance_score": "0.09495", "ticker_sentiment_score": "0.375484", "ticker_sentiment_label": "Bullish"}, {"ticker": "PACB", "relevance_score": "0.09495", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "DNA", "relevance_score": "0.142005", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "CPNG", "relevance_score": "0.09495", "ticker_sentiment_score": "0.102772", "ticker_sentiment_label": "Neutral"}]}, {"title": "Cathie Wood Buys $9M In Roblox Shares Following Q2 Miss - Dumps This Bitcoin-Linked Stock", "url": "https://www.benzinga.com/trading-ideas/long-ideas/22/08/28447421/cathie-wood-buys-9-million-worth-roblox-corp-shares-makes-a-major-sale-in-this-financial", "time_published": "20220811T110425", "authors": ["Bhavik Nair"], "summary": "Cathie Wood-led Ark Investment Management on Wednesday bulked up on the shares of video game developer Roblox Corp RBLX, which reported disappointing results earlier this week. What Happened: Ark bought 191,503 shares of Roblox, valued at over $9 million, via three of its exchange-traded funds ( ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/08/11/shutterstock_1934054426.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "Trading", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.988915"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}, {"topic": "Blockchain", "relevance_score": "0.158519"}], "overall_sentiment_score": 0.235351, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "RBLX", "relevance_score": "0.335367", "ticker_sentiment_score": "0.27097", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.137671", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "COIN", "relevance_score": "0.205225", "ticker_sentiment_score": "0.165258", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "MS", "relevance_score": "0.069094", "ticker_sentiment_score": "0.136584", "ticker_sentiment_label": "Neutral"}, {"ticker": "SQ", "relevance_score": "0.335367", "ticker_sentiment_score": "0.422265", "ticker_sentiment_label": "Bullish"}, {"ticker": "CRYPTO:BTC", "relevance_score": "0.205225", "ticker_sentiment_score": "0.137136", "ticker_sentiment_label": "Neutral"}]}, {"title": "Ark Innovation ETF Trades: Sells $5M In CRISPR Therapeutics, Adds Stake In EXACT Sciences, Pacific Biosciences of California", "url": "https://www.benzinga.com/news/22/08/28369047/cathie-wood-run-ark-innovation-etf-sells-crispr-therapeutics-loads-up-on-exact-sciences-corporation", "time_published": "20220805T043210", "authors": ["Bhavik Nair"], "summary": "Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG CRSP, valued at over $5.58 million, via its flagship fund. For ARK Innovation ETF ARKK, CRISPR is its fifth largest holding with a weight of 4.83%, according to holdings data on ...", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/08/05/shutterstock_607718810.jpg?width=1200&height=800&fit=crop", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Finance", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.87644"}], "overall_sentiment_score": 0.264338, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "C", "relevance_score": "0.079656", "ticker_sentiment_score": "0.227505", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CRSP", "relevance_score": "0.158519", "ticker_sentiment_score": "0.299178", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "EXAS", "relevance_score": "0.235823", "ticker_sentiment_score": "0.026075", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.158519", "ticker_sentiment_score": "0.42502", "ticker_sentiment_label": "Bullish"}]}, {"title": "PacBio's  ( PACB )  Q2 Earnings Match Estimates, Revenues Lag", "url": "https://www.zacks.com/stock/news/1964174/pacbios-pacb-q2-earnings-match-estimates-revenues-lag", "time_published": "20220804T163000", "authors": ["Zacks Investment Research"], "summary": "PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/79/359.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.538269"}, {"topic": "Earnings", "relevance_score": "0.999954"}, {"topic": "Finance", "relevance_score": "0.5"}], "overall_sentiment_score": 0.016766, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "HUM", "relevance_score": "0.150827", "ticker_sentiment_score": "0.155489", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "DGX", "relevance_score": "0.150827", "ticker_sentiment_score": "0.105468", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.150827", "ticker_sentiment_score": "0.147808", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.150827", "ticker_sentiment_score": "0.131251", "ticker_sentiment_label": "Neutral"}]}, {"title": "Can Pacific Biosciences  ( PACB )  Climb 261% to Reach the Level Wall Street Analysts Expect?", "url": "https://www.zacks.com/stock/news/1963929/can-pacific-biosciences-pacb-climb-261-to-reach-the-level-wall-street-analysts-expect", "time_published": "20220804T135515", "authors": ["Zacks Investment Research"], "summary": "The consensus price target hints at a 261.4% upside potential for Pacific Biosciences (PACB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default217.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.5855"}], "overall_sentiment_score": 0.264907, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.2842", "ticker_sentiment_score": "0.379226", "ticker_sentiment_label": "Bullish"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Reports Q2 Loss, Lags Revenue Estimates", "url": "https://www.zacks.com/stock/news/1963356/pacific-biosciences-of-california-pacb-reports-q2-loss-lags-revenue-estimates", "time_published": "20220803T214513", "authors": ["Zacks Investment Research"], "summary": "Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default122.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": 0.142679, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.139265", "ticker_sentiment_score": "0.079772", "ticker_sentiment_label": "Neutral"}]}, {"title": "Inogen  ( INGN )  Surges 5.1%: Is This an Indication of Further Gains?", "url": "https://www.zacks.com/stock/news/1961035/inogen-ingn-surges-51-is-this-an-indication-of-further-gains", "time_published": "20220801T062600", "authors": ["Zacks Investment Research"], "summary": "Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default274.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.961735"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.365926"}], "overall_sentiment_score": 0.197335, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.344074", "ticker_sentiment_score": "0.061318", "ticker_sentiment_label": "Neutral"}, {"ticker": "INGN", "relevance_score": "0.542261", "ticker_sentiment_score": "0.341358", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "10x Genomics Stock Rebound Depends on Growth", "url": "https://www.thestreet.com/investing/10x-genomics-stock-rebound-depends-on-growth", "time_published": "20220729T190800", "authors": ["Maxx Chatsko"], "summary": "The formerly high-flying growth stock is stalling against macroeconomic headwinds. How quickly can the business get back on track?", "banner_image": "https://www.thestreet.com/.image/ar_16:9%2Cc_fill%2Ccs_srgb%2Cfl_progressive%2Cg_faces:center%2Cq_auto:good%2Cw_620/MTg3MDkzMjc0MTIzNTc2ODE1/apple-imac-3.jpg", "source": "The Street", "category_within_source": "n/a", "source_domain": "www.thestreet.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999993"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.413559"}], "overall_sentiment_score": 0.21296, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "ONTTF", "relevance_score": "0.04912", "ticker_sentiment_score": "0.040888", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.501986", "ticker_sentiment_score": "0.377591", "ticker_sentiment_label": "Bullish"}, {"ticker": "BNGO", "relevance_score": "0.146618", "ticker_sentiment_score": "0.05276", "ticker_sentiment_label": "Neutral"}, {"ticker": "NSTG", "relevance_score": "0.146618", "ticker_sentiment_score": "0.05276", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.098054", "ticker_sentiment_score": "0.044053", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.241924", "ticker_sentiment_score": "0.191795", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "FOREX:USD", "relevance_score": "0.04912", "ticker_sentiment_score": "0.175826", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Global Long-Acting Beta-Agonists Market to Grow at a CAGR of ~9% During 2022-2031; Prevalence of Lung Diseases, such as, Chronic Obstructive Pulmonary Disease  ( COPD )  to Drive the Market Growth", "url": "https://www.benzinga.com/pressreleases/22/07/g28247616/global-long-acting-beta-agonists-market-to-grow-at-a-cagr-of-9-during-2022-2031-prevalence-of-lung", "time_published": "20220728T141211", "authors": ["Globe Newswire"], "summary": "New York, July 28, 2022 ( GLOBE NEWSWIRE ) -- According to the Lancet Respiratory Medicine, in 2017, about 545 million people worldwide had a chronic respiratory condition, a rise of 39.8 % since 1990.", "banner_image": "", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.09484, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "GIC", "relevance_score": "0.021504", "ticker_sentiment_score": "0.151877", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "A", "relevance_score": "0.021504", "ticker_sentiment_score": "0.149513", "ticker_sentiment_label": "Neutral"}, {"ticker": "META", "relevance_score": "0.021504", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.021504", "ticker_sentiment_score": "0.149513", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.021504", "ticker_sentiment_score": "0.149513", "ticker_sentiment_label": "Neutral"}, {"ticker": "BCEL", "relevance_score": "0.021504", "ticker_sentiment_score": "0.149513", "ticker_sentiment_label": "Neutral"}, {"ticker": "NHGP", "relevance_score": "0.021504", "ticker_sentiment_score": "0.151877", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.021504", "ticker_sentiment_score": "0.149513", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTTF", "relevance_score": "0.021504", "ticker_sentiment_score": "0.149513", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.021504", "ticker_sentiment_score": "0.149513", "ticker_sentiment_label": "Neutral"}]}, {"title": "Global Immune Repertoire Sequencing Market to Grow at a CAGR 0f ~6% During 2022-2031; Prevalence of Cancer and Autoimmune Disorders, along with Increasing Novel Products Development to drive the Market Growth", "url": "https://www.benzinga.com/pressreleases/22/07/g28187680/global-immune-repertoire-sequencing-market-to-grow-at-a-cagr-0f-6-during-2022-2031-prevalence-of-c", "time_published": "20220725T134929", "authors": ["Globe Newswire"], "summary": "New York, July 25, 2022 ( GLOBE NEWSWIRE ) -- According to the World Trade Organization ( WTO ) , the imports of finished pharmaceutical products have risen by 14% during the last 20 years, with imports worth at over USD 350 billion in 2018.", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Economy - Fiscal", "relevance_score": "0.158519"}, {"topic": "Retail & Wholesale", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}, {"topic": "Technology", "relevance_score": "0.333333"}], "overall_sentiment_score": 0.184356, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "GIC", "relevance_score": "0.023579", "ticker_sentiment_score": "0.15331", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "A", "relevance_score": "0.023579", "ticker_sentiment_score": "0.151176", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "META", "relevance_score": "0.023579", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.023579", "ticker_sentiment_score": "0.151176", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ILMN", "relevance_score": "0.023579", "ticker_sentiment_score": "0.151176", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "BCEL", "relevance_score": "0.023579", "ticker_sentiment_score": "0.151176", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "NHGP", "relevance_score": "0.023579", "ticker_sentiment_score": "0.15331", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "TMO", "relevance_score": "0.023579", "ticker_sentiment_score": "0.151176", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ONTTF", "relevance_score": "0.023579", "ticker_sentiment_score": "0.151176", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "QGEN", "relevance_score": "0.023579", "ticker_sentiment_score": "0.151176", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio Announces Appointment of Genomics Industry Veteran Jeff Eidel as Chief Commercial Officer", "url": "https://www.prnewswire.com/news-releases/pacbio-announces-appointment-of-genomics-industry-veteran-jeff-eidel-as-chief-commercial-officer-301589506.html", "time_published": "20220721T130000", "authors": ["Pacific Biosciences of California", "Inc."], "summary": "MENLO PARK, Calif., July 21, 2022 /PRNewswire/ -- PacBio ( NASDAQ: PACB ) , a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Jeff Eidel as Chief Commercial Officer, effective August 16, 2022.", "banner_image": "https://mma.prnewswire.com/media/1861430/PacBio_Logo.jpg?p=facebook", "source": "PR Newswire", "category_within_source": "n/a", "source_domain": "www.prnewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.451494"}], "overall_sentiment_score": 0.339122, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.113597", "ticker_sentiment_score": "0.188212", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ILMN", "relevance_score": "0.169676", "ticker_sentiment_score": "0.097559", "ticker_sentiment_label": "Neutral"}, {"ticker": "INO", "relevance_score": "0.056943", "ticker_sentiment_score": "0.069999", "ticker_sentiment_label": "Neutral"}]}, {"title": "Metagenomic Sequencing Market Size is projected to reach USD 5.78 Billion by 2030, growing at a CAGR of 17.5%: Straits Research", "url": "https://www.benzinga.com/pressreleases/22/07/g28054078/metagenomic-sequencing-market-size-is-projected-to-reach-usd-5-78-billion-by-2030-growing-at-a-cag", "time_published": "20220713T165000", "authors": ["Globe Newswire"], "summary": "New York, United States, July 13, 2022 ( GLOBE NEWSWIRE ) -- Metagenomics is a molecular tool in genomics that analyses mixed genomic materials extracted from a community of organisms using metagenomics sequencing. Metagenomics allows researchers to study organisms that are difficult to culture ...", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.108179"}, {"topic": "Technology", "relevance_score": "0.5"}], "overall_sentiment_score": 0.228819, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "META", "relevance_score": "0.023487", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTTF", "relevance_score": "0.023487", "ticker_sentiment_score": "0.139684", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.046953", "ticker_sentiment_score": "0.128595", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.046953", "ticker_sentiment_score": "0.089383", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.023487", "ticker_sentiment_score": "0.139684", "ticker_sentiment_label": "Neutral"}]}, {"title": "Next Generation Sequencing Market to Reach $33.73 billion By 2028 Thanks to Increased Attention Early Disease Diagnosis and High Prevalence of Cancer", "url": "https://www.benzinga.com/pressreleases/22/07/g28048698/next-generation-sequencing-market-to-reach-33-73-billion-by-2028-thanks-to-increased-attention-ear", "time_published": "20220713T124943", "authors": ["Globe Newswire"], "summary": "Westford, USA, July 13, 2022 ( GLOBE NEWSWIRE ) -- Next generation sequencing ( NGS ) is a game-changing technology that is revolutionizing how we study and understand biology.", "banner_image": "", "source": "Benzinga", "category_within_source": "News", "source_domain": "www.benzinga.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": 0.105962, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.018861", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.018861", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.018861", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "BDX", "relevance_score": "0.018861", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ONTTF", "relevance_score": "0.018861", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.018861", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "ERFSF", "relevance_score": "0.018861", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}, {"ticker": "PKI", "relevance_score": "0.018861", "ticker_sentiment_score": "0.0", "ticker_sentiment_label": "Neutral"}]}, {"title": "A Beaten-Down Biotech Stock That's Finally Attractive", "url": "https://www.thestreet.com/investing/10x-genomics-attractive-valuation", "time_published": "20220603T154300", "authors": ["Maxx Chatsko"], "summary": "This lab-hardware business is growing, cashed up, and close to profitability.", "banner_image": "https://www.thestreet.com/.image/ar_16:9%2Cc_fill%2Ccs_srgb%2Cfl_progressive%2Cg_faces:center%2Cq_auto:good%2Cw_620/MTY3NTM5NTUwMjA5NTgyOTkw/mccormick-posts-profit-beat-spices-up-full-year-earnings-outlook.jpg", "source": "The Street", "category_within_source": "n/a", "source_domain": "www.thestreet.com", "topics": [{"topic": "Earnings", "relevance_score": "0.503496"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.980716"}], "overall_sentiment_score": -0.219463, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "TXG", "relevance_score": "0.592942", "ticker_sentiment_score": "-0.12829", "ticker_sentiment_label": "Neutral"}, {"ticker": "NSTG", "relevance_score": "0.15173", "ticker_sentiment_score": "-0.65389", "ticker_sentiment_label": "Bearish"}, {"ticker": "PACB", "relevance_score": "0.15173", "ticker_sentiment_score": "-0.65389", "ticker_sentiment_label": "Bearish"}, {"ticker": "ILMN", "relevance_score": "0.201356", "ticker_sentiment_score": "0.195286", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "PacBio's  ( PACB )  Q1 Earnings Miss Estimates, Revenues Beat", "url": "https://www.zacks.com/stock/news/1916989/pacbios-pacb-q1-earnings-miss-estimates-revenues-beat", "time_published": "20220505T145400", "authors": ["Zacks Investment Research"], "summary": "PacBio (PACB) sees strength in Q1 segmental revenues, led by robust consumable and instrument sales.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/61/15920.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.333333"}, {"topic": "Financial Markets", "relevance_score": "0.360215"}, {"topic": "Earnings", "relevance_score": "0.999939"}, {"topic": "Technology", "relevance_score": "0.333333"}, {"topic": "Finance", "relevance_score": "0.333333"}], "overall_sentiment_score": -0.179439, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "OMCL", "relevance_score": "0.166054", "ticker_sentiment_score": "0.044343", "ticker_sentiment_label": "Neutral"}, {"ticker": "ALKS", "relevance_score": "0.206721", "ticker_sentiment_score": "0.036548", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.166054", "ticker_sentiment_score": "-0.049969", "ticker_sentiment_label": "Neutral"}, {"ticker": "UNH", "relevance_score": "0.166054", "ticker_sentiment_score": "0.040011", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences Clocks 14% Jump In Q1 Revenues", "url": "https://www.benzinga.com/news/earnings/22/05/27013219/pacific-biosciences-clocks-14-jump-in-q1-revenues", "time_published": "20220505T135012", "authors": ["Vandana Singh"], "summary": "Pacific Biosciences of California Inc's  ( NASDAQ: PACB )  Q1 sales increased 14% Y/Y to $33.2 million, driven by sales of instruments and consumables and beating the consensus of $32.82 million.\nInstrument revenue was $15.6 million, compared with $14.9 million a year ago. Consumables revenue was $1", "banner_image": "https://cdn.benzinga.com/files/images/story/2022/05/05/aapharma_0.png?optimize=medium&dpr=2&auto=webp&width=3840", "source": "Benzinga", "category_within_source": "General", "source_domain": "www.benzinga.com", "topics": [{"topic": "Earnings", "relevance_score": "0.266143"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": -0.040326, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.426944", "ticker_sentiment_score": "0.001591", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Reports Q1 Loss, Tops Revenue Estimates", "url": "https://www.zacks.com/stock/news/1916193/pacific-biosciences-of-california-pacb-reports-q1-loss-tops-revenue-estimates", "time_published": "20220504T220514", "authors": ["Zacks Investment Research"], "summary": "Pacific Biosciences (PACB) delivered earnings and revenue surprises of -15.63% and 1.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default103.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.999759"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.266143"}], "overall_sentiment_score": -0.050564, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "DCTH", "relevance_score": "0.18883", "ticker_sentiment_score": "-0.135056", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.12655", "ticker_sentiment_score": "-0.061828", "ticker_sentiment_label": "Neutral"}]}, {"title": "Pacific Biosciences: Q1 Earnings Snapshot", "url": "https://apnews.com/article/business-california-earnings-pacific-biosciences-of-inc-d9c0bfd3870ee7562ff0b133fdeaf547", "time_published": "20220504T205801", "authors": [], "summary": "Pacific Biosciences: Q1 Earnings Snapshot The Associated Press - en Espa\u00f1ol", "banner_image": "https://storage.googleapis.com/afs-prod/media/afs:Medium:751921853724/700.png", "source": "Associated Press", "category_within_source": "Business", "source_domain": "apnews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}], "overall_sentiment_score": -0.260295, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.888506", "ticker_sentiment_score": "-0.134007", "ticker_sentiment_label": "Neutral"}]}, {"title": "2 Reasons to Buy Illumina, and 1 Reason to Sell", "url": "https://www.fool.com/investing/2022/04/28/2-reasons-to-buy-illumina-and-1-reason-to-sell/", "time_published": "20220428T125000", "authors": ["Jason Hawthorne"], "summary": "Shares are near a 52-week low, but is that cheap enough?", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F676331%2Fgettyimages-1355235261.jpg&w=700&op=resize", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.214378"}, {"topic": "Earnings", "relevance_score": "0.158519"}, {"topic": "Mergers & Acquisitions", "relevance_score": "0.158519"}], "overall_sentiment_score": -0.189771, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.105141", "ticker_sentiment_score": "-0.676739", "ticker_sentiment_label": "Bearish"}, {"ticker": "ILMN", "relevance_score": "0.356317", "ticker_sentiment_score": "-0.260552", "ticker_sentiment_label": "Somewhat-Bearish"}, {"ticker": "NIHL", "relevance_score": "0.052685", "ticker_sentiment_score": "0.317521", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Pacific Biosciences of California  ( PACB )  Expected to Beat Earnings Estimates: Should You Buy?", "url": "https://www.zacks.com/stock/news/1909464/pacific-biosciences-of-california-pacb-expected-to-beat-earnings-estimates-should-you-buy", "time_published": "20220427T190334", "authors": ["Zacks Investment Research"], "summary": "Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default307.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "1.0"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}], "overall_sentiment_score": 0.010147, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.094688", "ticker_sentiment_score": "-0.024363", "ticker_sentiment_label": "Neutral"}]}, {"title": "PACB: Is Pacific Biosciences of California a Winner in the Diagnostics & Research Industry?", "url": "https://stocknews.com/news/pacb-co-qgen-a-is-pacific-biosciences-of-california-a-winner-in-the-diagnostics/", "time_published": "20220426T122905", "authors": [], "summary": "Pacific Biosciences of California, Inc.  (  PACB  )  in Menlo Park, Calif., provides life scientists with extremely precise sequencing technologies. The company's unique equipment is based on single molecule, real-time Sequencing technology, which provides a complete picture of genomes, transcriptomes, and epigenomes, allowing access to the whole spectrum of genetic diversity in any organism.", "banner_image": "https://stocknews.com/wp-content/uploads/2021/11/shutterstock_654542473-scaled.jpg", "source": "Stocknews.com", "category_within_source": "n/a", "source_domain": "stocknews.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.316726"}, {"topic": "Earnings", "relevance_score": "0.990786"}, {"topic": "Real Estate & Construction", "relevance_score": "0.5"}], "overall_sentiment_score": -0.156035, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.070956", "ticker_sentiment_score": "0.13371", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.141351", "ticker_sentiment_score": "0.13371", "ticker_sentiment_label": "Neutral"}, {"ticker": "CO", "relevance_score": "0.141351", "ticker_sentiment_score": "0.13371", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.752978", "ticker_sentiment_score": "-0.088694", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio and Children's Mercy Kansas City Expand Collaboration Taking a Multi-Omics Approach to Characterize Rare Disease", "url": "https://www.globenewswire.com/news-release/2022/04/21/2426623/16261/en/PacBio-and-Children-s-Mercy-Kansas-City-Expand-Collaboration-Taking-a-Multi-Omics-Approach-to-Characterize-Rare-Disease.html", "time_published": "20220421T131000", "authors": ["Inc.", "Pacific Biosciences of California"], "summary": "MENLO PARK, Calif., April  21, 2022   ( GLOBE NEWSWIRE )  -- PacBio  ( NASDAQ: PACB ) , a leading provider of high-quality, highly accurate sequencing solutions, today announced an expanded research collaboration with Children's Mercy Kansas City, one of the nation's top pediatric medical systems, t", "banner_image": "https://ml.globenewswire.com/Resource/Download/f408d681-e68c-4113-a7cd-be24486deefc?size=1", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Technology", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.23698, "overall_sentiment_label": "Somewhat-Bullish", "ticker_sentiment": [{"ticker": "FB", "relevance_score": "0.040239", "ticker_sentiment_score": "0.38376", "ticker_sentiment_label": "Bullish"}, {"ticker": "PACB", "relevance_score": "0.12031", "ticker_sentiment_score": "0.039179", "ticker_sentiment_label": "Neutral"}]}, {"title": "Illumina  ( ILMN )  Hurt by Rising Costs, Tough Competition", "url": "https://www.zacks.com/stock/news/1899454/illumina-ilmn-hurt-by-rising-costs-tough-competition", "time_published": "20220414T124400", "authors": ["Zacks Investment Research"], "summary": "Regulatory complications are raising the legal expenses for Illumina (ILMN), thereby building pressure on the bottom line.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ef/386.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}, {"topic": "Earnings", "relevance_score": "0.838487"}], "overall_sentiment_score": 0.100379, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "A", "relevance_score": "0.052836", "ticker_sentiment_score": "0.009935", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.259616", "ticker_sentiment_score": "0.19276", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "PACB", "relevance_score": "0.052836", "ticker_sentiment_score": "0.009935", "ticker_sentiment_label": "Neutral"}, {"ticker": "ABMD", "relevance_score": "0.259616", "ticker_sentiment_score": "-0.004376", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.533974", "ticker_sentiment_score": "0.081186", "ticker_sentiment_label": "Neutral"}, {"ticker": "TMO", "relevance_score": "0.052836", "ticker_sentiment_score": "0.009935", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMI", "relevance_score": "0.259616", "ticker_sentiment_score": "0.144815", "ticker_sentiment_label": "Neutral"}, {"ticker": "QGEN", "relevance_score": "0.052836", "ticker_sentiment_score": "0.009935", "ticker_sentiment_label": "Neutral"}]}, {"title": "3 Things About Pacific Biosciences of California That Smart Investors Know", "url": "https://www.fool.com/investing/2022/04/12/3-things-about-pacbio-smart-investors-know/", "time_published": "20220412T122500", "authors": ["Jason Hawthorne"], "summary": "Anyone thinking about buying shares should know them, too.", "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F674286%2Fgettyimages-1144984609.jpg&w=700&op=resize", "source": "Motley Fool", "category_within_source": "n/a", "source_domain": "www.fool.com", "topics": [{"topic": "Economy - Monetary", "relevance_score": "0.158519"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.161647"}, {"topic": "Earnings", "relevance_score": "0.684621"}], "overall_sentiment_score": -0.478546, "overall_sentiment_label": "Bearish", "ticker_sentiment": [{"ticker": "ONTTF", "relevance_score": "0.078277", "ticker_sentiment_score": "0.173585", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "CTVA", "relevance_score": "0.078277", "ticker_sentiment_score": "-0.012203", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.155803", "ticker_sentiment_score": "0.173585", "ticker_sentiment_label": "Somewhat-Bullish"}, {"ticker": "ILMN", "relevance_score": "0.155803", "ticker_sentiment_score": "0.173585", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "HiFi Reads Enable Telomere-to-Telomere Consortium to Fill the Final Gaps in the Human Genome, Heralding a New Era of Research into Genetic Diseases and Human Biology", "url": "https://www.globenewswire.com/news-release/2022/03/31/2414268/16261/en/HiFi-Reads-Enable-Telomere-to-Telomere-Consortium-to-Fill-the-Final-Gaps-in-the-Human-Genome-Heralding-a-New-Era-of-Research-into-Genetic-Diseases-and-Human-Biology.html", "time_published": "20220331T180000", "authors": ["Inc.", "Pacific Biosciences of California"], "summary": "Science magazine publication details how the human genome was finally completed with the help of PacBio long-read technology Science magazine publication details how the human genome was finally completed with the help of PacBio long-read technology", "banner_image": "https://ml.globenewswire.com/Resource/Download/363c6448-8c30-468e-b198-47d26f67a942?size=2", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.046988, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.121078", "ticker_sentiment_score": "0.046988", "ticker_sentiment_label": "Neutral"}]}, {"title": "PacBio Opens European Headquarters in London", "url": "https://www.globenewswire.com/news-release/2022/03/23/2408595/16261/en/PacBio-Opens-European-Headquarters-in-London.html", "time_published": "20220323T130000", "authors": ["Inc.", "Pacific Biosciences of California"], "summary": "Company Announces New European Headquarters to Serve Growing Customer Demand in Europe, Middle East and Africa Region", "banner_image": "https://ml.globenewswire.com/Resource/Download/5acf0dc7-6f53-4193-9443-25febb99c3e8?size=2", "source": "GlobeNewswire", "category_within_source": "n/a", "source_domain": "www.globenewswire.com", "topics": [{"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.080617, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.163909", "ticker_sentiment_score": "0.054556", "ticker_sentiment_label": "Neutral"}, {"ticker": "SKHCF", "relevance_score": "0.163909", "ticker_sentiment_score": "0.066756", "ticker_sentiment_label": "Neutral"}]}, {"title": "LHC Group  ( LHCG )  Ties Up to Improve Home Health Services", "url": "https://www.zacks.com/stock/news/1884050/lhc-group-lhcg-ties-up-to-improve-home-health-services", "time_published": "20220318T150000", "authors": ["Zacks Investment Research"], "summary": "LHC Group's (LHCG) latest joint venture with Archbold Medical Center to enhance home health services in Thomasville and across South Georgia.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/83/917.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.795202"}, {"topic": "Life Sciences", "relevance_score": "1.0"}], "overall_sentiment_score": 0.040201, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "BAX", "relevance_score": "0.203159", "ticker_sentiment_score": "0.081665", "ticker_sentiment_label": "Neutral"}, {"ticker": "LHCG", "relevance_score": "0.332122", "ticker_sentiment_score": "0.05947", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.203159", "ticker_sentiment_score": "0.022544", "ticker_sentiment_label": "Neutral"}, {"ticker": "DVA", "relevance_score": "0.268589", "ticker_sentiment_score": "0.010659", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.068384", "ticker_sentiment_score": "0.246016", "ticker_sentiment_label": "Somewhat-Bullish"}]}, {"title": "Illumina  ( ILMN )  Invests in Seven Additional Genomics Startups", "url": "https://www.zacks.com/stock/news/1884021/illumina-ilmn-invests-in-seven-additional-genomics-startups", "time_published": "20220318T140800", "authors": ["Zacks Investment Research"], "summary": "Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/41/899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.928139"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.108179"}], "overall_sentiment_score": 0.040488, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "QGEN", "relevance_score": "0.20279", "ticker_sentiment_score": "-0.006842", "ticker_sentiment_label": "Neutral"}, {"ticker": "TXG", "relevance_score": "0.300088", "ticker_sentiment_score": "-0.005419", "ticker_sentiment_label": "Neutral"}, {"ticker": "OMIC", "relevance_score": "0.051221", "ticker_sentiment_score": "0.020924", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.152821", "ticker_sentiment_score": "-0.033689", "ticker_sentiment_label": "Neutral"}, {"ticker": "ILMN", "relevance_score": "0.725201", "ticker_sentiment_score": "0.046432", "ticker_sentiment_label": "Neutral"}]}, {"title": "Why Is Pacific Biosciences  ( PACB )  Down 13.6% Since Last Earnings Report?", "url": "https://www.zacks.com/stock/news/1883596/why-is-pacific-biosciences-pacb-down-136-since-last-earnings-report", "time_published": "20220317T153032", "authors": ["Zacks Investment Research"], "summary": "Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.", "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default124.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.96136"}, {"topic": "Life Sciences", "relevance_score": "1.0"}, {"topic": "Financial Markets", "relevance_score": "0.929393"}], "overall_sentiment_score": -0.240821, "overall_sentiment_label": "Somewhat-Bearish", "ticker_sentiment": [{"ticker": "PACB", "relevance_score": "0.052271", "ticker_sentiment_score": "-0.694231", "ticker_sentiment_label": "Bearish"}]}, {"title": "PacBio  ( PACB )  Supports SickKids With Sequencing Technology", "url": "https://www.zacks.com/stock/news/1878533/pacbio-pacb-supports-sickkids-with-sequencing-technology", "time_published": "20220307T155700", "authors": ["Zacks Investment Research"], "summary": "PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.", "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/2a/3899.jpg", "source": "Zacks Commentary", "category_within_source": "n/a", "source_domain": "www.zacks.com", "topics": [{"topic": "Earnings", "relevance_score": "0.983605"}, {"topic": "Life Sciences", "relevance_score": "0.5"}, {"topic": "Retail & Wholesale", "relevance_score": "0.5"}], "overall_sentiment_score": 0.02348, "overall_sentiment_label": "Neutral", "ticker_sentiment": [{"ticker": "AMN", "relevance_score": "0.245649", "ticker_sentiment_score": "0.038247", "ticker_sentiment_label": "Neutral"}, {"ticker": "HSIC", "relevance_score": "0.185543", "ticker_sentiment_score": "0.033596", "ticker_sentiment_label": "Neutral"}, {"ticker": "MCK", "relevance_score": "0.185543", "ticker_sentiment_score": "0.047372", "ticker_sentiment_label": "Neutral"}, {"ticker": "PACB", "relevance_score": "0.124325", "ticker_sentiment_score": "0.018071", "ticker_sentiment_label": "Neutral"}, {"ticker": "HCSG", "relevance_score": "0.062352", "ticker_sentiment_score": "0.056959", "ticker_sentiment_label": "Neutral"}]}]}